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Abstract
High-grade serous ovarian cancer (HGSOC) is the most common form of ovarian
cancer. The majority of women are disproportionately diagnosed at an advanced stage (stage
III-IV) of the disease when tumours have progressed beyond the ovaries or fallopian tubes and
into the peritoneal cavity. Survival rates at late-stage are as low as 25% and chemoresistant
disease recurrence is common, affecting up to 90% of patients. Multicellular clusters called
spheroids contribute to dormancy, chemoresistance, and metastases and are a major challenge
to treatment of HGSOC. Spheroid cells undergo reversible quiescence to evade chemotherapy
in a process mediated by the mammalian DREAM complex and its initiating kinase, DYRK1A.
Depletion of DYRK1A reduces spheroid cell survival and increases sensitivity to
chemotherapy, highlighting it as an attractive therapeutic target. Herein we demonstrate the
long-term consequences of DREAM loss in adult mice. DREAM deficient mice do not have
proliferative control defects but develop systemic amyloidosis as a result of overexpression of
apolipoproteins Apoa1 and Apoa4. Overexpression of Apoa1 and Apo4 were marked with
increased B-MYB-MuvB (MMB) and decreased H2AZ deposition within gene bodies. The
prolonged latency before developing amyloidosis suggests depriving cells of quiescence is
tolerable for short periods of time. To broadly identify genetic vulnerabilities in spheroid cells,
we employed an integrated strategy in which we investigated the transcriptional programming
and also performed a loss-of-function genome-wide CRISPR screen in HGSOC spheroid cells.
Towards this aim, we developed novel bioinformatic tools and methodology to facilitate highthroughput discovery of essential genes and pathways and anticipate these tools will have
broad usability in transcriptional and loss-of-function studies. Using these tools, we identified
the netrin signaling pathway as an essential mediator of HGSOC spheroid cell survival.
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Specifically, components of netrin signaling are upregulated in spheroid cells and depletion of
netrin ligands or receptors was sufficient to reduce spheroid cell viability. Our work highlights
netrin signaling as a potential target for new metastatic ovarian cancer therapies. Taken
together, the work presented herein provide more insight into the roles of DREAM and
DYRK1A in HGSOC spheroid survival as well as implications of therapeutically targeting this
pathway. HGSOC is a very deadly disease and there is an urgent need to develop new
therapeutic strategies that can specifically target dormant chemoresistant spheroids in patients
to treat or prevent relapse.
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Summary for Lay Audience
The majority of ovarian cancer cases are diagnosed at an advanced stage when the
disease has spread into the abdominal cavity. Survival rates in these women are extremely low.
Treatment in these women is made difficult due to the presence of spheroids, which are clusters
of cancer cells that have dislodged from tumours and float within the abdominal fluid.
Spheroids are resistant to drugs and persist in a “sleeping” state called dormancy. These cells
travel through the abdominal fluid and reawaken to spread the disease to new sites in the body.
We previously identified the protein complex known as DREAM and the protein known as
DYRK1A as essential factors that promote the survival of spheroids. DYRK1A is required to
mobilize DREAM. Loss of DREAM or DYRK1A in spheroids reduces survival and enhances
sensitivity to drugs, suggesting these are attractive targets for therapies. However, the
mechanisms by which DREAM and DYRK1A promote spheroid survival and dormancy are
not fully understood and the long-term consequences of DREAM loss in adults is not known.
Herein we demonstrate the side-effects of prolonged DREAM loss in adult mice to investigate
what would happen if DREAM is inhibited. We found that prolonged DREAM loss leads to
the development of amyloidosis indicating this must be an import consideration for antiDREAM drug therapies in ovarian cancer. Next, to identify new drug targets in dormant
ovarian cancer, we screened spheroids and identified a family of genes that were previously
uncharacterized in ovarian cancer and we show that they are regulated by DYRK1A. We show
that disabling these genes reduces spheroid survival, indicating their potential as drug targets.
We also describe new computational tools that facilitated this discovery and anticipate these
tools will have broad usability in other studies. In summary, the work presented here add to
our understanding of the roles of DREAM and DYRK1A in ovarian cancer and inform of the

v

implications of targeting this pathway with drugs. Ovarian cancer is a very deadly disease and
there is an urgent need to develop new treatment strategies to improve patient survival.
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Chapter 1

1

Introduction

1.1 Ovarian cancer
Ovarian cancer represents a heterogenous group of carcinomas that involve the
ovary and fallopian tube. The incidence rate of ovarian cancer is disproportionate to its
mortality rate. It is estimated that there are 240,000 new cases globally each year
representing approximately 3.6% of annual cancer cases1. It was estimated that 152,000
women succumbed to the disease worldwide in the same year1. In 2020, the Canadian
Cancer Society estimated 3,100 new cases and 1,950 deaths annually2. The American
Cancer Society estimated there would be 22,240 new cases and 14,070 deaths in 20183.
These incidence rates and alarming mortality figures have established ovarian cancer as
the most devastating of all female reproductive cancers4. Despite increased awareness and
advancements in ovarian cancer research, patient survival trends have failed to improve
significantly over the last decade5,6. The startling mortality figures are largely due to latediagnosis in the majority of women (70%)6. The five-year survival rate of women
diagnosed with stage I disease is 90% but beyond stage II, this falls sharply to less than
25%6. The poor prognosis of women diagnosed with late-stage disease indicates a critical
requirement for both improved screening and therapeutics.
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1.2 Subtype classification
Although it was originally considered to be a unitary disease, it is now understood
that ovarian cancer encompasses several different malignancies of various origins which
can be further divided into subtypes based on their molecular and histological composition,
cells of origin, and clinical features6-8. The vast majority of ovarian cancers, about 90%,
arise through the transformation of epithelial cells and are therefore classified as epithelial
ovarian cancer (EOC)5,6. In contrast, only about 10% of ovarian cancers are designated as
non-epithelial ovarian cancer (NEOC) and originate from germ-cell, sex-cord stromal
tissues or mixed-cell types5. EOC is itself a broad classification which can be further
divided into four subtypes based on morphology and clinical features, including clear-cell
(10%), endometrioid (10%), mucinous (10%), and serous (70%) carcinomas5,9. Serous
carcinomas can be further classified as high-grade serous ovarian carcinoma (HGSOC)
(90%) or low-grade serous ovarian carcinoma (LGSOC) (10%)5,6 (Figure 1.1).
Molecular and genetic analyses of EOC have led to two distinct tumour grade
categories: type I and type II tumours10,11. Type I tumours are indolent and less aggressive
than their type II counterparts6. These slow-growing tumours are generally found localized
to the ovary at the time of diagnosis, which usually occurs at an early-stage of disease
development6,12. Type I tumours include LGSOC as well as low-grade endometrioid, clearcell, and mucinous carcinomas13. In contrast, type II tumours are very aggressive, progress
rapidly, present at an advanced stage, and are widely disseminated beyond the site of
origin12,13. Compared to type I tumours, type II tumours are also genetically unstable and
harbor more mutations12-14. Type II tumours include high-grade endometrioid and
undifferentiated carcinomas, but HGSOC is by far the most prevalent and considered to
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Figure 1.1 Classification of ovarian cancers
Figure 1.1. Classification of ovarian cancers. The majority of ovarian cancers (90%)
occur through the transformation of epithelial cells and are called epithelial ovarian cancer
(EOC). EOC can be further classified into subtypes based on morphology and clinical
features: serous carcinoma (70%), endometrioid carcinoma (10%), clear-cell carcinoma
(10%), and mucinous carcinoma (10%). Serous cancer can be further subdivided into lowgrade serous ovarian carcinoma (LGSOC) and high-grade serous ovarian carcinoma
(HGSOC). HGSOC cases account for 90% of all serous carcinomas and represent the
majority of all ovarian cancer cases worldwide. EOC can also be subdivided by molecular
and genetic characteristics into Type I (LGSOC, endometrioid, clear-cell, mucinous;
highlighted in purple) or type II (HGSOC; highlighted in red). Non-EOC subtypes account
for 10% of all ovarian carcinomas and include sex-cord, germ-cell, and mixed-cell types.
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the prototypical type II neoplasm13,14. HGSOC accounts for over 81% of all type II
tumours, over 60% of all ovarian carcinoma cases, and over 70% of all EOC deaths5,6,12.
Therefore, despite some shared similarities, HGSOC and LGSOC are two distinct
neoplasms with contrasting disease progression and patient outcomes.

1.3 High-grade serous ovarian carcinoma
1.3.1

Origin
The site of origin for HGSOC has been long debated since the histology of tumours

do not always resemble ovarian tissues. It was originally thought to arise from the ovarian
surface epithelium (OSE), a layer of cells related to the lining of the peritoneal cavity15-17.
The OSE was favoured because patients with LGSOC had tumours localized to the ovary
at the time of diagnosis which was similar to some early-stage HGSOC patients presenting
with only ovarian involvement6. Additionally, omitting distant metastases, late-stage
HGSOC patients showed both ovarian and fallopian involvement. HGSOC was therefore
regarded as a more advanced phase of LGSOC that also originated from the ovary,
specifically the OSE. That the OSE is derived from the coelomic epithelium which is
closely related to the mesothelial lining of the peritoneal cavity supported this viewpoint
since advanced stage HGSOC most often presented with widespread peritoneal
dissemination18. This gave rise to the “incessant ovulation” hypothesis, which suggested
the local rupturing and regeneration of the OSE during ovulation may contribute to
carcinogenesis as a result of a failure to repair DNA damage caused by increased
inflammation17,19,20. Further supporting this hypothesis was the observation that ruptured
OSE may invaginate toward the ovarian stroma to form cortical inclusion cysts (CICs)16.
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Exposure of CICs to the pro-growth and pro-differentiation hormones typically found
within the ovarian stroma was thought to be sufficient to transform the pre-cancerous
lesions into neoplasms if they already harbored mutations6,16,17,21.
Still, this hypothesis was strongly contested since the histology of HGSOC tumours
do not resemble ovarian tissues. Several transgenic mouse models have provided evidence
for tumorigenesis of the OSE due to inactivation or mutation of a small subset of genes
including Brca1, Kras, Lkb1, Pten, Rb1, and Trp536. However not all of these mice
developed advanced stage (stage III-IV) tumours or aggressive metastases as observed in
human HGSOC cases, suggesting the OSE may not be the primary source for human
HGSOC. A new hypothesis suggesting HGSOC arises from the Müllerian epithelium – an
epithelial lining found throughout the female urogenital system including the fallopian
tubes – was proposed in 199922. The Müllerian epithelium closely resembles the histology
of HGSOC tumours, unlike the OSE15. This theory gained increased acceptance as
advances in genetic and histological analyses revealed that women carrying germline
BRCA1/2 mutations had an increased lifetime risk of developing ovarian cancer,
particularly HGSOC12. BRCA mutant carriers were susceptible to developing tumours on
ovarian, fallopian, and peritoneal surfaces which led to the prophylactic bilateral salpingooophorectomy (surgical removal of the ovaries and fallopian tubes)19,23. Histological
analyses of these ovaries and fallopian tubes found more preneoplastic changes in the
fallopian tubes compared to the ovaries, providing further evidence to support the fallopian
tubes as the site of origin16,24. Analyses of the fimbria of fallopian tubes revealed the
presence of precancerous lesions which are now known as serous tubal intraepithelial
carcinomas (STICs)16 (Figure 1.2).
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Figure 1.2 Origin of HGSOC
Figure 1.2. Origin of HGSOC. The STIC lesion model is the prevailing theory of HGSOC
carcinogenesis. Serous tubal intraepithelial carcinomas (STICs) arise from the fallopian
tube epithelium (FTE) on the fimbriae of the fallopian tube. STICs are premalignant and
noninvasive but have features that resemble HGSOC including chromosome abnormalities
and perturbations of BRCA1/2, PTEN, and TP53. STICs could develop in the FTE and
progress into malignant HGSOC. Malignant cells could also exfoliate from the site of
origin and transplant into the ovarian surface epithelium (OSE) on the ovary.

6

STICs are premalignant and noninvasive lesions with histological features that
closely resemble HGSOC, such as enlarged nuclei, hyperchromasia, and coarse chromatin
aggregates7,25-27. STICs also have increased genomic instability and tend to possess gene
alterations in BRCA1/2, PTEN, and TP53 – features that are characteristic of
HGSOC6,7,28,29. Paired analyses of HGSOC tumours and STICs from the same patients
have exposed shared genetic alterations including a case in which CCNE1 – the gene
encoding G1/S-specific cyclin E1 – was amplified in both STICs and primary tumours30.
Paired genetic analyses of ovarian and fallopian tube tumours, as well as metastatic
peritoneal tumours from the same patients, have shown that these tumours are
evolutionarily related to STICs31,32. Transcriptional profiling of HGSOC tumours have also
shown similar gene expression patterns between HGSOC and the fallopian tube epithelium
(FTE)33.
Together, these studies provide strong evidence that the most likely origin of
HGSOC may be the FTE. Yet a subset of HGSOC patients present with ovarian but not
fallopian tube involvement34. A new theory suggests STICs could develop in the FTE and
then exfoliate and transplant into the OSE where they can be incorporated into CICs and
be subject to the microenvironment of the ovarian stroma which is more favourable for
neoplastic development as previously described16,34-36 (Figure 1.2). Indeed, the fimbriae
are located on the distal fallopian tube, directly adjacent to the ovary. Novel mouse models
have provided support for this notion that transformed lesions could originate on the
fallopian tubes and transplant into the ovaries35. Mice engineered with targeted mutations
in the FTE give rise to STICs which can later progress to advanced stage HGSOC37. In one
study, 35% of mice with inactivated Brca1, Nf1, Rb1, and Trp53 in the FTE developed
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STICs and more than 65% developed fallopian tube tumours while only 40% developed
ovarian tumours38. Since mutations were only targeted to the FTE, it can be inferred that
the resulting ovarian tumours in these mice were of fallopian tube origin.
Engineered mouse models as described above with targeted mutations in the FTE
have provided valuable insight into HGSOC progression37. In the above study, over 12%
of mice also developed peritoneal tumours and ascites – the accumulation of fluid in the
peritoneal cavity that accompanies late-stage HGSOC and likely caused by impaired lymph
node drainage38. In another mouse model, inactivation of just three genes (Brca1, Pten,
Trp53) in the FTE was sufficient to produce STICs (40%) and subsequent HGSOC
(80%)38. A similar study utilizing a larger cohort of mice with inactivation of Brca1/2 and
Pten combined with overexpression of mutant p53 found over 80% of mice developed
STICs and over 70% had ovarian tumours and peritoneal tumours39. In contrast, several
mouse models engineered to induce STIC formation do not progress to HGSOC or do not
progress to advanced stage HGSOC with peritoneal involvement37. Such models have
revealed further investigation is necessary and question whether STICs are absolutely
critical for HGSOC development.
Although earlier studies sampling women undergoing prophylactic bilateral
salpingo-oophorectomy identified STICs in up to 50% of cases, the most recent clinical
data suggests STICs only occur in less than 12% of high-risk women23,37,40. BRCA1/2
mutations may potentially accelerate the transformation of premalignant STICs into
HGSOC, likely explaining why STICs are found in larger portions among BRCA1/2 mutant
carriers6. However, a study in 2011 of BRCA1/2 carriers diagnosed with early-stage
HGSOC revealed approximately 78% had ovarian tumours while only 21% had fallopian
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tube tumours. In sporadic, non-hereditary HGSOCs (90% of all HGSOCs), the presence of
STICs ranges widely from less than one quarter to almost two-thirds of all cases37. While
the evidence thus far indicates STICs are a risk factor for HGSOC, the absence of STICs
from a majority of HGSOC cases, in conjunction with mouse models that develop STICs
but not advanced stage HGSOC, suggests there is perhaps an as-yet undiscovered
mechanism. The cell of origin for a majority of HGSOC cases remains unclear, and
HGSOC progression – from initiation to peritoneal metastases – is still poorly
understood13,41.

1.3.2

Staging
The majority of women present with late-stage (stage III-IV) HGSOC and have a

poor five-year survival rate of only 25%5,6. In contrast, patients diagnosed at stage I have
a five-year survival rate of 90% as the disease is highly curable at early-stage. The cause
of this significant difference in survival is due to the rapid progression of HGSOC beyond
stage II, involving peritoneal tissue, lymph nodes, and distant organs6. Pathological
evaluation of patients and tumour staging is dependent on tissue biopsies, surveying of
lymph nodes, and assessment of abdominal fluid5. The widely accepted International
Federation of Gynecology and Obstetrics (FIGO) staging system has recently been revised
to reflect the acceptance of Müllerian epithelium-derived tumours with ovarian or fallopian
tube origins42.
In stage I, tumours are confined to one (stage IA) or both (stage IB) ovaries or
fallopian tubes without any tumours on the surfaces of the ovaries or fallopian tubes42,43.
Stage IC indicates the presence of tumours on either surface, ruptured tumour capsules, or
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the presence of malignant ascites42,43. At stage II, tumours develop beyond the ovaries or
fallopian tubes and into the pelvic region, often invading into the uterus or pelvic
intraperitoneal tissues42,43. Stage III indicates tumour invasion into the peritoneal lining
outside the pelvis and may also be accompanied by metastases to the retroperitoneal lymph
nodes (stage IIIA) or involvement beyond the pelvic region (stage IIIB)42,43. Stage IIIC
indicates the presence of metastatic nodules greater than 2 mm and may include liver or
spleen involvement42-44. By stage IV, distant metastases can be observed in organs outside
of the abdominal cavity, including the liver, spleen and lungs42,43. Pleural effusion may
also be present in the lungs and distant lymph nodes outside the abdominal cavity may have
metastases42,43.
The confinement of tumours to the pelvic region in stage I-II HGSOC means
patients are mostly asymptomatic or experience pain or discomforts that are incorrectly
attributed to other ailments5,10,42,45. Although increased awareness and screening has
increased diagnosis at early-stage, the relatively mild early symptoms have contributed to
the problem of the majority of HGSOC cases being diagnosed at late-stage (70%)45. By the
time these women present to the clinic, distant metastases are widespread, often with
numerous tumour nodules in the peritoneal lining and extra-abdominal organs10. The
accumulation of malignant ascites fluid also causes bloating of the abdomen and increases
the pressure exerted on visceral organs which can cause immense pain5,10,28. Moreover,
ascites fluid contains multicellular aggregates of tumour cells – termed spheroids – which
have exfoliated from primary tumours and/or secondary tumours46. The presence of
numerous secondary microscopic lesions and spheroids in ascites fluid complicates
treatment procedures for late-stage patients. Whereas early-stage patients may undergo
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surgical debulking and/or salpingo-oophorectomy, it is difficult to confidently and
precisely remove every secondary lesion in late-stage patients. Additionally, spheroids may
act as a source of recurrence and reseed disease in patients following surgical procedures47.
The heterogeneity of HGSOC, and indeed the diversity between all ovarian cancer subtypes
as a whole, have made development of successful and reliable screening strategies difficult.
Therefore, there is an urgent need to improve outcomes for late-stage patients.

1.3.3

Dissemination & metastases
The majority of cancer-related deaths are due to the metastatic spread of the primary

tumours and this is especially true for HGSOC48-50. When women present with late-stage
HGSOC, widespread metastatic disease within the peritoneal cavity has already taken
shape whereby rapidly growing tumour nodules obstruct organs and lead to ascites
formation15. Organ obstruction and cachexia is the leading cause of patient mortality51.
HGSOC metastases are unique to the disease and does not follow the paradigms observed
in other metastatic cancers. The rapid progression towards metastatic disease in HGSOC
patients and the challenges in treating such patients necessitates an understanding of
HGSOC dissemination and metastases.
Compared to metastasis of other cancers, HGSOC metastasis is poorly
understood15. Unlike other cancers, HGSOC predominantly disseminates within the
peritoneal cavity instead of hematogenously. This occurs through a passive process, termed
transcoelomic metastasis, by which tumour cells exfoliate from primary tumour sites and
are carried to distant sites by the physiological flow of peritoneal fluid without a
requirement to invade and extravasate from vasculature52 (Figure 1.3A). Without any
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anatomical barriers between the female reproductive system and visceral organs, there is
nothing to occlude transcoelomic metastasis events52. Once they are detached, the cells
circulate within the peritoneal fluid and reattach to new sites and tend to favour, but are not
limited to, the peritoneal lining and omentum52 (Figure 1.3B). Almost all HGSOC patients
with metastases have tumours implanted on the omentum, a fatty pad covering the
abdominal cavity and bowel15,52. HGSOC tumour cells only reattach and invade the
mesothelium which is a layer of epithelial cells covering the surface of visceral organs, the
omentum, and the diaphragm15,53. Once colonized, secondary HGSOC tumours do not
invade beyond the surface of affected tissues6,15.
Before HGSOC tumour cells exfoliate from the primary tumour, they undergo
epithelial-to-mesenchymal transition (EMT) to aid in disruption of cell-cell attachments
that bind the tumours to the basement membrane47,54. During this event, a “cadherin
switch” occurs whereby the cells downregulate expression of CDH1 (E-cadherin) and
upregulate CDH2 (N-cadherin) and CDH3 (P-cadherin)47,55. Loss of the cell adhesion
factor E-cadherin with a concomitant increase of matrix metalloproteases (MMPs) disrupts
anchoring of the cells to the solid tumour mass and allows the cells to shed47. Recent liveimaging revealed that HGSOC tumour cells shed from primary tumours either as single
cells or in clusters. However, the majority of single cells died due to detachment from the
basement membrane whereas multicellular clusters – called spheroids – survived56. Indeed,
in vitro studies have shown that spheroid formation allows disseminated HGSOC tumour
cells to survive anoikis (anchorage deprivation) and remain in suspension for long periods
of time6,15,57. Multicellular spheroids float in suspension as they are passively circulated
within the peritoneal cavity by the physiological peritoneal fluid and they maintain a
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Figure 1.3 Dissemination and metastases of HGSOC
Figure 1.3. Dissemination and metastases of HGSOC. (A) Cells from the primary
tumour can exfoliate from the solid tumour and shed into the peritoneal fluid. Cells may
detach as single cells or in multicellular clusters called spheroids. Single cells cannot
survive anchorage-independent conditions and undergo cell death due to anoikis. Spheroid
cells can survive anchorage deprivation and are carried by the peritoneal fluid (ascites
fluid) to distant sites. Invasive spheroids can them embed into the mesothelium of new sites
and colonize the new tissue surface. The omentum (subsection shown) is a common site
for HGSOC metastases. (B) Spheroids cells (red) are carried throughout the peritoneal
cavity by the natural flow of ascites fluid (green arrows). Spheroid cells may circulate
within ascites for prolonged periods before encountering a new surface to colonize.
Spheroid cells can reattach to new mesothelial surfaces to form metastatic tumours (black).
Some common metastatic sites include the bowels, liver, diaphragm, lungs, and omentum
(not shown).
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mesenchymal phenotype with low E-cadherin and high N/P-cadherins52,54,58. Reduced Ecadherin expression in disseminated tumour cells compared to the primary HGSOC tumour
correlates with increased invasiveness and poor survival among patients47.
The vast majority of HGSOC patients present with an accumulation of fluid in the
peritoneal cavity, known as ascites, which often accompanies the presence of spheroids47.
The accumulation of ascites can be attributed to several factors such as poor drainage of
lymphatics due to obstructions by spheroids, or increased vascular permeability due to an
increase of vascular endothelial growth factors (VEGFs) secreted by normal and tumour
cells59. Reduced reabsorption of fluid through mesothelium and increased peritoneal
oncotic pressure can also lead to accumulation of ascites47. It is not known at which stage
of disease ascites develops – whether it is an early event required for HGSOC metastasis
or if it is a hallmark of late-stage disease – but clinical observations from patients suggests
the latter, and its presence signifies poor prognosis52. This is primarily because ascites
facilitates the spread of metastatic disease by disseminating malignant spheroids as
previously mentioned (section 1.3.2). Ascites also contains several acellular factors that
promote survival of spheroid cells and enhances growth of secondary tumours, including
mitogens, immune cells, cytokines, and soluble extracellular matrix (ECM) proteins60.
These factors have been found to vary with HGSOC stage with more advanced HGSOC
disease correlating with higher concentrations of factors in ascites. Factors such as
mitogens and cytokines are not only secreted by normal cells but also by tumour cells,
which greatly exacerbates the pro-survival, pro-proliferative, and pro-angiogenic
peritoneal environment while suppressing immune response60. Adipocytes in the omentum
also secrete cytokines, namely interleukins including IL-6 and IL-8, which can contribute
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to spheroid invasion of the omentum. IL-6 activates the JAK/STAT pathway and AKT
phosphorylation leading to pro-growth and anti-apoptotic signaling cues in spheroid
cells61. Increased IL-6 expression is indicative of chemoresistance and poor prognosis.
Similarly, increased concentration of VEGF ligands in ascites improves spheroid cell
survival and correlates with poor patient outcomes28. VEGFA binding to VEGFR2
receptors found on spheroid cells protects the cells from anoikis15. Ascites fluid also
upregulates the expression of CD44, a cell surface glycoprotein, increasing the migratory
and invasive properties of spheroid cells that facilitates implantation into new peritoneal
surfaces15. Ascites fluid is therefore part of the active tumour microenvironment (TME)
for tumour cells and spheroid cells alike and is a challenging component of HGSOC
dissemination and metastases.
Following dissemination, spheroid cells undergo a coordinated process consisting
of intricate steps involving ECM proteins, transcriptional changes, and mesenchymal-toepithelial transition (MET) to colonize the mesothelium of distant sites47. Integrins
facilitate reattachment of suspended spheroid cells to new mesothelial surfaces through
interactions with collagen type I/IV, laminin, and fibronectin, as well as CD44-binding
hyaluronan54. Upregulation of E-cadherin, even while N/P-cadherin expression is high, can
also promote adhesion in a subset of “hybrid” epithelial/mesenchymal spheroid cells15. The
hybrid epithelial/mesenchymal phenotype provides added survival benefits in suspension
and promotes chemoresistance54,58. Once attached to the mesothelium, spheroid cells
initiate mesothelial clearance through several MMPs, integrins, and myosin-mediated force
to remove adjacent mesothelial cells62. Mesothelial clearance is improved in spheroid cells
expressing mesenchymal markers or EMT transcriptional profiles and inhibition of these
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markers, such as TWIST1 or ZEB1, decreases clearance activity63. Spheroid cells then
undergo MET to revert to an epithelial phenotype that promotes proliferation and growth
of the new tumour54,58. Additionally, primary cells isolated from patient ascites and
cultured in vitro are able to maintain their spheroid-forming capacity and with no
discernible differences to spheroids found in vivo64.
The present understanding of HGSOC tumour exfoliation, aggregation into
spheroids, and implantation at distant sites is limited, but clinical observations, cell culture
models, and pre-clinical mouse models have provided substantial evidence that spheroids
play a crucial role in the dissemination and metastases of HGSOC. Spheroids present many
challenges to therapy and is an important area of study if HGSOC patient outcomes are to
be improved.

1.3.4

Preclinical models of ovarian cancer
A study in 2013 that characterized the ovarian cancer cell lines used at the time

revealed that the two most commonly used cell lines (SKOV3 and A2780) accounted for
approximately

60%

of

publications65.

Unfortunately,

comparative

genomic

characterization of these cell lines with the TCGA data published in 2011 revealed that
these two lines, along with others, were not representative of HGSOC65-67. This study led
to a shift in experimental design to favour cell lines that more accurately represented the
disease6. Moreover, it encouraged the development of patient-derived primary cell lines6.
Several institutions across the world now use patient-derived HGSOC cells for both in vitro
cell culture and in vivo xenograft studies68. Not only do ascites-derived cells represent the
genomic landscape that characterizes HGSOC, such as TP53 mutation and chromosome
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rearrangements, they also more closely represent clinically observed chemoresistance to
platinum treatment68-70.
Several in vitro models have been employed to investigate HGSOC spheroid
formation and metastases. These models use either cell lines or patient-derived primary
cells to investigate spheroid cells in a three-dimensional ex-vivo environment71. In a
fallopian tube model that recapitulates the FTE, fallopian tube secretory and ciliated
epithelial cells isolated from fallopian tube fimbriae were co-cultured with on a collagen
type IV-coated substrate to study stress response and carcinogenesis72. Another method
cultured fallopian tube secretory epithelial cells on specially-coated plates to resemble the
FTE ECM and induce spheroid formation71. The hanging drop method has also been used
to induce spheroid formation73. In contrast, the in vitro data presented herein employs a
three-dimensional model that recapitulates HGSOC spheroid dissemination found in
vivo64. HGSOC cell lines or ascites-derived HGSOC cells are cultured in ultra-low
attachment (ULA) plates which are coated in a neutrally charged, non-ionic, covalentlybound hydrophilic hydrogel (Figure 1.4). When transferred from adherent or monolayer
conditions to ULA plates, HGSOC cells remain in suspension and spontaneously form
spheroids57,64. These spheroids can then be incubated in suspension conditions for extended
periods before being transferred to regular plasticware to facilitate reattachment. Hence
this process recapitulates spheroid formation and reattachment to a new surface and allows
for the investigation of metastases in a controlled in vitro environment64. Ascites-derived
spheroid aggregates formed using this method have been shown to histologically and
morphologically resemble those found in vivo64. HGSOC cell lines and ascites-derived
spheroids can also be transplanted intraperitoneally into xenograft mice to recapitulate

17

Figure 1.4 In vitro model of HGSOC spheroid dissemination
Figure 1.4. In vitro model of HGSOC spheroid dissemination. HGSOC cell lines or
ascites-derived HGSOC cells can be cultured in vitro in regular plasticware under
monolayer or adherent conditions. This recapitulates pro-growth conditions as in the
primary solid tumour. When these cells are collected and transferred to suspension
conditions established using ultra-low attachment (ULA) plates, the cells spontaneously
form spheroids without any further stimulation and resemble spheroids formed in vivo in
patients. Spheroid cells can be cultured in ULA plates for prolonged periods to investigate
spheroid biology. These spheroids can then be collected and transferred to regular
plasticware to enable reattachment under adherent conditions. In this way, spheroid
formation and reattachment can be investigated in vitro.
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dissemination and metastases in vivo74. These spheroids invade much of the same tissues
and organs observed clinically in patients74. Xenograft mice will even develop ascites
which can be collected to extract disseminated tumour cells and TME factors 75.
Unfortunately, many of the HGSOC cell lines deemed to represent clinical HGSOC with
high genomic fidelity do not grow well following intraperitoneal transplantation in nude
mice. These cell lines require severe combined immunodeficient (SCID) or NOD/SCID/
IL2rγnull (NSG) mice which do not allow for the investigation of immune cell contributions
to HGSOC76.

1.3.5

Summary of HGSOC
HGSOC is the most common type of ovarian cancer5,6. In the large majority of

cases, women present to the clinic at an advanced stage in which the disease has spread
beyond the primary tumour and into the peritoneal cavity, affecting multiple tissues and
organs. Metastases of HGSOC tumour cells are unique in that they rarely metastasize
hematogenously. Instead, tumour cells can exfoliate from solid tumours and shed directly
into the peritoneal fluid. These tumour cells then aggregate together to form multicellular
clusters called spheroids. The formation of spheroids allows the cells to survive in
suspension conditions. Spheroids are carried by the physiological peritoneal fluid to distant
sites where they invade the mesothelium to form secondary lesions. The accumulation of
peritoneal fluid, called ascites, accompanies the presence of spheroids. It is not clear at
which stage of the disease ascites develops, but it signifies poor prognosis. Ascites fluid
contains several factors that promote survival, chemoresistance, and invasiveness of
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spheroid cells. Several in vitro and in vivo models of ovarian cancer have been developed
to recapitulate the phenomenon of spheroid dissemination.

1.4 Genomic & transcriptomic characterization of HGSOC
1.4.1

Recurrent mutations & alterations
A landmark study by The Cancer Genome Atlas (TCGA) in 2011 uncovered the

invariable heterogeneity present across all HGSOC cases and provided the first broad
insights on the relatively few gene alterations shared across patients compared to other
cancers67,77. Many genes and pathways are disrupted in HGSOC and the most common are
shown in Figure 1.5. A predominant gene found to be mutated almost universally across
all HGSOC cases is the TP53 tumour suppressor gene77,78. TP53 mutations have also been
discovered in STICs, suggesting that TP53 mutations may potentially be early driver events
for HGSOC development31. TP53 mutations found in HGSOC patients can be
characterized as missense (70.4%), nonsense (8.67%), frameshift (12%), or splice
mutations (5.1%)79. The vast majority of these mutations, approximately 80%, are found
on the DNA-binding domain (DBD) of p5379,80. These mutations can be translated into
altered p53 protein structure, either through truncations or misfolding, causing loss of
function, gain of function (oncogenic), or dominant negative phenotypes81. Mutant p53 is
also more stable than wild type p53 because it can no longer bind to MDM2/4 and evades
protein degradation82. Stabilizing p53 mutations in fallopian tube secretory epithelial cells
improves survival in suspension conditions83. Missense mutations such as R273H, R175H,
and R248Q can also lead to more aggressive and invasive phenotypes84. Studies have
therefore shown that the type and location of TP53 mutations can have an effect on patient
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Figure 1.5 Most common gene & pathway alterations in HGSOC
Figure 1.5. Most common gene & pathway alterations in HGSOC. TP53 mutations are
almost universal in HGSOC with 96% of tumours carrying mutant p53. While other genetic
mutations in individual genes are not as prevalent, cellular pathways are widely disrupted
across HGSOC. Disrupted pathways include: RB pathway (67%), PI3K/AKT/mTOR
pathway (45%), Homologous recombination (HR)-mediated DNA repair pathway (50%),
and the Notch signaling pathway (22%). Of particular note are the prevalence of BRCA1/2
(15-0%) mutations in HGSOC. BRCA1/2 mutations (20%) are the most common form of
DNA repair pathway disruption in HGSOC.
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outcomes85,86. Patients with mutations in the DNA major groove interacting residues of
p53 have improved overall survival (OS) compared to those with mutations in the DNA
minor groove interacting residues85. Specific oncogenic TP53 mutations can also be used
to stratify HGSOC patients with chemoresistant or recurrent tumours87,88. Aberrant p53
function may also occur through amplification of MDM2/4 caused by copy number
alterations since MDM2/4 are required for normal p53 equilibrium80. The broad spectrum
of mutations found in TP53 alone reflect the heterogeneity present in HGSOC.
Beyond TP53, the next most commonly mutated genes in HGSOC are BRCA1 and
BRCA2, although their occurrence is not universal as TP53 mutations66,89. The
contributions of germline BRCA1/2 mutations to EOC are clear and this led to the
development of prophylactic bilateral salpingo-oophorectomy19,89-92. BRCA1 and BRCA2
function in the DNA repair pathway and homologous recombination (HR)93,94. When
double-stranded DNA breaks occur during DNA replication, HR provides cells with a
reliable error-free mechanism to repair breaks95. When this pathway is impaired, cells
revert to non-homologous end joining (NHEJ) which is error-prone and can lead to
genomic instability and carcinogenesis, most notably ovarian cancer or breast cancer93-95.
BRCA1 also plays a role in cell cycle control, mitosis, chromatin remodeling, and
transcriptional regulation96-98. While inheriting mutant BRCA1 or BRCA2 alleles increases
the risk of developing ovarian cancer (44% for BRCA1; 11-27% BRCA2), only 15-20% of
HGSOC cases have germline or somatic BRCA1/2 mutations66,99-103. A broader search
inclusive of all HR-mediated DNA repair pathway members reveals even more recurrent
mutations. These genes include ATM, ATR, BARD1, BRIP1, CDK12, CHEK2, MRE11A,
PALB2, PTEN, RAD50, RAD51 paralogs (RAD51B, RAD51C, and RAD51D), and the

22

Fanconi anemia genes5,6,99,104-108. Collectively, mutations in genes required for HRmediated DNA repair can be found in at least 50% of all HGSOC cases66. The involvement
of these genes suggests that while BRCA1/2 may not account for a majority of HGSOC
cases, alterations in the HR-mediated DNA repair are frequently found in HGSOC and
contributes to the genomic instability and heterogeneity of the disease6,66.
Less frequent recurrent mutations involve CSMD3 (6%), CDKN2A (2%), FAT3
(6%), NF1 (11%), and RB1 (10%)6,66,99,109. The roles of CSMD3, FAT3, and NF1 in
HGSOC are not clear but their mutations have also been detected in other cancers110-116.
FAT3

and

NF1

may

potentially

act

as

tumour

suppressors

or

mediate

chemoresistance113,116,117. Despite the low prevalence of direct RB1 or CDKN2A mutations,
retinoblastoma (RB) pathway disruption is common in HGSOC, occurring in
approximately 67% of cases66. Cyclin-dependent kinases (CDK), namely CDK4/6,
phosphorylate and inactivate RB protein which releases it from E2Fs and enables
transcriptional activity of E2F target genes, including BRCA1118-120. The CDK/cyclin-RBE2F axis functions in cell cycle control and alterations can amount to dysfunctional
proliferation. CDKN2A encodes p16INK4A which is a negative regulator of CDK4/6 and acts
to suppress the G1/S transition118,119,121. In contrast, alterations in genes that promote the
G1/S transition are more common, including CCNE1, CCND1, and MYC, and are each
found in over 20% of HGSOC tumours66. CCND1 encodes cyclin D1 which activates the
aforementioned CDK4/6. CCNE1 encodes cyclin E1 which similarly promotes G1/S
transition by activating CDK2122,123. CCNE1 is found on the 19q12 locus which is
susceptible to copy number alterations in EOC13,124,125. An in vitro study showed that
CCNE1 knockdown in HGSOC cells resulted in G1 arrest and reduced viability but only
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in cells with 19q12 amplification124. Another study showed that high CCNE1 expression,
with or without 19q12 amplification, can be used to stratify patients by genomic instability,
response to chemotherapies and OS126-128. Overexpression of CCNE1 combined with a
missense mutation in TP53 in fallopian tube secretory epithelial cells increases
proliferation and resistance to anoikis30,129. Interestingly, HGSOC patients with amplified
CCNE1 typically have intact HR-mediated DNA repair pathway genes, including BRCA1
and BRCA2, indicating that gain of CCNE1 may be a unique early driver event in HGSOC
tumorigenesis13. Indeed, concomitant increase of CCNE1 transcription and cyclin E1
protein levels have been found in precursor STICs129-131. Additionally, a synthetic lethality
screen identified HR-mediated DNA repair components are essential in HGSOC cell lines
with 19q12 amplification132. This suggests genomic instability caused by 19q12
amplification and HR-mediated DNA repair are mutually exclusive and at least one of these
pathways must be retained for tumour cell survival13. These data demonstrate that although
recurrent alterations in CDK/cyclin-RB-E2F axis members occur at low frequency
compared to TP53 or BRCA1/2, their alterations are collectively found in a large majority
of HGSOC cases13,66. Analogous to the diversity of alterations found in HR-mediated DNA
repair genes, the variety of alterations in CDK/cyclin-RB-E2F axis members demonstrate
the heterogeneity that is widely apparent in HGSOC.
Recurrent mutations and copy number alterations found in other pathways include
FOXM1 (87%), PI3K/Ras (45%), and Notch (22%)66. Normally, p53 is a negative
regulator of FOXM1, a transcription factor that regulates G2/M-specific genes133.
Consequently, overactivation of the FOXM1 pathway may be a result of mutant p53 in
these cases. Amplification of PI3K/Ras components, including PIK3CA and AKT, correlate
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with reduced OS66,134,135. PTEN loss or decreased PTEN expression has been observed in
50-75% of cases136. Overall, PI3K/Ras alterations increase proliferation of tumours and
decrease response to chemotherapies135,137,138. The majority (50%) of Notch alterations
were found in NOTCH3, encoding the Notch3 receptor, and a recent study has implicated
a ligand encoding gene, DLK1 to have an important role in EMT and metastases66,139,140.

1.4.2

Genomic & transcriptomic subtyping
The variety of these mutations characterizes the genetic diversity present in

HGSOC. Advances in genomic and transcriptomic sequencing technologies have greatly
added to the current understanding of HGSOC and several groups have attempted to stratify
HGSOC as subtypes based on genomic or transcriptomic signatures141,142. The first of these
studies defined four distinct subtypes of HGSOC: C1-mesenchymal, C2-immunoreactive,
C4-differentiated, and C5-proliferative142. C1 had gene expression relating to ECM
proteins, cell adhesion, and angiogenesis and is associated with poor patient outcomes31,142.
Both C2 and C4 had some overlapping expression of genes involved in immune cell
activation with the latter also having reduced stromal response; both have better patient
outcomes31,142. C5 had the worst patient outcomes and expressed mesenchymal genes with
increased cadherin signaling and low immune expression31,142. The reduced survival
exhibited by patients with C1 or C5 tumours displaying mesenchymal activity can
potentially be attributed to increased aggressiveness and chemoresistance sustained by
spheroids.
This subtyping method is now widely accepted and other groups have confirmed
its findings, however, recently a new “anti-mesenchymal” subtype has been proposed to
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address the heterogeneity in the C4-differentiated cluster, demonstrating the continued
evolution of our current understanding of HGSOC141,143. The nature of peritoneal
dissemination onto multiple sites further adds to the genomic and transcriptional
complexities as stroma signatures and immune signatures of the TME confound such
analyses144. This was exemplified by a recent study in which PTEN loss was found to be a
common driver event in 36% of the TCGA HGSOC cohort whereas the original 2011 study
only found PTEN loss in 6% of cases66,136. This study used a novel computational approach
to correct PTEN expression bias caused by tumour stroma136. Novel computational
approaches are therefore necessary to obtain prognostically valuable data from complex
studies confounded by heterogeneity144.

1.4.3

Copy number alterations & signatures
Copy number alterations are universally pervasive in HGSOC. An in-depth

computational study in 2018 analyzing 117 HGSOC cases demonstrated that patients can
also be stratified by copy number signatures, ranging from 1 to 7145. In this study,
Macintyre et al. linked unique copy number signatures to the underlying mechanisms, such
as breakage-fusion-bridge events due to telomere shortening and oncogenic Ras/MAPK
(mitogen-activated protein kinase) signaling in copy number signature 1; or impaired cell
cycle control amounting to focal amplification in copy number signature 6145. Copy number
signature 6 also displayed the largest copy number changes among all patients (8-30
copies) and included amplifications in CCNE1, CCND1, CDK2, CDK4, or MYC as well as
deletion or inactivation of RB1 or CDK12145. Patients in this cohort were also more likely
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to have mutations in Toll-like receptor signaling and PI3K/AKT signaling145. This study
highlighted the heterogeneity across HGSOC patients.
High-throughput genomic studies have revealed that heterogeneity not only exists
across patients, but also within individual patients in the form of intratumoural
heterogeneity (ITH)146-148. Chromosomal instability and tumorigenesis directed by early
oncogenic driver events stimulates additional gene alterations that confer selective
advantages149-151. This leads to subclones within the same tumour that are genetically
distinct but have overlapping alterations152. The burden of multiple mutations, especially
in HR-mediated DNA repair genes, can lead to loss of essential functions in some cases
and increase sensitivity to chemotherapy as observed in patients with germline BRCA2
mutations153-156. However, genomic instability and ITH can also give rise to chemoresistant
tumour cell populations150,151. Several studies have shown that both spatial and temporal
ITH play a role in HGSOC progression and metastases. One study found that alterations in
oncogenic driver genes (CTNNB1, NF1, PDGFR, PIK3CA, RBM15, and SH3GL1) existed
only in spatially separated subclones157. Another study highlighted that spatial and
temporal ITH can exist at the time of late-stage diagnosis and before initiation of
chemotherapy158. A retrospective computational study demonstrated that the degree of
clonal expansion can vary following chemotherapy, and patients with increased clonal
expansion have shorter survival and are at increased risk of developing chemoresistant
HGSOC recurrence146. The barrier-free dissemination of HGSOC spheroids into the
peritoneal cavity may potentially accelerate ITH clonal expansion at secondary sites.
Therefore, genomic and transcriptomic characterizations of primary HGSOC tumours
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alone may not be sufficient to stratify tumours since late-stage diagnosis can present in
concert with ITH and varying degrees of clonal expansion152.

1.4.4

Summary of HGSOC genomics
The aneuploidy and heterogeneity are indisputable hallmarks of HGSOC66. Unlike

other cancers, frequent recurrent genetic alterations are low, but several pathways are
known to be commonly altered in HGSOC patients allowing for genomic or transcriptomic
clustering and subtyping66. The genomic characterization presented herein reveals that
multiple combinations of signaling pathways may be driving HGSOC progression with
few unifying features across patients. This heterogeneity has made the development of
effective therapies challenging. Several pathways may be simultaneously impaired and
inhibition of one means the tumour cells are able to bypass inhibition through another
pathway. It may also be likely that specific mutations are not widespread across the
majority of HGSOC patients – as implied by the low frequency of recurrent mutations –
limiting the broad application of potential targeted inhibitors limited. However, despite the
inherent and invariable genomic instability that persists in all HGSOC cases, tumour cells
must still retain function of essential genes, particularly those that facilitate EMT/MET,
mesothelial clearance, angiogenesis, immune evasion, chemoresistance – and in the case
of spheroid cells – genes that allow for multicellular aggregation and protection from
anoikis in suspension conditions. The mechanisms entailing widespread peritoneal
dissemination – which afflicts the vast majority of HGSOC patients – shares a common
route: spheroid dissemination through physiological peritoneal fluid (ascites). Therefore,
understanding the biology of spheroids is critical to HGSOC etiology. There may
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potentially be specific essential genes or processes during spheroid formation and
dissemination that can be targeted to improve the current standard of care despite genetic
diversity. Treatment of HGSOC and the role of spheroids in tumour recurrence will be
explored in subsequent sections.

1.5 Treatment of HGSOC and chemoresistance
1.5.1

Surgery & chemotherapy
Upon diagnosis of HGSOC, a patient is referred for cytoreductive surgery5.

Depending on the aggressiveness of the cancer at the time of diagnosis, this procedure
seeks to debulk the tumour burden by removing all macroscopic tumours and may include
peritonectomy, omentectomy, and en bloc resection of the viscera5. It is challenging to
achieve complete removal of all macroscopic residual disease in advanced stage patients159.
The presence of 1 cm residual disease following surgery is considered “optimal”; >1 cm
residual disease is “suboptimal”5. Late-stage patients that receive complete tumour
debulking without any residual disease have significantly better outcomes following
chemotherapy compared to “optimal” late-stage patients160,161. Late-stage “optimal”
patients have increased progression-free survival (PFS) than “suboptimal” late-stage
patients160-162.
The standard HGSOC adjuvant chemotherapy for the last 20 years has been a
platinum-taxane polytherapy consisting of either cisplatin or carboplatin in combination
with paclitaxel or docetaxel163-167. There have been attempts to improve this treatment
regimen by varying the delivered dose-density or mode of delivery, such as intraperitoneal
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delivery but clinical trials have shown reduced patient tolerability and limited
improvements in OS or PFS159,168,169. For example, while intraperitoneal delivery of
cisplatin increases the peritoneal concentration of cisplatin leading to improved OS and
PFS, toxicity was also found to increase which has restrained adoption of the
technique168,169. Patients unable to endure cytoreductive surgery will instead receive
neoadjuvant chemotherapy where they undergo the first half of chemotherapy, followed by
cytoreductive surgery, and finally the remainder of the chemotherapy170,171. Clinical trials
have shown that neoadjuvant chemotherapy followed by cytoreductive surgery has similar
OS and PFS to primary cytoreductive surgery followed by adjuvant chemotherapy170,171.
Importantly, neoadjuvant chemotherapy reduced the number of postoperative deaths,
suggesting its usefulness for critically ill patients171. Regardless of the method employed –
adjuvant or neoadjuvant chemotherapy – the goal of HGSOC treatment is to mitigate the
symptoms with palliative care to prolong survival of patients.

1.5.2

Relapse
Relapse is a challenging and – especially for advanced-stage patients – a defining

feature of HGSOC. Over 70% of patients with HGSOC respond positively to cytoreductive
surgery in combination with adjuvant or neoadjuvant chemotherapy51. Unfortunately, over
80% of these patients will experience relapse5. Recurrent HGSOC is generally considered
to be incurable5. It occurs asymptomatically in most patients and imaging-based detection
methods routinely fail to identify residual disease in the months following first-line
chemotherapy5. Relapse is usually detected by increased serum levels of cancer antigen
125 (CA125), a peptide secreted by HGSOC cells172,173. However, relapse can occur
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without increased levels of CA125 and CA125 alone is not sufficient to initiate secondline therapy. A study comparing delayed second-line treatment (initiated at the onset of
observable symptoms) to early second-line treatment (initiated upon high CA125
detection) showed no significant improvements in OS174. Approximately half of recurrent
patients present with chemoresistance5. Patients with recurrent disease who respond well
to second-line chemotherapy also face challenges as the burden of additional chemotherapy
regimens reduces quality of life and affects the overall efficacy of treatment5,175. With each
recurrence, the sensitivity to chemotherapy decreases significantly; a study found that
second-line chemotherapy had clinical response in 52% of patients compared to only 12%
in third-line chemotherapy5. Ultimately, 90% of advanced-stage patients develop platinumresistance during the course of the disease34.
Treatment of recurrent HGSOC is guided by sensitivity to chemotherapy which is
determined by a patient’s platinum-free interval (PFI) – the time between the end of firstline chemotherapy and the onset of relapse5. The PFI has been shown to have prognostic
value5,176-179. A short PFI (<6 months) indicates platinum-resistant recurrent disease and
poor outcomes177. A PFI greater than 12 months is considered to be very platinum-sensitive
with potentially improved PFS180. Second-line chemotherapy for platinum-sensitive
recurrent disease is generally the same as first-line therapy, but may include additional
options such as pegylated liposomal doxorubicin (PLD)181,182. Platinum-resistant disease is
more challenging as chemotherapy options are limited, but various combinations are now
available with the advent of targeted therapies.
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1.5.3

Targeted therapies
The use of targeted therapies seeks to exploit vulnerabilities of HGSOC cells to

create synthetic lethality. DNA damage response pathways have become an attractive
target since they are impaired in 50% of all HGSOC cases, with 15-20% of patients
harboring mutations specifically in BRCA1/2 which are involved in HR-mediated DNA
repair66,183. Cells with impaired HR-mediated DNA repair must rely on base excision repair
(BER) or error-prone NHEJ to repair damaged DNA184. A major component of BER is
poly (ADP-ribose) polymerase (PARP), which binds directly to DNA to initiate
repair185,186. Inhibition of PARP with PARP inhibitors (PARPi), especially in cells
deficient for HR-mediated DNA repair, promotes error-prone NHEJ which increases
genomic instability and ultimately leads to apoptosis185,187. Clinical trials have investigated
the use of PARPi (niraparib, olaparib, rucaparib, and veliparib) in combination with
chemotherapy to treat HGSOC188-190. Olaparib is the most studied and early clinical trials
showed increased PFS in recurrent HGSOC with BRCA1/2 mutations159,189,191-194. It has
also been shown to be more effective in these patients compared to PLD. A phase II trial
found olaparib was also effective at improving PFS in 50% of patients with BRCA wild
type recurrent HGSOC, however the response was significantly lower (4%) in platinumresistant recurrent disease195,196. Rucaparib and niraparib have been approved for use as
maintenance therapy for both platinum-sensitive and platinum-resistant patients regardless
of BRCA1/2 status due to beneficial improvements in PFS197-199. Veliparib was recently
evaluated for its efficacy as a first-line therapy in conjunction with platinum-based
chemotherapy200. The combination, followed by veliparib maintenance therapy, improved
PFS compared to chemotherapy alone200. Overall PARPi have now been approved as first-
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line or maintenance therapy for patients with recurrent disease as clinical data reveals
improvements in PFS but not in OS201.
IL-6, which activates the JAK/STAT pathway and AKT phosphorylation as
previously discussed (section 1.3.3), contributes to spheroid dissemination in the peritoneal
cavity and chemoresistance202,203. Phase I and II clinical trials evaluated siltuximab (a
monoclonal antibody targeting IL-6) for its potential as a therapy for recurrent HGSOC but
it had limited benefit and did not improve overall survival (OS)204,205. Similarly, increased
concentration of VEGF ligands in ascites improves spheroid cell survival and correlates
with poor patient outcomes206. VEGFA binding to VEGFR2 receptors found on spheroid
cells protects the spheroids from anoikis and facilitates angiogenesis during invasion15.
Bevacizumab (a monoclonal antibody targeting VEGFA) has been approved for use in latestage and recurrent HGSOC in combination with first-line chemotherapy to improve PFS
although it had no effect on OS206,207. Other anti-angiogenic therapies that target the VEGF
pathway and related receptor tyrosine kinases have also been evaluated and they have
shown analogous improvements in PFS but not OS208.
Targeted therapies have undoubtedly provided benefits to HGSOC patients6.
Numerous clinical trials have demonstrated that pairing second-line and third-line
treatments with targeted therapies can improve PFS in patients. However, even these novel
combinations have failed to achieve meaningful improvements in OS. In 2010 it was
unanimously agreed that PFS is the preferred measurable endpoint and the aim of treatment
should be to palliate symptoms and delay the inevitable relapse in advanced-stage HGSOC
patients207,209. The combination of tumour heterogeneity, aneuploidy, and peritoneal
dissemination contribute to chemoresistance which makes treating HGSOC a challenge.
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1.5.4

Chemoresistance
Retrospective studies have shown that chemoresistance in HGSOC can manifest as

intrinsic resistance or acquired resistance210. In both cases, the invariable ITH and genomic
instability play a significant role in the failure to manage the disease. As previously
discussed (section 1.4.3), patients may present with spatial and temporal heterogeneity at
the time of late-stage diagnosis and may already have platinum-resistant tumours (intrinsic
resistance)210. Alternatively, during first-line or subsequent (second-line or third-line)
therapies, clonal expansion may also give rise to advantageous populations of HGSOC
cells which can evade chemotherapy and become platinum-resistant (acquired
resistance)152,210. Therefore, the ITH and genomic instability present several opportunities
for chemoresistant niches to form, either on already established primary tumour sites or on
distant metastases propagated by disseminated HGSOC spheroids152. The mechanisms
whereby HGSOC cells achieve acquired resistance in HGSOC are aided by DNA repair
pathways, the TME, or disseminating spheroid cells210.
Compared to patients with wild type BRCA genes, patients with BRCA1/2
mutations respond better to platinum-based chemotherapy and this also translates to better
prognosis152. Out of the 15-20% of HGSOC cases that have germline or somatic BRCA1/2
mutations, 73% occur in platinum-sensitive patients66. This data correlates well with
clinical trials for PARPi in which olaparib combined with chemotherapy improved
platinum sensitivity, suggesting that HR-mediated DNA repair plays a role in
chemoresistance190,191,193,195,196. In the presence of platinum-based chemotherapy drugs that
crosslink DNA, cells that maintain the ability to efficiently repair damaged DNA will avoid
apoptosis and progress though the cell cycle while cells deficient for adequate DNA repair
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will undergo programmed cell death211. The role of DNA repair pathways in
chemoresistance is emphasized in BRCA1-deficient patients with recurrent tumours that
had undergone reversions to restore BRCA1 function following first-line chemotherapy212.
The TME for HGSOC is unique in that it is composed of the peritoneal cavity and
all of its constituents, including immune cells, ECM proteins, secreted ligands and growth
factors, vasculature, the omentum, and – in advanced-stage HGSOC patients – the ascites
fluid which acts as a medium for peritoneal spheroid dissemination. Immune cells such as
tumour-associated macrophages (TAMs) and tumour infiltrating lymphocytes (TILs) can
affect chemoresistance as well as HGSOC recurrence213-216. One study performed
transcriptomic profiling of paired primary and recurrent tumours from platinum-sensitive
recurrent HGSOC patients and showed that tumours clustered as “immune active” or
“immune silent” based on expression of immune-related genes217. Other studies have
revealed the balance of CD8+ TILs and regulatory T cells (Tregs) is related to patient
survival218-220. The concentration of TAMs and interleukins (IL-6 and IL-10) have been
shown to be inversely proportional to patient survival; higher levels of these interleukins
and CD163+ TAMs are correlated with chemoresistance and relapse221. Additionally, the
previously discussed transcriptomic-based subtyping of HGSOC patients (section 1.4.2)
demonstrated that patients with low immune expression (C1 and C5 subtypes) have poor
survival outcomes142. These studies demonstrate the TME may have a role in
chemoresistance and relapse.
The ascites fluid contains another major source of chemoresistance and relapse in
patients: multicellular spheroid cell aggregates47. These free-floating three-dimensional
aggregates are complexes of exfoliated HGSOC cells. Spheroids present several
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advantages relative to exfoliated HGSOC cells: aggregated spheroid cells survive longer
in anchorage-independent conditions compared to single cells, the three-dimensional
nature of spheroids inhibits drug penetration, and spheroids cells escape DNA-damaging
chemotherapy agents by exiting the cell cycle and entering a quiescent (G0) state where
replication and metabolic activity are decreased57,222-226. Several studies have shown that
spheroid cells are resistant to platinum- and taxane-based chemotherapy agents227.
Additionally, spheroid cells have been shown to express markers of stemness, such as Oct4, c-Kit, Nanog, and Myc, leading to postulations that spheroids function as ovarian cancer
stem cells (CSCs)228,229. Indeed, spheroid cells have been shown to display characteristics
of CSCs, including regulating tumorigenesis, progression, and invasiveness. Spheroid cells
can remarkably control cell cycle progression to enter quiescence and remain dormant or
perform self-renewal functions57,229,230. Clinical evidence and in vitro studies provide
evidence that populations of spheroids can survive chemotherapy and give rise to a
chemoresistant niche that can remain undetected and eventually lead to relapse231,232.
Hence understanding the mechanisms of spheroid cell biology can significantly improve
treatment and survival of advanced-stage HGSOC patients.

1.5.5

Summary of HGSOC treatment
The standard care for HGSOC patients consists of cytoreductive debulking surgery

and platinum-taxane chemotherapy (carboplatin, cisplatin, and paclitaxel). This has
remained largely unchanged in the last 20 years, although variations of adjuvant or
neoadjuvant chemotherapy are available. Cytoreductive debulking surgery is difficult in
late-stage patients who present with wide-spread dissemination of tumours within the
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peritoneal cavity. Furthermore, while patients may initially respond to chemotherapy,
relapse is frequent and nearly inevitable in late-stage patients. The high degree of
heterogeneity and genomic instability of HGSOC complicates treatment and reduces PFS
survival as relapse can present with platinum-resistant tumours. Novel targeted therapies
such as PARPi (niraparib, olaparib, rucaparib, and veliparib) and anti-angiogenic inhibitors
(bevacizumab) used either alone or in combination with standard chemotherapy have
prolonged PFS but have not provided meaningful improvements to OS. Unfortunately, the
current arsenal of therapies available for HGSOC – especially for late-stage patients – aim
to palliate symptoms and prolong the inevitable relapse that occurs in over 80% of cases.
Spheroids play a large role in chemoresistance and relapse by forming a chemoresistant
niche that can reseed disease. These spheroids express markers of stemness and are highly
invasive and metastatic and are naturally disseminated by peritoneal fluid (ascites). Studies
have shown that exfoliated HGSOC cells gain several advantages by aggregating into
spheroids: survival in anchorage-independent conditions, and proliferative control
whereby spheroid cells enter a state of quiescence. Quiescent or dormant cells evade
chemotherapy, can survive in suspension for extended periods of time, and can eventually
lead to relapse upon invasion of distant mesothelial tissues. Disseminated chemoresistant
spheroid populations are the primary culprits of this as yet insurmountable hurdle28.
Elucidating the mechanisms of spheroid dormancy and viability are critical to developing
novel therapeutic strategies to specifically target the chemoresistant niche to prevent
relapse in patients.
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1.6 Tumour dormancy
1.6.1

Types of dormancy in cancer
Metastasis in HGSOC is uniquely and predominantly transcoelomic whereby

HGSOC cells exfoliate from tumours and shed into the peritoneal fluid52. There, they
aggregate together to form multicellular clusters of cells called spheroids47. Peritoneal fluid
carries spheroids to distant sites where they can invade the mesothelial lining of visceral
organs233. Spheroids can also exist in a clinically undetectable and a reversible dormant
state234. Dormant spheroid cells are especially dangerous because they can survive firstline chemotherapy for prolonged periods and cause relapse56.
Tumour dormancy is divided into three categories: cellular dormancy, angiogenic
dormancy, and immune-mediated dormancy235 (Figure 1.6). In cellular dormancy, tumour
cells enter a reversible state of dormancy and exit the cell cycle. In angiogenic dormancy,
the tumour mass is maintained by a balance between proliferation and apoptosis due to
poor vascularization. In immune-mediated dormancy, the tumour mass is maintained in
equilibrium by constant cytotoxic activity. These categories are not mutually exclusive and
tumour dormancy can be caused by different events including transcriptional control from
the primary tumour, TME-induced stress, or chemotherapy236. HGSOC spheroids remain
dormant during anchorage-independent conditions until they reattach to new mesothelial
surfaces and this has been observed both clinically and in ex vivo environments234.
Much of the present understanding of cellular dormancy comes from CSC studies
in other highly metastatic cancer types, such as breast, colon, glioblastoma, head and neck,
melanoma, and prostate cancer, and also from hematopoietic stem cells (HSCs)237. The
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Figure 1.6 Types of tumour dormancy
Figure 1.6. Types of tumour dormancy. There are three methods for tumour cells to
achieve dormancy. In cellular dormancy, tumour cells can enter a reversible growth
arrested state whereby they exit the cell cycle. Growth arrested cells are not susceptible to
anti-proliferative chemotherapy agents. In angiogenic dormancy, poor vascularization
prevents further growth of the tumour mass. Cells may undergo apoptosis due to lack of
nutrients or growth factors, which can then allow some cells to grow. The tumour mass is
maintained by a balance of proliferation and cell death. In immune-mediated dormancy,
the tumour mass is maintained by immune-mediated cytotoxic activity. Infiltrating immune
cells are able to kill tumour cells, but not sufficiently to cause to the entire tumour mass to
regress. Instead, the tumour mass is maintained by a balance of immune cell activity and
proliferation. These three categories are not distinct and tumours may use one of more
methods to achieve dormancy. When dormant cells re-enter the cell cycle, achieve
angiogenesis to direct new vasculature, or evade immune-mediated cytotoxic activity, they
can exit dormancy and undergo tumorigenesis and proliferation.
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current understanding of dormancy in HGSOC is comparatively lacking. Although these
cancer types primarily metastasize hematogenously unlike HGSOC, parallels can still be
drawn from their respective disseminated dormant cells. The mechanisms of dormancy
identified in these cancer types also have a strong resemblance to HSCs which undergo
reversible dormancy and self-renewal236. It is widely accepted that dormancy contributes
to residual disease in highly metastatic cancers and that dissemination to distant tissues can
potentially promote adaptations to new microenvironments and conditions238-240. Dormant
cancer cells are inherently able to respond to stimuli (or lack thereof) in growthconstraining conditions to survive nutrient deprivation, hypoxia, or chemotherapy241.
Subsequently, stimuli from growth-promoting conditions can induce proliferation236. It has
been suggested that dormancy is an intrinsic characteristic of cancer cells that allows them
to perform maintenance and self-renewal functions, gain new mutations that allow for
colonization of new tissues, or to evade the immune system or chemotherapy237. These
stimuli act on various signaling pathways to modulate dormant cancer cell activity.

1.6.2

Quiescence
The mammalian cell cycle consists of four distinct phases: mitosis (M), DNA

synthesis (S), and the two gap phases G1 and G2242. In cellular dormancy, tumour cells exit
the cell cycle and become arrested in a phase termed G0 that is often referred to as
quiescence243. Quiescence is reversible and is maintained until adequate growth-promoting
conditions are met in the TME244. Studies from multiple cancer types and HSCs have
revealed a myriad of signaling pathways that can influence quiescence in CSCs237. These
stimuli can be intrinsic, such as intracellular signaling or transcriptional reprogramming,
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or extrinsic, such as extracellular signaling or changes in the TME237. These stimuli can be
grouped into three broad categories: mitogen deprivation, contact inhibition, or loss of cell
adhesion. Mitogen deprivation, contact inhibition, and loss of adhesion are highly relevant
to HGSOC spheroids persisting in suspension in ascites and each process may play a role
in the prolonged survival of dormant spheroids in patients.
Studies from CSCs have shown that quiescence can be induced through stem cell
signaling pathways. Increased Notch activity has been shown to maintain quiescence in
breast cancer cells245. Notch signaling is important for embryogenesis and self-renewal of
stem cells and is also a hallmark of CSCs237. One study demonstrated that Notch signaling
induces quiescence in HSCs through cyclin D repression and this pathway may also be
active in quiescent tumour cells246,247. Hedgehog signaling is another important
embryogenesis pathway that has been implicated in CSC quiescence248,249. Deletion of the
Patched receptor activates the Hedgehog signaling pathway and induces quiescence in
neural stem cells and lung epithelial cells, potentially as a result of Hedgehog-mediated
activation of CDK inhibitors (CKIs)246,250. Similarly, Wnt signaling has also been found to
be involved in the maintenance of quiescence in HSCs251. Transforming growth factor beta
(TGF-β) present in the external milieu of disseminated head and neck cancer and prostate
cancer cells induce quiescence through TGF-β-mediated repression of CDK4
expression252,253. In contrast, TGF- β ligands have also been shown to promote growth,
migration, and invasion in cancer. This incongruous behaviour is consistent with TGF-β’s
ability to act as both a tumour suppressor, but also promote tumorigenesis through EMT
and angiogenesis254.
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The p38 MAPK pathway has been shown to play a role in dormancy and many
growth factors and cytokines converge on this pathway. For example, one study showed
that the TGF-βIII receptor and the cell adhesion molecule, endoglin, is required for the
maintenance of p38 MAPK-mediated quiescence252,255. Additionally, activation of p38
MAPK in the absence of proliferative signals results in low extracellular signal-regulated
kinase 1/2 (ERK1/2) activity and induces quiescence255. This is particularly important for
disseminated tumour cells that lack integrin-mediated cell adhesion signaling256,257.
Importantly, high p38 MAPK activity and low ERK1/2 activity – first identified in dormant
head and neck cancer – is now considered a signature of dormant cancer cells258. This
signature was later identified in the vast majority (90%) of dormant cancer cell lines
including ovarian cancer240,253. Both p38 MAPK and ERK1/2 activity were found to be
regulated by the urokinase-type plasminogen activator receptor (uPAR)259. Decreased
uPAR activity in turn resulted in reduced focal adhesion kinase (FAK) and Src activity
which suppressed ERK1/2 and activated p38 MAPK, promoting quiescence260. Studies
have also shown that p38 MAPK can induce quiescence through the activation of p53, p21,
and cyclin D237,260.
The PI3K/AKT/mTOR pathway also plays a role in tumour dormancy and
quiescence. Reduced AKT signaling was observed in quiescent patient-derived HGSOC
spheroids64,261. AKT activation can also stimulate Notch signaling to promote stemness
and quiescence in CSCs237. In contrast, mTOR is a key regulator of proliferation and its
suppression is necessary to maintain quiescence in HSCs and cancer cell lines262-265. The
Forkhead box class O (FOXO) transcription factors, which are downstream effectors of
PI3K/AKT/mTOR, modulate adaptive metabolic mechanisms during oxidative stress
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responses in dormant cancer cells266. Studies suggest that external stress, such as nutrient
deprivation, reduce PI3K/AKT/mTOR activity and induce autophagy and quiescence in
dormant breast cancer, head and neck cancer, and ovarian cancer267. Under hypoxic
conditions, mTOR activation can induce hypoxia-inducible factor-1α (HIF-1α) which can
subsequently lead to quiescence and autophagy237,268. Inhibition of PI3K/AKT/mTOR
signaling in patient-derived HGSOC spheroids promotes autophagy as a survival
mechanism64,261. Liver kinase B1 (LKB1) has a critical role in metabolic activity during
hypoxia and has been shown to modulate mTOR, FOXO, and AMP-activated protein
kinase (AMPK)269. Loss of LKB1 not only reduces quiescent HSC populations, but also
ablates HGSOC spheroids and reduces peritoneal metastases in xenograft mice226,269,270.
PI3K/AKT/mTOR signaling is therefore a mediator of proliferation and quiescence that
can dynamically respond to environmental cues to preserve survival in dormant cells.

1.6.3

Loss of cell cycle control
Regardless of the upstream signaling pathways driving quiescence, dormant cells

must successfully block cell cycle progression in order to remain arrested in G0. However,
in order to permit reentry into the cell cycle, this block must be reversible. Dormant cancer
cells can achieve this by modulating the CDK/cyclin-RB-E2F axis which includes cyclins,
cyclin dependent kinases and their inhibitors, the RB family members, and E2F
transcription factors118,212. The RB family (RB, RBL1/p107, and RBL2/p130) and E2F
transcription factors cooperate to form complexes that transcriptionally regulate a
multitude of genes that control progression through the cell cycle271. RB proteins bind
directly to E2F family members to sequester them and repress their transcriptional
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activity271 (Figure 1.7). Transcriptional inhibition is relieved by CDK-mediated
hyperphosphorylation of RB proteins resulting in the dissociation of RB proteins from the
E2F-DP1 heterodimer and allowing the de-repression of E2F target genes118,272. The E2F
family is composed of eight members including activators and repressors, but only E2Fs
1-5 are known to interact with the RB family118,271,273,274. E2Fs 1-3 primarily associate with
RB and are known as activators118,271,273,274. E2Fs 4-5 are known as repressors and mostly
associate with the two RB-like proteins, p107 and p130118,271,273,274. E2F4 has also been
shown to bind to RB118,271,273,274. Cell cycle control in this manner through the CDK/cyclinRB-E2F axis is frequently abrogated in cancer as previously discussed (section 1.4.1).
Although the most common form of CDK/cyclin-RB-E2F axis deregulation in HGSOC
manifests as functional loss of the CKI p16INK4A (CDKN2A), which occurs in 30% of cases,
experiments show that the CKI p21 (CDKN1A) is required for the maintenance of
quiescence in stem cells and cancer cell lines66,260,275. Amplification of cyclins D1
(CCND1) and E1 (CCNE1) occur in 20% and 4% of HGSOC cases, respectively66. Direct
functional loss of RB1 occurs in 10% of patients as a result of mutations or deletions in
RB166. Aberrations in the CDK/cyclin-RB-E2F axis can therefore promote proliferation or
quiescence by directly modulating the activity of pathway members or by deregulating the
expression of downstream transcriptional targets or crosstalk with other effectors such as
p53 and PI3K/AKT237,276.
Loss of cell cycle control may also occur through dysregulation of Survivin, p53,
Myc, cul-1, or cdc20277. Survivin displays biphasic activity depending on metastasis or
invasion and participates in cell cycle control and autophagy278-281. It is regulated by many
upstream pathways including CDK/cyclin-RB-E2F, JAK/STAT, PI3K/AKT/mTOR, p53,
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Figure 1.7 Cell cycle control by the CDK/cyclin-RB-E2F axis
Figure 1.7. Cell cycle control by the CDK/cyclin-RB-E2F axis. The established model
of cell cycle control by the retinoblastoma protein (RB). RB binds to heterodimeric E2FDP transcription factors to repress their transcriptional activity during G0/G1 by recruiting
co-repressors that can remodel chromatin such as histone deacetylases (HDACs) or histone
lysine demethylases (KDMs). Upon mitogenic stimulation, cyclin-dependent kinase
(CDK) complexes phosphorylate and inactivate RB during S phase. This releases E2F-DP
heterodimers, allowing for the progression of transcriptional programs required for DNA
replication.
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TGF-β, and Wnt. One study showed the introduction of mutant p53 abolished quiescence
in wild type HSCs282. Myc expression has been shown to be inversely correlated to
proliferative activity in CSCs237,283-285. Both cul-1 and cdc20 control cell cycle progression
by mediating the G1/G0 transition and by controlling proteosome-mediated degradation of
cell cycle regulators, respectively282,286-288. Impaired chromatin remodeling can also lead
to loss of cell cycle control. For example, dysregulated histone lysine demethylase,
KDM5B, slowed cell cycle progression in a population of chemoresistant melanoma
cells289. Additionally, various KDMs were found to be upregulated in cancer cells that
survived anti-proliferative therapy260. Histone deacetylases (HDACs) can cause G2 arrest
when depleted or repress p53 functions when overexpressed as well as contributing to RBE2F-mediated gene expression260.
RB family members also play a role in a recently discovered cell cycle regulatory
complex called the mammalian DREAM complex290,291. DREAM is a highly conserved
multi-subunit complex that was originally identified in Drosophila and consists of DP, an
RB-like protein (either p107 or p130, but never RB), an E2F, and the MuvB (multi-vulval
class B) core292. DREAM assembly is initiated by dual-specificity tyrosine
phosphorylation-regulated kinase (DYRK1A)290,291. Osteosarcoma cells deficient for
DYRK1A were unable to enter quiescence290. DYRK1A has also been shown to maintain
quiescence by degrading cyclin D and stabilizing the CKI p27293,294. Both DYRK1A and
its paralog DYRK1B play a role in initiating and maintaining G0 arrest in breast, colon,
melanoma, ovarian, and pancreatic cancer cells57,295-297.
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1.6.4

Targeting dormancy in cancer
Although the current understanding of dormancy in cancer has increased

significantly in the last decade, there is still no consensus on the best approach to target
dormancy. Three distinct approaches have been suggested: i) maintain the dormant state of
cells to prevent relapse; ii) awaken dormant cells to increase sensitivity to chemotherapy;
or iii) target quiescence-promoting pathways to directly eliminate dormant cells260 (Figure
1.8). Each method has advantages and disadvantages. For example, while maintaining the
dormant state of cells could prevent metastases and relapse, some dormant cells may
continue to slowly progress through the cell cycle so minimal residual disease may require
lifelong treatment. Forcing dormant cells to re-enter the cell cycle can increase
susceptibility to existing anti-proliferative chemotherapy, but treatment could fail if the
cells gain resistance or do not completely respond to chemotherapy. Directly killing
dormant cells, especially in combination with first-line therapy, could potentially eliminate
all dormant populations, but it may also provide selection for more aggressive phenotypes.
Therefore, the most optimal approach is still debated and remains controversial.
Breast cancer studies have provided evidence that maintaining a dormant state by
suppressing proliferative signals is sufficient to maintain quiescence and prevent
recurrence298. Hormone-deprivation therapy in estrogen receptor (ER) positive breast
cancer is sufficient to maintain dormancy and improve OS299,300. Moreover, treatment with
a selective inhibitor of ERK (UO126) successfully blocked proliferative signals and
maintained dormancy of disseminated tumour cells257. Itraconazole inhibits growth and
maintains dormant phenotypes by acting on Hedgehog signaling, the PI3K/AKT/mTOR
axis, and Wnt signaling in colorectal cancer and melanoma301,302. Three-dimensional cell
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Figure 1.8 Treating dormancy in cancer
Figure 1.8. Treating dormancy in cancer. Dormancy in cancer can be targeted using
three methods. (i) Maintain the dormant state of cells: Following first-line chemotherapy,
dormant cells can be treated with inhibitors that suppress proliferative signals in order to
sustain dormancy. These inhibitors may include CDK inhibitors or ERK inhibitors to block
growth signals. The goal of this method is to indefinitely maintain dormancy to prevent
relapse. However, minimal residual disease may be unavoidable and would require lifelong
treatment. Additionally, slow cycling cells could acquire mutations and escape dormancy
to cause relapse. (ii) Awaken dormant cells: Dormant cells can be treated with specific
growth factors, such as granulocyte colony-stimulating factor (GCSF) or DYRK1A
inhibitors to force re-entry into the cell cycle. This would allow anti-proliferative
chemotherapy agents to target dividing cells and induce cell death. The disadvantage is that
cells may acquire mutations and escape chemotherapy and cause relapse. (iii) Directly
eliminate dormant cells: In this method, first-line chemotherapy is followed by specific
treatments that inhibit processes required for quiescence, such as oxidative
phosphorylation, autophagy, and chromatin remodeling. This allows for the direct killing
of dormant cells without forcing re-entry into the cell cycle.
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culture models of breast cancer have also suggested that targeting integrin, MMPs, and
epidermal growth factor receptor (EGFR) could keep cells in a dormant state303-306.
Suppression of mitogen signaling is therefore a potentially beneficial route to treat
dormancy.
Alternatively, targeting specific TME factors or enzymes could reverse quiescence
and coax cells to re-enter the cell cycle307,308. Stimulation of quiescent leukemia cells with
granulocyte colony-stimulating factor (GCSF) causes re-entry into the cell cycle and
increases sensitivity to chemotherapy309,310. Depletion of the E3 ubiquitin ligase Fbxw7
stabilizes Myc, Notch, and cyclin E which forces quiescent leukemia cells to re-enter the
cell cycle and become susceptible to imatinib237. Similarly, inhibition of DYRK1A can
induce cell cycle progression and increase sensitivity to chemotherapy. DYRK1A
inhibition with harmine also increases sensitivity to imatinib in gastrointestinal stromal
tumours (GIST)311. A small molecule inhibitor of DYRK1B was also shown to enhance
sensitivity to gemcitabine in quiescent pancreatic cancer cells296.
The fear of awakening dormant cells is that it could potentially lead to rapid cell
division cycles and unmanageable metastases if it is not immediately followed by effective
anti-proliferative chemotherapy260. It has therefore been suggested that identifying specific
therapeutic vulnerabilities of dormant cells and developing appropriate novel drugs may
be more effective and avoid worsening a patient’s condition260. For example, mitochondrial
respiration was required for dormant pancreatic cell survival and they were eliminated with
an oxidative phosphorylation inhibitor312. Targeting KDMs or HDACs using selective
inhibitors has also shown promise in eliminating dormant cancer cells in various cancers313315

. Inhibition of autophagy reduced survival of dormant breast cancer cells316. A similar
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study was also recently conducted in HGSOC spheroids317. The heterogeneity of HGSOC
affords tumour cells with many mutations that could potentially provide spheroid cells with
selective advantages that mediate entry into quiescence and escape from anoikis and
chemotherapy. Therefore, identifying such mechanisms that are essential for HGSOC
spheroid survival can potentially lead to new drug therapies that can specifically target and
eliminate spheroid cells before relapse.

1.6.5

Summary of HGSOC dormancy
HGSOC spheroid cells constitute a chemoresistant and dormant niche in patients

that can cause relapse and multi-organ metastases in patients. The present understanding
of ovarian cancer dormancy is very limited and much of the knowledge comes from CSCs
found in other cancer types as well as HSCs. CSCs have striking resemblance to HSCs in
that they express stem cell markers, can undergo self-renewal, and enter a reversible state
of dormancy – called quiescence – upon loss of mitogen signaling in the TME. Dormancy
is an inherent feature of cancer cells that allows them to evade the immune system and
chemotherapy and gain new mutations for survival. Quiescence occurs through G0 cell
cycle arrest and can be achieved by dysregulation of many pathways, including
PI3K/AKT/mTOR, p38 MAPK, CDK/cyclin-RB-E2F and others. Methods to treat
dormancy remain controversial and each have advantages and disadvantages that must be
evaluated in order to effectively suppress or eliminate dormant cells and prevent relapse,
which is a major cause of mortality in HGSOC. HGSOC heterogeneity across patients and
ITH may present challenges since a multitude of aberrant pathways could facilitate
dormancy in spheroid cells. However, encouraging evidence from other cancer types
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suggests that targeting dormancy by awakening them to enhance anti-proliferative drug
sensitivity, or directly eliminating quiescent cells by exploiting vulnerabilities can be
successful and could potentially improve OS.

1.7 The mammalian DREAM complex
1.7.1

DREAM and MuvB
The RB family consists of three closely related pocket proteins: RB, p107, and

p130118,271,273,274. The regulation of E2F transcription factors by RB family members occurs
in a cell cycle-dependent manner118,271,273,274. At the start of G1, the promoters of E2F
responsive genes are largely populated with p130-E2F4 complexes that silences these
genes318. In mid- to late G1, p107 replaces p130 at the promoters of E2F responsive genes
and by late G1, RB-E2F complexes are the most abundant and prevent gene activation by
masking the E2F activation domain of E2Fs118,271,273,274,318. In G0, p130 is bound to E2F4containing complexes and it maintains the highest level of expression out of the three
pocket proteins, suggesting an important role for p130 during quiescence318. Studies have
shown that p130-E2F4 are part of the mammalian DREAM complex which is assembled
in quiescence292,318-321. Many unknowns remain about DREAM but its roles in normal
growth and development as well its implications in cancer are becoming apparent.
DREAM assembly is mediated by DYRK1A which phosphorylates LIN52 and
provides an interaction surface for p130290,292,322 (Figure 1.9A). This allows p130-E2F4DP to bind to LIN52 which itself is part of the MuvB core complex consisting of LIN9,
LIN37, LIN52, LIN54, and RBBP4323,324. DREAM disassembly occurs when CDK2/4
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phosphorylate p130 and MuvB proteins291,323,325,326. MuvB then dissociates from DREAM
and binds to either B-MYB or FOXM1 to form MYB-MuvB (MMB) or FOXM1-MuvB,
respectively318,323,324,327 (Figure 1.9B). In the absence of DREAM, MuvB promotes gene
expression and cell cycle progression57,318,328. Thus, DREAM and MuvB have opposing
roles in the cell cycle. Recent studies have revealed that DREAM plays an essential role in
differentiation, proliferation, and tumour suppression by acting as a transcriptional
repressor57,323. Additionally, the transcription factors B-MYB and FOXM1 are
overexpressed in many cancers including ovarian cancer66,329,330. Hence understanding the
function of DREAM and MuvB in cancer progression and dormancy is an important area
of research.
DREAM and MuvB are evolutionarily conserved protein complexes that were first
identified in Drosophila and C. elegans292. Over the last decade, studies have uncovered
the roles of each subunit in DREAM and MuvB. The Ser28 residue of LIN52 is
phosphorylated by DYRK1A which allows its LxSxExL motif to interact with the LxCxE
binding cleft of either p130 or p107290,331. LIN52 is also required for binding B-MYB to
form MMB332. LIN54 provides the ability to interact with the cell cycle genes homology
region (CHR) motif in promoters while E2F4-DP recognize the cell cycle-dependent
element (CDE) motifs328,333,334. RBBP4 potentially helps to recruit chromatin remodeling
factors since it is known to interact with SIN3B and the nucleosome remodeling and
deacetylation (NuRD) complex which are HDAC-containing complexes292. In vitro and in
vivo studies suggest that LIN9 is structurally important for DREAM and MuvB and
interacts directly with LIN52 and RBBP4331,335-337. LIN9 also appears to be important for
FOXM1-MuvB assembly and has recently been shown to interact with SIN3B338,339. LIN37
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Figure 1.9 Cell cycle control by DREAM and MuvB
Figure 1.9. Cell cycle control by DREAM and MuvB. (A) DREAM consists of: DP; an
RB-like (either p107 or p130); E2F4/5; And the MuvB core (which itself is a complex
containing LIN9, LIN37, LIN52, LIN54, and RBBP4). DREAM assembly is mediated by
dual-specificity-tyrosine-phosphorylation regulated kinase (DYRK1A). The kinase
phosphorylates LIN52 at its Ser28 residue which permits binding of the MuvB core to the
p107/p130-E2F4/5-DP complex and allows the cell to enter quiescence. (B) DREAM is
assembled at G0 to enter and maintain quiescence. When cells re-enter the cell cycle, p130E2F4/5-DP dissociates from the MuvB core complex. MuvB then binds to the transcription
factor B-MYB to form B-MYB-MuvB (MMB). MMB binds to target promoters in S-phase
to induce transcriptional activation of cell cycle genes. In G2, MuvB dissociates from BMYB and instead binds to the transcription factor FOXM1 to form FOXM1-MuvB. Cyclin
A/CDK2-mediated phosphorylation of B-MYB and FOXM1 is required for assembly. In
this way, FOXM1-MuvB transcriptionally activates late cell cycle gene expression.
DREAM and MuvB therefore cooperate to control quiescence and cell cycle progression
as a transcriptional repressor and activator, respectively.
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appears to be important for transcriptional repression by DREAM but not for MMBmediated activation340. Together, these components assemble to form DREAM in G0,
MMB in S phase, and FOXM1-MuvB in G2 to control gene expression in a cell cycledependent manner.

1.7.2

Cell cycle control by DREAM and MuvB
Many studies have shown that DREAM is required for entering and maintaining

quiescence. DREAM binds to several hundred cell cycle genes that are known to achieve
their peak expression during G1/S or G2/M phases of the cell cycle291,325. Depletion of
components required for DREAM assembly leads to de-repression of these genes.
Knockdown of LIN9 increased cell cycle gene expression in quiescent cells and decreased
mitotic gene expression in cycling cells suggesting it is important for both DREAM and
MuvB function291,324,341,342. Similarly, depletion of LIN52 or LIN54 leads to increased
expression of cell cycle genes291,333,342,343. In contrast, knockout of LIN37 suggests that it
is not essential for MuvB activity but required for DREAM-mediated repression and
quiescence292. Although p130 is the most abundant RB-like protein during quiescence, its
depletion increases p107 which can then compensate for p130 deficiency and assemble
DREAM57,318,322. However, when both p107 and p130 are concurrently depleted, DREAM
assembly is impaired and there is a shift towards MMB, gene activation, and cell cycle
progression322. Experiments from p107-/-;p130-/- mice show that mouse embryonic
fibroblasts (MEFs) deficient for both RB-like proteins have increased expression of
DREAM target genes and exit quiescence earlier than wild type MEFs344. Simultaneous
mutation of the LxCxE binding cleft of p107 combined with knockout of p130 impaired
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DREAM assembly in mice322. These mice displayed abnormal endochondral bone
development and demonstrated that DREAM is required to induce growth arrest in
chondrocytes322. Mice homozygous for these mutations were found to be neonatal lethal322.
Similarly, knockout of LIN9, which is important for DREAM and MuvB, also causes
lethality in mice337. It has been suggested that E2F4 and E2F5 may also compensate for
each other in DREAM318. Together, these studies demonstrate that disruption of DREAM
or MuvB leads to loss of cell cycle control.
DREAM binds to its target genes by recognizing CHR and CDE motifs near the
transcription start site (TSS) of promoters345,346. These motifs are shared by many cell cycle
genes and are often found in close proximity to each other345. Binding to CHR and CDE is
mediated by LIN54 and E2F-DP, respectively318. None of the subunits in DREAM have
any enzymatic activity and therefore must rely on other factors to silence gene expression.
Initial hypotheses for how DREAM may induce gene repression followed from the wellestablished interactions of RB-E2F and chromatin modifiers. RB-E2F interacts with
HDAC1/2 and the SIN3B/HDAC complex347,348. It has been suggested that RBBP4 may
also interact with these chromatin modifiers. However, RB interacts with the
aforementioned chromatin modifiers through the LxCxE motif which is occupied in
DREAM by the p130-LIN52 interaction292. The mechanism of gene repression by DREAM
is therefore likely to be distinct from RB-E2F mediated repression292.
A study in C. elegans showed that DREAM represses genes by altering nucleosome
positioning349. Enrichment of the histone variant H2AZ is routinely observed at promoters
and is associated with gene expression350. On the other hand, gene body deposition is
associated with repression350. Loss of DREAM in C. elegans did not alter deposition of
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H2AZ at promoters but led to reduced H2AZ within gene bodies, suggesting a mechanism
for repression. DREAM assembly was correlated with a significant increase of gene body
H2AZ at known DREAM target genes351. Evidence of this has also come from studies in
Drosophila where the DREAM ortholog acts as a repressor and activator292. Loss of
DREAM leads to decreased H2AZ resulting in de-repression of cell cycle genes351.
When DREAM assembly is impaired by depletion of required subunits or inhibition
of DYRK1A, quiescence cannot be maintained and the cells instead assemble MMB57.
MMB localizes to promoters of target genes, such as MYBL2 which encodes B-MYB, using
CHR motifs or MYB binding sites352. For example, mutation of the MYB binding site on
BIRC5, which encodes Survivin, reduced LIN9 and B-MYB binding352. Transcriptional
activation by MMB is dependent on phosphorylation of B-MYB by cyclin A/CDK2353,354.
Depletion of B-MYB or MuvB core proteins leads to decreased late cell cycle (G2/M) gene
expression and mitotic arrest indicating that MMB is required for normal cell cycle
progression318. Mitotic arrest was observed in mice deficient for LIN9 as well as F9
embryonal carcinoma cells deficient for either LIN9 or B-MYB341. Recent studies have
demonstrated that B-MYB and MuvB also cooperate with FOXM1 to regulate late cell
cycle gene expression323. Similar to B-MYB, cyclin A/CDK2 phosphorylation of FOXM1
is required for assembly of FOXM1-MuvB318. Loss of FOXM1 also leads to deficiencies
in mitosis and reduced levels of cell cycle gene expression. Mutation of the aforementioned
MYB binding site on BIRC5 also ablated FOXM1 recruitment to the promoter355. This is
consistent with other studies that show MuvB is required for FOXM1 binding at
promoters356,357. Together, these studies show that DREAM, MuvB, B-MYB, and FOXM1
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are interrelated through shared or opposing functions to control quiescence and cell cycle
progression.

1.7.3

DREAM and MuvB in cancer
B-MYB is frequently mutated or overexpressed in cancer and is used as part of a

proliferative signature to predict prognosis as well as a biomarker test for breast cancer358.
Increased MYBL2 gene expression is generally associated with poor OS in many different
cancer types359. Similarly, FOXM1 is overexpressed in many cancer types, including
ovarian cancer, and indicates poor OS360-362. In these cancers, overexpression of MuvB, BMYB, or FOXM1 could promote MMB/FOXM1-MuvB activity which can drive
proliferation and increase tumorigenesis. Inhibition of these factors in breast cancer cells
reduced proliferation363. One study showed that loss of B-MYB or LIN9 reduced
tumorigenesis in a mouse model of lung cancer364. Alternatively, alterations that promote
DREAM assembly could potentially promote quiescence and chemoresistance. Depletion
of LIN52 or combined depletion of both LIN54 and E2F4 were sufficient to increase
sensitivity to chemotherapy in GIST, indicating DREAM contributes to chemoresistance
in GIST365,366.
The presence of MuvB in DREAM and MMB/FOXM1-MuvB complexes presents
a challenge for targeting DREAM in cancer. Inhibiting individual MuvB core subunits
would impair DREAM assembly but also affect transcriptional activation as previously
discussed318. An attractive target to disrupt DREAM assembly, and specifically
quiescence, is DYRK1A. Studies across many cancer cells have shown that DREAMmediated quiescence can be inhibited by inactivation of DYRK1A or its paralog DYRK1B.
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Treatment of non-small-cell lung cancer (NSCLC) cells with harmine, a potent DYRK1A
inhibitor367, increased sensitivity to osimertinib368. Harmine inhibition also increased
sensitivity to Bcl-2 inhibitors in primary NSCLC cells369. Treatment with harmine reversed
quiescence and enhanced imatinib sensitivity in GIST, consistent with combined
LIN54/E2F4 depletion studies370. Inhibition of DYRK1A in pancreatic ductal
adenocarcinoma suppressed tumour progression by inhibiting proliferation371. Together,
these cell culture and mouse model studies provide overwhelming evidence that inhibiting
DREAM assembly can force cell cycle re-entry and increase susceptibility to
chemotherapy.

1.7.4

DREAM in HGSOC
We previously identified components of DREAM as essential for the survival of

HGSOC spheroids cultured from a panel of EOC cell lines57. Specifically, depletion of
MuvB core subunits, RB-like proteins, or DYRK1A decreased survival of spheroid cells
but not asynchronously growing cells57. Additionally, HGSOC spheroids cultured from a
patient-derived cell line (iOvCa147) upregulate the G0 markers p130 and p2757,372-374.
Upon shRNA-mediated depletion of DYRK1A in iOvCa147 cells, DREAM fails to
assemble in spheroids57. Instead, the MuvB complex co-immunoprecipitates with B-MYB,
indicating that DREAM assembly is impaired. Consistent with reduced DREAM assembly,
DREAM target genes such as CDK1, CCNA2, and MYBL2 were de-repressed57. This derepression was detected at 6 hours after spheroid formation in DYRK1A or p130 depleted
spheroid cells57. Tritiated-thymidine assays revealed that DYRK1A depleted spheroid cells
failed to achieve quiescence and continued to synthesize new DNA at 6- and 12 hours
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following spheroid formation57. Neither de-repression of DREAM target genes or
increased DNA synthesis were detectable after 24 hours, likely as a result of increased
apoptosis and loss of spheroid cell viability due to anoikis57. DYRK1A depleted spheroid
cells exhibited increased S-phase from 6 hours through to 12 hours, indicating that without
DREAM, these spheroid cells fail to arrest and continue to replicate DNA57. Compared to
control spheroid cells, there was a dramatic increase in cell death in DYRK1A depleted
spheroid cells at 24 hours57.
Pharmacological inhibition of DYRK1A across a panel of ovarian cancer cell lines
(iOvCa147, HEYA8, OVCAR8, iOVCA185) recapitulated these findings57. Inhibition of
DYRK1A with harmine or INDY (a potent DYRK1A/B inhibitor375) decreased spheroid
cell viability in suspension57. Harmine or INDY treatment disrupted p130 binding to
MuvB. INDY also significantly enhanced sensitivity of spheroid cells to carboplatin57.
Together, this data demonstrated that DREAM is an important factor for mediating
quiescence in HGSOC spheroid cells. Without DREAM, spheroids cells fail to enter
quiescence and continue to cycle and ultimately become susceptible to anoikis.

1.7.5

Pharmacological inhibition of DYRK1A
DREAM inhibition using pharmacological inhibitors of DYRK1A provide a

translational approach to targeting DREAM and quiescence in cancer. Indeed, several
studies have shown inhibitors such as harmine and INDY can disrupt DREAM assembly
and enhance sensitivity to chemotherapy in various cancer types367,369-371. Unfortunately,
the inhibitors used in these studies either have not been evaluated for clinical use or have
toxic side effects376. For example, INDY has not undergone preclinical testing and harmine
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is also a monoamine oxidase A inhibitor which can lead to adverse effects376,377. Recently,
CX-4945 was described to have efficacy to inhibit DYRK1A375. CX-4945 is a previously
described casein kinase 2 (CK2) inhibitor378. CX-4945 has higher potency than both INDY
and harmine375. Clinical trials are currently underway to determine the safety and efficacy
of CX-4945 in treating recurrent medulloblastoma (NCT03904862), advanced or
metastatic basal cell carcinoma (NCT03897036), and relapsed multiple myeloma
(NCT01199718).
Inhibition of DYRK1A as a therapy may be challenging due to DYRK1A’s
involvement in multiple pathways. DYRK1A has been characterized in neurogenesis and
its genetic locus is within the Down Syndrome critical region (DSCR)379,380. As such,
DYRK1A overexpression has been associated with Down Syndrome, Alzheimer’s disease,
and Parkinson’s disease379. In some tumors, inhibition of DYRK1A alone may not be
sufficient to inhibit DREAM. DYRK1B is overexpressed in some tumors and may be the
predominant kinase that assembles DREAM290,381. We previously demonstrated this in
HGSOC spheroids as a subset of cell lines had reduced viability in suspension following
DYRK1B depletion57. DYRK1B amplification is also present in 10% of ovarian cancer
cases66,323. Therefore, it may be beneficial to simultaneously inhibit both DYRK1A and
DYRK1B. Pharmacological inhibition of DYRK1A/B has been demonstrated to reverse
quiescence and increase sensitivity to chemotherapy and the identification of a clinically
safe inhibitor may prove to be a valuable tool in targeting quiescence and dormancy in
HGSOC and other cancers57,382.
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1.7.6

Summary of the DREAM complex
DREAM and MuvB are evolutionarily conserved multisubunit complexes that

cooperate to regulate the cell cycle and permit entry into quiescence291,292,318,356. Studies
have shown that DREAM is required for normal growth arrest in cells and MuvB, together
with binding partners B-MYB and FOXM1, are required for late cell cycle gene expression
and mitosis318,323. DREAM’s repressive activity is mediated by H2AZ deposition within
the gene bodies of target genes351. In the absence of DREAM, B-MYB and FOXM1
cooperate with MuvB to form MMB and FOXM1-MuvB, respectively, which act as
transcriptional activators318. Importantly, DREAM is assembled in quiescent HGSOC
spheroid cells and is essential for their survival57. Impairment of DREAM activity, either
through depletion of required components or pharmacological inhibition of the assembly
factor DYRK1A, is sufficient to block assembly and force spheroid cells to re-enter the
cell cycle. These spheroid cells are then susceptible to anoikis due to cycling in anchorageindependent conditions and also have increased sensitivity to chemotherapy such as
carboplatin57. Inhibition of DREAM through DYRK1A therefore has potential therapeutic
value to directly target and eliminate the chemoresistant niche of HGSOC spheroid cells.

1.8 Summary of HGSOC
HGSOC is very deadly disease if not identified early in patients5. Unfortunately, in
many women it is not diagnosed until late-stage, primarily because it is asymptomatic
during early stages and shares the symptoms of less severe ailments. Presently, there is no
reliable screening test available for HGSOC which means many patients will continue to
be diagnosed at late-stage6. Therefore, there is an urgent need to develop new therapies to
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treat this disease. Current treatment options include cytoreductive surgery followed by
adjuvant or neoadjuvant chemotherapy. However, a characteristic of late-stage HGSOC is
the presence of multicellular aggregates, called spheroids, which complicates treatment and
surgical resection. Spheroids contribute to widespread dissemination of tumour cells,
amounting to many secondary lesions throughout the peritoneal cavity, making surgical
resection very difficult. Additionally, spheroid cells are dormant, enabling them to survive
anti-proliferative chemotherapy and act as a chemoresistant niche that can reseed disease57.
Indeed, relapse is a major cause for concern in HGSOC; while over 70% of patients respond
well to chemotherapy, over 80% will unfortunately experience relapse5. Recurrent HGSOC
is generally considered to be incurable5.
HGSOC is characterized by a high degree of heterogeneity and genomic instability
with multiple perturbed genes and pathways, some of which include TP53, BRCA1/2,
CDK/cyclin-RB-E2F,

PI3K/AKT/mTOR,

and

Notch

signaling66.

Additionally,

intratumoural spatial and temporal heterogeneity has been observed in treatment-naïve
HGSOC patients, highlighting how quickly tumour cells can gain selectively advantageous
mutations152. Hence HGSOC spheroid cells may potentially acquire many abrogated
pathways that allow proliferation, differentiation, metastases, and dormancy. The
multitude of mutated pathways and genomic instability may potentially mean that a “onesize fits all” therapeutic approach may not broadly apply to all patients. However, some
studies have shown that the mutational burden of HGSOC tumour cells can be exploited to
create synthetic vulnerabilities13. For example, functional DNA repair pathways are
important for a subset of HGSOC tumours13. Spheroid cells that subvert the cell cycle by
assembling DREAM can be targeted using DYRK1A inhibitors to force cell cycle re-entry
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and cell death due to anoikis or enhanced chemosensitivity57. As demonstrated by previous
studies, identifying novel vulnerabilities in spheroid cells that exploit these and other
essential processes in HGSOC cells can be aided by novel computational and experimental
approaches144. There is an urgent need for novel therapies that can effectively prevent or
reduce relapse in advanced-stage HGSOC patients. The discovery and characterization of
spheroid-specific vulnerabilities is therefore a critical area of research.

1.9 Scope of thesis
Dormancy and quiescence mediate resistance to anti-proliferative chemotherapy in
HGSOC patients5,56. Spheroid populations are responsible for peritoneal dissemination of
tumours and relapse following first-line therapy15. We have previously shown that
DREAM is upregulated in spheroid cells and contributes to quiescence and
chemoresistance57. Depletion of DYRK1A or its pharmacological inhibition impaired
DREAM assembly and enhanced spheroid cell sensitivity to carboplatin57. This presents
an appealing therapeutic option for HGSOC. However, DREAM assembly is required for
normal growth arrest and we have previously shown that it is essential for early
development in mice322. Loss of DREAM assembly factors leads to abnormal bone
development and eventual lethality322. The role of mammalian DREAM in adults remains
unexplored and requires investigation as it is a likely target for cancer therapy.
To elucidate the role of DREAM in adults, we developed a mouse model to
conditionally disrupt DREAM assembly in adult mice (Chapter 2). We did not observe
proliferative defects or neoplasms as a result of DREAM loss. However, after a prolonged
latency, DREAM deficient mice develop systemic amyloidosis. Amyloid fibrils were
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found in the liver, kidney, spleen, and heart tissues of these mice. Kidney tissues were the
most affected and this was accompanied by proteinuria and increased creatinine, signifying
kidney failure. Compared to mice with intact DREAM, DREAM deficient mice had
reduced survival. Amyloid subtyping of affected mouse tissues revealed that the major
amyloid-causing constituent of the amyloid deposits was apolipoprotein A-IV (apoA-IV).
Interestingly, both apoA-IV protein and Apoa4 gene expression levels were increased in
DREAM deficient mice. Finally, we show that in mice with intact DREAM, DREAM
localizes to CDE/CHR motifs found in the Apoa4 promoter leading to increased gene body
deposition of H2AZ. In DREAM deficient mice, this is abrogated and instead MMB binds
to the promoter to induce gene expression. Together, this shows that DREAM loss in adults
can lead to amyloidosis as a result of increase apolipoprotein expression.
DREAM and DYRK1A cooperate to enable quiescence in spheroid cells, but the
present understanding of dormancy and quiescence in the context of ovarian cancer is
lacking compared to other cancer types. Our goal was to therefore broadly identify genes
and pathways that may provide spheroid cells with selective advantages to enable survival
in suspension. Identification of such genes and their involved pathways could potentially
allow for the development of novel therapeutic strategies to specifically target
chemoresistant spheroids in HGSOC. To enable high-throughput discovery of genes and
pathways, we developed a bioinformatics tool called BEAVR (A Browser-based tool for
the Exploration And Visualization of RNAseq data) (Chapter 3)383. BEAVR provides an
easy-to-use interface for the analysis and visualization of RNA-sequencing (RNA-seq)
datasets and generates publication-quality figures.
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We also employed a loss-of-function genome-wide CRISPR screen to enable highthroughput discovery of genes and pathways that are specifically essential for spheroid cell
survival. Standard genome-wide CRISPR screening methodology – both experimental and
computational – failed to identify essential genes in our model system. This was attributed
to the complexity of a three-dimensional in vitro spheroid model and the spontaneous cell
death that can occur in spheroid cells under the stress of suspension culture conditions.
This can lead to loss of single guide RNAs (sgRNAs) which can be incorrectly attributed
to bona fide loss-of-function due to gene editing. To overcome this, we developed GOCRISPR (Guide-Only control CRISPR), a scalable loss-of-function screening method that
can be used to discover essential genes in standard monolayer (two-dimensional) or
complex three-dimensional culture conditions such as dormant HGSOC spheroids. We also
developed TRACS (Toolset for the Ranked Analysis of GO-CRISPR Screens) to automate
the analysis of GO-CRISPR screens in an easy-to-use graphical software package (Chapter
4)384.
Together with the use of BEAVR, GO-CRISPR, and TRACS, we identified a novel,
previously uncharacterized pathway in the context of HGSOC that mediates survival of
spheroid cells (Chapter 5). Specifically, using BEAVR, we identified genes and their
respective pathways that are differentially expressed in spheroid cells and also dysregulated
in DYRK1A-/- spheroid cells. We performed GO-CRISPR in a panel of three HGSOC cell
lines (iOvCa147, TOV1946, OVCAR8). Analysis with TRACS showed that the netrin
signaling pathway was mutually essential across all three cell lines. Importantly, this
pathway was also identified in our transcriptional analyses by BEAVR. Netrin is wellcharacterized in axon development but has recently been implicated in cancer. Strikingly,
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knockout of netrin receptors across a wider panel of HGSOC cell lines reduced survival in
spheroid cells. Together, this work highlights the netrin signaling pathway as a new
therapeutic target to specifically eliminate spheroid cells in HGSOC.
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Chapter 2

2

Disrupting the DREAM transcriptional repressor
complex induces apolipoprotein overexpression and
systemic amyloidosis in mice

2.1 Abstract
DREAM is a transcriptional repressor complex that regulates cell proliferation and
its loss causes neonatal lethality in mice. To investigate DREAM function in adult mice,
we utilized an assembly defective p107 protein and conditional deletion of its redundant
family member p130. In the absence of DREAM assembly, mice displayed shortened
survival characterized by systemic amyloidosis, but no evidence of excessive cellular
proliferation. Amyloid deposits were found in the heart, liver, spleen, and kidneys, but not
the brain or bone marrow. Using laser capture microdissection followed by mass
spectrometry, we identified apolipoproteins as the most abundant components of amyloids.
Intriguingly, apoA-IV was the most detected amyloidogenic protein in amyloid deposits,
suggesting AApoAIV amyloidosis. AApoAIV is a recently described form whereby
wildtype apoA-IV has been shown to predominate in amyloid plaques. We determined that
DREAM directly regulates Apoa4 by chromatin immunoprecipitation and that the histone
variant H2AZ is reduced from the Apoa4 gene body in DREAM’s absence, leading to
overexpression. Collectively, we describe a mechanism by which epigenetic misregulation
causes apolipoprotein overexpression and amyloidosis, potentially explaining the origins
of non-genetic amyloid subtypes.
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2.2 Introduction
Amyloidosis is a disease characterized by the misfolding and aggregation of
proteins into ordered β-sheet fibrils that are deposited extracellularly within organs or
tissues1. Presently, there are over thirty-five different proteins known to be amyloidogenic
in humans which has led to the classification of amyloidosis into different subtypes based
on the causative protein and the organs or tissues affected2,3. Systemic amyloidosis
involves multiple organs and/or tissues as a result of protein deposition at distal sites due
to circulation4. Several members of the apolipoprotein family have been associated with
systemic amyloidosis, these include apolipoprotein A-I (apoA-I), apolipoprotein A-II
(apoA-II), and apolipoprotein A-IV (apoA-IV)5. These proteins are predominantly made
in the liver, although their expression has also been reported in the heart and spleen6-8.
ApoA-I and apoA-II are constituents of high-density lipoproteins (HDL) and are
commonly implicated in hereditary amyloidosis9,10. ApoA-IV can exist as part of HDL or
circulate in a lipid-free state11-13. Like apolipoprotein E (apoE) and serum amyloid Pcomponent (APCS), apoA-IV was originally considered to be an amyloid signature protein
present in many different amyloid pathologies14,15. However, new mass spectrometry based
methods of characterizing protein identities has suggested apoA-IV has amyloidogenic
properties leading to the clinical designation of apoA-IV amyloidosis (AApoAIV)16.
Importantly, the expansion of protein identities in amyloidosis revealed by mass
spectrometry creates a more complex landscape of disease etiology and raises new
questions of the origins of non-hereditary forms of the disease.
Epigenetic mechanisms often govern gene expression levels in eukaryotic cells. In
particular, deposition of nucleosomes containing the histone variant H2AZ represses gene
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expression in a number of different biological scenarios through its accumulation in target
genes17-19. A key regulator of H2AZ is the DREAM complex that possesses nucleosome
binding activity and is thought to function as a chaperone to deposit H2AZ at its target
genes17,20. DREAM was initially described as a cell cycle regulatory complex that targets
proliferation-related genes through a bipartite promoter element composed of a cell cycle
homology region (CHR) and a cell cycle-dependent element (CDE)17,20,21. These elements
are well conserved in metazoan promoters and much of our understanding of DREAM
regulation is derived from cell proliferation studies in culture22,23, or development in fruit
flies and worms24-26. In fruit flies, DREAM not only represses transcription, but also
associates with MYB like proteins to serve as a transcriptional activator27. In mammals
DREAM disassembles upon the initiation of proliferation and is replaced at promoters by
MYB containing complexes that activate transcription23. For this reason, it is unclear if
DREAM deficiency in lower organisms can be related to its physiological role in
mammals, particularly because many phenotypes relate to fruit fly and worm specific
aspects of gonadal development21,26.
In mammals, under quiescent conditions, DREAM is comprised of a DP protein,
an RB family protein (either p107 or p130), an E2F, and the MuvB core of proteins (made
up of LIN9, LIN37, LIN52, LIN54, and RBBP4)21,28. Upon cell cycle entry, DREAM is
disassembled and the MuvB core partners with B-MYB to form MYB-MuvB complexes
that activate gene expression required for progression through mitosis28-30. Consequently,
mammalian DREAM function has been difficult to study as all of its components have nonDREAM functions, and deletions of their encoding genes in mice has resulted in embryonic
or neonatal lethality31-34. Consequently, much of our knowledge of DREAM function in
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mammals is largely derived from cell culture experiments investigating proliferative
control, leaving its role in mammalian physiology largely unexplored.
To circumvent the early developmental consequences of DREAM loss, we devised
a conditional model for inactivation of DREAM in adult mice. We utilized tamoxifeninducible deletion of the p130 encoding gene35, in combination with a constitutive p107
mutant that is unable to interact with the MuvB core36. Therefore, these mice express the
components of DREAM, but are unable to assemble the complex. We show that these mice
have diminished survival, exhibit symptoms of renal failure, and develop systemic
amyloidosis affecting the heart, kidney, liver, and spleen. Transcriptional and proteomic
analyses demonstrate that Apoa4 is overexpressed in the liver and apoA-IV is the most
abundant protein found in amyloids of these mice. Chromatin immunoprecipitation (ChIP)
analyses demonstrate that DREAM is replaced by B-MYB at the promoter of Apoa4 with
a concurrent decreased localization of H2AZ within the gene body. These data reveal a
connection between DREAM, altered epigenetic regulation of hepatic apolipoprotein
expression, and development of systemic AApoA-IV amyloidosis.

2.3 Results
2.3.1

Generation of adult DREAM assembly deficient mice
Early lethality of mice deficient for DREAM components has limited insight into

its function in mammals. Consequently, we generated a conditional mouse model to disrupt
DREAM complex assembly in young adult animals by eliminating the physical contact
between the MuvB subunit LIN52 and p107/p130 (Figure 2.1A). We utilized a previously
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Figure 2.1 DREAM assembly is disrupted in p107D/D;p130-/- mice

Figure 2.1. DREAM assembly is disrupted in p107D/D;p130-/- mice. (A) Either one of
the RB-like proteins, p107 or p130, can participate in DREAM assembly by binding to
MuvB in wild type mice and repressing transcription. In p107D/D;p130+/+ mice, the p107D
mutation prevents it from binding MuvB, rendering p107D unable to participate in DREAM
assembly but is still able to form p107-E2F complexes at CHR elements. p130 is now the
only RB-like family member able to mediate DREAM assembly in p107D/D;p130+/+ mice.
In p107D/D;p130-/- mice, ablation of p130 (p130-/-) combined with p107D prevents DREAM
assembly. The MuvB core now binds to B-MYB to form MYB-MuvB and activates
transcription. (B) Protein extracts were prepared from the livers and spleens of 3-month
old p107D/D;p130-/- and p107D/D;p130f/f control mice. The expression of p107D and p130
protein levels was detected by western blotting and Tubulin serves as a loading control.
(C) ChIP-qPCR assay to detect p107D and B-MYB binding at the TSS of Mybl2, a known
DREAM target. Illustration depicts primers used for qPCR and the regions of interest:
black arrows = negative control 1 kb upstream of TSS; red arrows = approximately 100 bp
region surrounding TSS and containing CDE (blue box) and CHR (green) motifs.
Chromatin was prepared from livers and p107 and B-MYB antibodies were used to
precipitate associated DNA (n=4 for each). Graphs show mean quantities of the indicated
genome locations precipitated and error bars indicate one standard deviation. Two-way
ANOVA was performed for each and significance levels are indicated (* denotes P < 0.05;
and **** denotes P < 0.0001).
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described missense allele of Rbl1 in which the encoded p107 protein is unable to interact
with LIN5236,37(Figure 2.1A). Since this mutation leaves p130 available to participate in
DREAM assembly, we employed a ubiquitously expressed UBC-Cre-ERT2 system to
conditionally delete Rbl2 (that encodes p130) in adult mice and prevent DREAM
assembly38(Figure 2.1A). The inability to assemble DREAM has previously been shown
to result in ectopic MYB-MuvB assembly at DREAM regulated genes, even in growth
arrested conditions23,36(Figure 2.1A), therefore we first sought to determine if tamoxifen
treatment of these mice resulted in DREAM loss and a gain of MYB-MuvB assembly.
For simplicity we will refer to the mutant allele of p107 as p107D, the conditional
allele of p130 as p130f, and its Cre inactivated form as p130-. At eight weeks of age, UBCCreERT2;p107D/D;p130f/f mice were injected with tamoxifen (Figure 2.2A). We confirmed
successful deletion of p130 exon 2 in the brain, heart, liver, kidney, spleen, bone, and tail
by PCR at one week post injection, and also demonstrate that it persists 2 years after
tamoxifen treatment in p107D/D;p130-/- mice (Figure 2.2B-D). We next determined the
protein levels of both p107 and p130 in p107D/D;p130f/f control and p107D/D;p130-/- mice.
We prepared cell lysates from the liver and spleen four weeks after tamoxifen
administration. Western blotting demonstrated that the p130 protein was undetectable in
both the liver and spleen of p107D/D;p130-/- mice, further validating successful deletion of
p130 (Figure 2.1B). Additionally, p107D protein was detectable in the livers and spleens
of both p107D/D;p130f/f and p107D/D;p130-/- mice.
To validate loss of DREAM assembly in p107D/D;p130-/- mice, we performed ChIPqPCR assays to interrogate p107 and B-MYB occupancy at the promoter for Mybl2, the

99

Figure 2.2 Strategy to create DREAM assembly deficient mice
Figure 2.2. Strategy to create DREAM assembly deficient mice. (A) Tamoxifen
treatment of control (p107D/D;p130f/f) and UBC-Cre-ERT2+/-;p107D/D;p130f/f at 8 weeks of
age was used to produce adult control mice that are p107D/D;p130f/f and the comparative
cohort that are p107D/D;p130-/-. (B) PCR genotyping strategy to detect knockout of p130
by conditional deletion of exon 2. Horizontal black arrows indicate annealing sites for
genotyping primers to confirm deletion of exon 2. LoxP sites flank exon 2 and upon Cre
activation, exon 2 is excised removing approximately 1.47 kb of genomic sequence. (C)(D): Validation of p130 exon 2 deletion by genotype PCR. Tissues obtained from mice 1week (C) or 2 years (D) following tamoxifen treatment. The primer pair shown in (B) was
used to detect successful excision of exon 2. PCR was performed on the indicated samples
and products were resolved on agarose gels. Wildtype amplicon: 1.8 kb. Deleted allele
amplicon: 330 bp.
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gene for B-MYB itself and a known DREAM target23,28,30,39,40. We designed primer pairs
to encompass the CDE and CHR elements at the transcriptional start site (TSS), as well as
a -1 kb upstream control (Figure 2.1C). Since p130 is absent in p107D/D;p130-/- mice, we
surveyed p107D occupancy and found it present at the Mybl2 promoter in p107D/D;p130f/f
mice, indicative of some p107-E2F4 binding at the CHR site independent of DREAM
(Figure 2.1C). Occupancy of p107D at this site was diminished in p107D/D;p130-/- mice and
this was coupled with a marked increase in B-MYB occupancy, consistent with MYBMuvB binding and displacing p107D-E2F complexes when p130 is no longer able to
assemble into DREAM (Figure 2.1C). We also confirmed DREAM disruption in
p107D/D;p130-/- mice using an in vitro promoter pulldown assay that relies on tandem CDE
and CHR elements for stable DREAM binding (Figure 2.3A). In these experiments p130
is detectable on this probe in p107D/D;p130f/f derived extracts, but not p107D/D;p130-/(Figure 2.3B). Furthermore, p107D is undetectable on this probe in either genotype of
extract, consistent with its inability to be assembled into DREAM36,37 (Figure 2.3B).
Collectively, these data demonstrate that p130 protein expression is missing in
p107D/D;p130-/- mice leading to compromised DREAM assembly and its replacement with
MYB-MuvB. This suggests that phenotypes from p107D/D;p130-/- mice will reveal the role
of DREAM in adult mammals.

2.3.2

p107D/D;p130-/- mice exhibit compromised renal function and
disrupted tissue structure in multiple organs
Cohorts of eight week old UBC-CreERT2;p107D/D;p130f/f mice were injected with

a course of tamoxifen (p107D/D;p130-/-) and aged alongside tamoxifen injected

101

Figure 2.3 In vitro DREAM assembly defect in p107D/D;p130-/- mice
Figure 2.3. In vitro DREAM assembly defect in p107D/D;p130-/- mice. (A) Schematic to
illustrated biotinylated DNA probes used for affinity capture of protein complexes. In these
in vitro assays, stable binding by DREAM requires simultaneous contact with CDE and
CHR elements to capture components. Failure to assemble the complex will prevent
detection of any components on the Ccna2 probe. The Actb probe is used as a negative
control. (B) Control p107D/D;p130f/f and p107D/D;p130-/- mice were used to produce liver
extracts and proteins were bound to the indicated probes and associated protein complexes
were isolated. Probe-bound proteins were separated by SDS-PAGE and western blotted to
detect p107D or p130 to ascertain if DREAM is assembled in these extracts.
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p107D/D;p130f/f control mice. There was a 16% reduction in lifespan for p107D/D;p130-/compared to controls that is significantly different (Log-rank test, P = 0.0236) (Figure
2.4A). Lifespan was similar for both male and female mice and their demise was often
without prior symptoms. Some p107D/D;p130-/-displayed distress characterized by shallow
breathing and a disheveled coat at this age and these ‘endpoint’ mice were euthanized for
further investigation. In contrast, p107D/D;p130f/f controls experienced classical aging,
characterized by kyphosis and predictable endpoints. To explore the underlying causes of
premature mortality in p107D/D;p130-/- mice, we examined tissues from p107D/D;p130-/mice at their endpoint and compared them histologically with control mice at the end of
their full lifespan. There was little evidence to support ectopic cell proliferation in these
mice. While some p107D/D;p130-/- mice displayed enlarged organs there was no significant
differences in average mass of livers, spleens, or kidneys (Figure 2.5). Examination of
hematoxylin and eosin (H&E) stained tissues failed to reveal hyperplasia, and Ki67
staining levels and patterns were not altered between genotypes (Figure 2.6). However,
H&E staining revealed abnormalities in the heart, kidney, liver, and spleen of
p107D/D;p130-/- mice (Figure 2.4B). Distinctive extracellular, amorphous, hypocellular,
and eosinophilic material in these tissues suggested the presence of amyloid fibril deposits.
These were found markedly and diffusely in the interstitium of the heart and kidneys,
expanding vessel walls in the liver, and on the periphery of the white pulp extending to the
red pulp of the spleen (Figure 2.4B, indicated by arrows).
The kidneys of p107D/D;p130-/- mice displayed the most visually dramatic deposits
with diffusely expanded interstitium, from the cortex to the medulla with variable
glomerular involvement (Figure 2.4B). Importantly, renal tubular epithelium were swollen
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Figure 2.4 p107D/D;p130-/- mice have shortened lifespan and compromised organ
function
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Figure 2.4. p107D/D;p130-/- mice have shortened lifespan and compromised organ
function. (A) Cohorts of p107D/D;p130-/- (n=30) and p107D/D;p130f/f control mice (n=37)
were aged to humane endpoints. Kaplan-Meir survival plots reveal survival proportions
and a log-rank test was used to compare outcomes (P = 0.0236). (B) H&E staining of
tissues obtained from p107D/D;p130f/f and p107D/D;p130-/- mice at endpoint. Examples of
poorly staining homogeneous, acellular, eosinophilic areas found in p107D/D;p130-/- mice
are indicated by arrows. Data is representative of 21 p107D/D;p130f/f and 25 p107D/D;p130/mice. Scale bars represent 400 m for heart, liver, and spleen. Scale bars represent 100
m for kidney. (C) Frequency of histologic abnormalities in p107D/D;p130f/f (n=21) and
p107D/D;p130-/- mice (n=25) for each of the indicated organs. (D) Urine samples were
collected from endpoint p107D/D;p130f/f and p107D/D;p130-/- mice and proteins were
resolved on SDS-PAGE gel and stained with Coomassie Blue. MUPs = major urinary
proteins. (E) Serum samples were collected from endpoint mice and were analyzed for
levels of creatinine. Bar graph represents mean quantities for the indicated genotypes and
error bars indicate one standard deviation (n=8). A student’s t-test was performed and ****
denotes P < 0.0001.
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Figure 2.5 Normal liver, spleen, and kidney mass in p107D/D;p130-/- mice
Figure 2.5. Normal liver, spleen, and kidney mass in p107D/D;p130-/- mice. (A) Whole
mount images of the indicated organs are shown, along with their genotypes. (B)
Comparison of organ mass relative to the animal’s body mass is shown for p107D/D;p130f/f
controls and p107D/D;p130-/- mice.
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Figure 2.6 Similar Ki67 staining in control and p107D/D;p130-/- tissues
Figure 2.6. Similar Ki67 staining in control and p107D/D;p130-/- tissues. (A) Tissue
sections were prepared from FFPE kidneys and hearts from mice of the indicated genotypes
at the indicated ages. Serial sections were stained with H&E and Ki67. Scale bars represent
200 m. (B) A similar analysis was performed on spleens and livers. Scale bars represent
200 m.
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due to cytoplasmic vacuolation, consistent with deposition leading to progressive decline
in renal function41-43. Indeed, almost 90% of endpoint p107D/D;p130-/- mice possessed this
type of organ damage, while the other affected organs were observed much less frequently
(Figure 2.4C). To investigate kidney function, we collected urine from endpoint
p107D/D;p130f/f and p107D/D;p130-/- mice and resolved equal volumes of urine by SDSPAGE to search for evidence of proteinuria44. All samples showed evidence of murine
major urinary proteins (MUPs), however the urine of p107D/D;p130-/- mice included a
prominent ~60 kD band that we confirmed by mass spectrometry to be serum albumin
(Figure 2.4D), indicating albuminuria in these mice45. Lastly, we tested serum creatinine
levels in endpoint mice and determined that it is significantly elevated in p107D/D;p130-/mice (Figure 2.4E). These data suggest that at their endpoint, p107D/D;p130-/- mice exhibit
defective kidney function. This is consistent with histological findings in the kidney, and
together they indicate kidney failure is the most common ailment in p107D/D;p130-/- mice.
Because sudden mortality in a portion of p107D/D;p130-/- mice prevented physiological and
histological investigation, it is possible some p107D/D;p130-/- mice succumb to a more rapid
cause of death such as cardiac arrest. Overall, multiple organs are damaged in
p107D/D;p130-/- mice leading to premature mortality.

2.3.3

Systemic amyloidosis is evident in p107D/D;p130-/- mice
We investigated the affected organs for potential amyloid deposition through

histological stains and transmission electron microscopy (TEM). Heart, kidney, liver, and
spleen tissue sections from p107D/D;p130-/- mice were stained with Congo Red and
examined under bright field optics and polarized light46-48. This demonstrated that weakly
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stained eosinophilic material corresponded with regions of apple-green birefringence, a
hallmark of amyloid fibril deposition (Figure 2.7A-D). The presence of amyloid fibril
structures in the medullar regions of kidney tissue was confirmed by TEM from formalinfixed paraffin-embedded (FFPE) tissue sections (Figure 2.7E).

Measurement of these

medullar amyloid fibrils revealed a mean diameter of 12 nm that is consistent with
amyloidosis49 (Figure 2.7F). We similarly detected fibrils using TEM in heart and liver
tissues of p107D/D;p130-/- mice (Figure 2.7G-H). These experiments confirm that the
disrupted tissue structures observed in the heart, kidney, liver, and spleen of p107D/D;p130/-

mice are amyloid in nature.
We next determined the prevalence and impact of amyloids in p107D/D;p130-/- mice

compared to p107D/D;p130f/f controls. Heart, kidney, liver, spleen, and brain tissue sections
from p107D/D;p130-/- and control mice were stained with Congo Red and scored to
quantitate amyloid deposition based on the quantity of affected area on a scale from 0 to 3
(Figure 2.8). Amyloid deposition scores were plotted for p107D/D;p130-/- and control mice
for each age cohort (1-year old and endpoint) (Figure 2.9A). We also enumerated these
amyloid deposition scores with other abnormal histological features, including relative
degree of cellular degeneration and inflammatory cell infiltrates, and plotted the aggregate
score for each mouse on an ordinal scale from 0 to 3 that is representative of the observed
diagnostic severity (Figure 2.8)50,51. In heart, kidney, liver, and spleen, p107D/D;p130-/mice consistently had increased amyloid deposition, cellular degeneration, and
inflammation at their endpoint compared to p107D/D;p130f/f control mice (Figure 2.9B),
and a similar trend was also apparent in comparisons of 1-year old p107D/D; p130-/- mice
and their age-matched controls. Notably, the striking amyloid deposition and other
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Figure 2.7 Systemic amyloidosis in p107D/D;p130-/- mice
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Figure 2.7. Systemic amyloidosis in p107D/D;p130-/- mice. (A)-(D) Tissue sections of
heart (A), kidney (B), liver (C), and spleen (D) from endpoint p107D/D;p130-/- mice were
stained with Congo Red. Bright field images were captured along with corresponding apple
green birefringence under polarized light. Scale bars represent 20 m. (E) FFPE tissues
were processed for transmission electron microscopy (TEM). Ultrastructure of acellular
material in the kidney is shown. Black arrows indicate fibril structure in this organ. (F)
Fibril diameters in kidney TEM images were measured. Bar graph represents mean
diameter obtained from individual fibril measurements and error bars indicate one standard
deviation (n=9). (G)-(H) TEM of FFPE heart (G) and liver (H) tissue. Black arrows
indicate areas of fibril deposition. For orientation, * indicates mitochondria in
cardiomyocytes and # denotes red blood cells in a hepatic capillary.
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Figure 2.8 Aggregate pathology scores for phenotypes observed in tissue sections
Figure 2.8. Aggregate pathology scores for phenotypes observed in tissue sections.
Tissues from 1-year and 2-year old endpoint mice from both cohorts were scored for three
criteria (amyloid deposition, cellular degeneration, inflammation) on a scale of 0-3 (n=6).
Scores were aggregated for each mouse as described.
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Figure 2.9 Tissue distribution and disease severity of amyloidosis in p107D/D;p130-/mice
Figure 2.9. Tissue distribution and disease severity of amyloidosis in p107D/D;p130-/mice. (A) Tissues from 1-year and endpoint mice from p107D/D;p130f/f and p107D/D;p130/cohorts were scored for amyloid deposition on a scale of 0-3 (n=6). Average scores were
plotted for 1-year old and endpoint mice and error bars represent one standard deviation.
Means were compared by two-way ANOVA and significance levels are indicated (***
denotes P < 0.001; **** denotes P < 0.0001; and ns denotes not significant, P > 0.05). (B)
Tissues from 1-year old and endpoint mice from p107D/D;p130f/f and p107D/D;p130-/cohorts were scored for three criteria (amyloid deposition, cellular degeneration,
inflammation) on a scale of 0-3 (n=6). Scores were aggregated for each mouse and plotted.
Mean scores are indicated along with one standard deviation. Means were compared by
two-way ANOVA and significance levels are indicated (* denotes P < 0.05; ** P < 0.01;
*** denotes P < 0.001; **** denotes P < 0.0001; and ns denotes not significant, P > 0.05).
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histologic abnormalities found in these tissues was absent from the brain (Figure 2.9A-B,
and Figure 2.10). Collectively, these results indicate p107D/D;p130-/- mice accumulate
extensive amyloid fibril deposition in the heart, liver, kidney, and spleen leading to defects
in normal organ structure and function. These characteristics are indicative of systemic
amyloidosis in p107D/D;p130-/- mice.

2.3.4

Apolipoproteins predominate in amyloid fibrils and are
overexpressed in p107D/D;p130-/- mice
There are more than 35 amyloid subtypes that have been identified in humans1,2.

To relate the amyloidosis phenotype in p107D/D;p130-/- mice with human clinical subtypes,
we utilized fluorescent optics of Congo Red stained tissue to identify amyloid deposits
(Figure 2.11A-B). We then performed laser capture microdissection from FFPE tissue
sections and used tandem mass spectrometry to determine its protein composition
(LMD/MS)52-54 (Figure 2.11C). In LMD/MS analysis, mutations in amyloid causing genes
correlate with abundance of their encoded proteins in amyloid deposits52. Combined with
the increased specificity enabled by focusing only on the Congo Red-stained areas, highly
abundant proteins in our analysis may be amyloidogenic in p107D/D;p130-/- mice. Within
this proteome, “amyloid signature proteins” are present, which serve as an internal control
to denote that amyloid deposition is present. These include apolipoprotein E (apoE), serum
amyloid P-component, and possibly clusterin and vitronectin52,55,56. Therefore, by
examining this enriched Congo Red-stained proteome for the most abundant proteins
present, we can identify causative protein candidates from the amyloid plaques in
p107D/D;p130-/- mice.
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Figure 2.10 H&E histology of control and p107D/D;p130-/- brains
Figure 2.10. H&E histology of control and p107D/D;p130-/- brains. Tissue sections were
prepared from FFPE brains and stained with H&E or Congo Red. Representative sections
used for amyloid scoring, cellular degeneration, and inflammation are shown and ages and
genotypes are indicated. Scale bars represent 400 m.
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Figure 2.11 ApoA-IV is the most abundant amyloidogenic protein in p107D/D;p130-/amyloid deposits

Figure 2.11. ApoA-IV is the most abundant amyloidogenic protein in p107D/D;p130-/amyloid deposits. (A) H&E staining of kidney from an endpoint p107D/D;p130-/- mouse.
Arrows indicate acellular eosinophilic material. Scale bar is 50 m. (B) Congo Red
staining of a serial section of the same kidney as in (A). Black arrows indicate the same
acellular material under bright field optics as in (A). White arrows mark the same locations
under polarized and fluorescent optics. Scale bars are 50 m. (C) Schematic illustration of
LMD/MS procedure: Congo red-positive regions are laser-captured and processed for mass
spectrometry to identify peptides present in amyloids. (D) Per spectral match quantities
were scaled relative to the most abundant protein in each sample, apoE. Rows (proteins)
were clustered and values are represented as indicated by the scale at the bottom. Each
column represents an organ from an endpoint p107D/D;p130-/- mouse. (E)-(G) Total RNA
used to synthesize cDNA. Gene expression was determined by qPCR in 3-month, 1-year,
and endpoint p107D/D;p130f/f and p107D/D;p130-/- mice and normalized to Gapdh for each
age group (n=4). Bar graphs show mean expression values for Apoa1 (E), Apoa2 (F),
Apoa4 (G) and error bars represent one standard deviation. Values are normalized to that
of p107D/D;p130f/f at each age for each gene. Two-way ANOVA was performed for each
gene and significance levels are indicated (**** denotes P < 0.0001; and ns denotes not
significant, P > 0.05). (H) Protein extracts from the livers of 3-month old p107D/D;p130f/f
and p107D/D;p130-/- mice were western blotted for the indicated proteins. Numerical values
represent band intensity ratio of apoA-IV relative to vinculin.
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LMD/MS analysis was performed on hearts, kidneys, livers, and spleens from
endpoint p107D/D;p130-/- mice. This identified a number of known amyloidogenic proteins,
as well as common amyloid-accompanying peptides. A representative list of proteins that
are known to be causative or associated with amyloidosis in humans, and present in an
endpoint p107D/D;p130-/- liver, is shown (Table 2.1). Consistent with human clinical cases,
the most abundant protein identified in all samples was apoE. Therefore, we normalized
spectral counts from each sample to its own apoE and compared the abundance of the
remaining amyloidogenic and amyloid-accompanying proteins. Figure 5D shows a
heatmap depicting relative spectral counts for each protein across five identically
microdissected samples. Among the known amyloidogenic proteins, apolipoprotein A-IV
(apoA-IV) consistently had the highest normalized spectral counts (Figure 2.11D),
followed by apoA-II and apoA-I (Figure 2.11D). Immunoglobulin light and heavy chains
were also detected in most of these samples at relatively low spectral counts (Figure
2.11D). This data suggests that apolipoproteins are the most likely cause of amyloidosis in
p107D/D;p130-/- mice.
Amyloid tissue deposition patterns identified by histological analyses and
amyloidogenic proteins identified by LMD/MS in p107D/D;p130-/- mice suggests apoA-IV,
apoA-II, or apoA-I, or a combination of these as the cause of amyloidosis in these mice.
Since DREAM is a transcriptional repressor and its loss promotes assembly of the
activating MYB-MuvB complex, we investigated expression levels of these
apolipoproteins. We performed qPCR analysis of RNA isolated from livers of 3-month, 1year, and endpoint p107D/D;p130f/f and p107D/D;p130-/- mice (Figure 2.11E-G). Each of
Apoa1, Apoa2, and Apoa4 were found to be over expressed in at least one of the time points
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Table 2.1 LMD/MS analysis of an endpoint p107D/D;p130-/- liver
Per spectral match quantities for each protein in the amyloid samples are shown in
descending order. Presumptive amyloidogenic proteins are indicated with *, while known
amyloid-associated proteins are
Identified peptides

Per spectral match

Apolipoprotein E#

34

Serum albumin#

33

Apolipoprotein A-IV*

21

Apolipoprotein A-II*

9

Vitronectin#

9

Clusterin#

7

Serum amyloid P-component#

6

Apolipoprotein A-I*

3

Ig kappa chain

3

Ig mu

3
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investigated. Only Apoa4 was significantly increased in p107D/D;p130-/- mice at all ages of
investigation (Figure 2.11G), and its protein levels were approximately 4-fold increased
in liver extracts from 3-month old p107D/D;p130-/- mice (Figure 2.11H), further suggesting
that it is the best candidate to be a causative protein in the amyloidosis observed. In
addition, we investigated the expression of amyloid associated components albumin, serum
amyloid P-component, and apolipoprotein E. Consistent with an associated role, Alb, Apcs,
and Apoe expression in the livers of p107D/D;p130-/- mice was unaltered (Figure 2.12).
An alternative interpretation of the LMD/MS data is that, although the spectral
counts for immunoglobulin chains were low, they may play a causative role too. Since
DREAM is known to function in proliferative control, and immunoglobulin amyloidosis is
common in myeloma patients, we investigated this possibility further. We found the
expression of Ighm to be significantly increased in the bones and spleens of 1-year and
endpoint p107D/D;p130-/- mice compared with controls (Figure 2.13). However, a key
difference between apolipoprotein- and immunoglobulin-based amyloidoses in human
patients is the presence of amyloid deposits in bone marrow and the gastrointestinal track57.
Neither H&E or Congo Red staining in endpoint p107D/D;p130-/- mice identified amyloid
deposits in bone marrow, nor did it reveal the presence of abnormally proliferating plasma
cells (Figure 2.14A). Examination of the small intestines of endpoint p107D/D;p130-/- mice
stained with Congo Red showed scattered amyloid deposits, but nothing distinct by H&E
staining as in the previously described organs above (Figure 2.14B). Overall, the lack of
bone marrow amyloids and only minor intestinal amyloids, but prominent cardiac, renal,
hepatic, and splenic involvement is most consistent with an apolipoprotein-derived
amyloid condition. In addition, apolipoprotein misexpression and greater detection levels
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Figure 2.12 Normal expression of amyloid associated protein coding genes in
p107D/D;p130-/- mice

121

Figure 2.12. Normal expression of amyloid associated protein coding genes in
p107D/D;p130-/- mice. (A)-(C): Gene expression in 3-month, 1-year, and 2-year old
endpoint p107D/D;p130f/f and p107D/D;p130-/- livers was assayed by real time qPCR for Alb
(serum albumin) (A), Apcs (serum amyloid P-component) (B), and Apoe (apolipoprotein
E) (C) (n=4). Expression values are normalized using Gapdh to that of p107D/D;p130f/f at
each age for each gene. Two-way ANOVA was performed for each gene; ns=not
significant.
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Figure 2.13 Ighm is overexpressed in p107D/D;p130-/- bone and spleen
Figure 2.13. Ighm is overexpressed in p107D/D;p130-/- bone and spleen. (A)-(B):
Expression of Ighm in 1-year and 2-year old endpoint p107D/D;p130f/f and p107D/D;p130-/mice was assayed by real time qPCR in bone (A) and spleen (B) tissue (n=4). Expression
values are normalized to Gapdh in p107D/D;p130f/f samples at each age. Two-way ANOVA
was performed and significance levels are indicated (**** denotes P < 0.0001; and ns
denotes not significant, P > 0.05).
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Figure 2.14 Absence of myeloma like amyloid deposits in p107D/D;p130-/- mice
Figure 2.14. Absence of myeloma like amyloid deposits in p107D/D;p130-/- mice. (A)
Bone tissues were harvested from 1-year and 2-year old endpoint p107D/D;p130f/f and
p107D/D;p130-/- mice. Bones were formalin fixed, demineralized, and stained with H&E or
Congo Red. Amyloid deposition was investigated by apple green birefringence and red
fluorescence. Scale bars represent 100 m. (B) Intestines were harvested from endpoint
p107D/D;p130f/f and p107D/D;p130-/- mice, fixed, and stained with H&E or Congo Red and
analyzed microscopically as before. Scale bars represent 500 m.
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in LMD/MS experiments suggest that they are the more likely cause of amyloidosis in
p107D/D;p130-/- mice. Lastly, the most consistent and highly overexpressed apolipoprotein
in the liver was apoA-IV and its prominent detection in amyloids indicates that it is the
most likely source of misexpressed protein to seed amyloid formation.

2.3.5

DREAM disruption leads to H2AZ loss at apolipoprotein
genes.
Based on MYB-MuvB binding to the Mybl2 promoter upon p130 deletion in our

initial characterization of this genetic model, we sought to determine if DREAM loss
misregulated apolipoprotein genes. A genome-wide analysis of predicted CHR and CDE
motifs has identified candidates for DREAM/ MYB-MuvB regulation20. From this dataset,
Apoa1 and Apoa4 were found to possess both elements and others such as Alb and Apoa2
possess CHR motifs. We performed quantitative chromatin immunoprecipitation (ChIPqPCR) assays on chromatin from livers of 3-month old mice to determine if
DREAM/MYB-MuvB bind any of these promoters (Figure 2.15A-D). We detected p107D
binding to the transcriptional start site (TSS) region of each of these genes in
p107D/D;p130f/f mice. However, the recruitment of p107D was significantly reduced in
p107D/D;p130-/- livers at Apoa1 and Apoa4 promoters (Figure 2.15A&C). The decrease in
p107D occupancy was accompanied by an increase in B-MYB at the same locations,
comparable to what was observed at the Mybl2 promoter (Figure 2.1C) that is indicative
of MYB-MuvB binding (Figure 2.15A&C). H2AZ – the histone H2A variant that
accompanies DREAM-mediated repression in lower organisms17 – was similarly analyzed.
We performed ChIP-qPCR for H2AZ at Apoa1 and Apoa4 gene bodies and saw a marked
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Figure 2.15 B-MYB is recruited to Apoa1 and Apoa4 promoters in DREAM
assembly-deficient p107D/D;p130-/- mice

126

Figure 2.15. B-MYB is recruited to Apoa1 and Apoa4 promoters in DREAM
assembly-deficient p107D/D;p130-/- mice. (A)-(D) Chromatin was prepared from livers of
3-month old p107D/D;p130f/f and p107D/D;p130-/- mice and utilized in ChIP assays to detect
p107D, B-MYB, and H2AZ occupancy at promoters (n=4). For each of Apoa1 (A), Apoa2
(B), Apoa4 (C), and Alb (D) genes, a schematic is shown to illustrate primer annealing
sites. Arrows depicting primers are color coded: black represents a neutral location 1 kb
upstream of the transcriptional start site (TSS); red is an approximately 100 bp region
encompassing the CHR and/or CDE motifs near the TSS; purple is within the gene body.
ChIP protein targets p107, B-MYB, and H2AZ are organized in columns across the top.
Bar graphs depict the mean quantity of chromatin associated with each protein target as
detected by qPCR and error bars represent one standard deviation. Two-way ANOVA was
performed for each and significance levels are indicated (* denotes P < 0.05; ** P < 0.01;
*** denotes P < 0.001; and ns denotes not significant, P > 0.05).
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decrease in p107D/D;p130-/- livers (Figure 2.15A&C). Importantly, Apoa2 and Alb
exhibited only background levels of H2AZ that were not altered between genotypes,
suggesting that these genes are not bona fide DREAM targets (Figure 2.15B&D). Overall,
these data provide evidence of direct transcriptional regulation of Apoa1 and Apoa4 by
DREAM/MYB-MuvB through the CHR and CDE motifs found in their proximal
promoters. Furthermore, Apoa1 and Apoa4 lose H2AZ from their gene bodies when
DREAM loss is replaced by MYB-MuvB. This data connects DREAM assembly defects
to loss of transcriptional control of apolipoprotein genes that leads to protein
overexpression and systemic amyloidosis in p107D/D;p130-/- mice.

2.4 Discussion
In the present study, we demonstrated loss of DREAM assembly leads to the
development of systemic amyloidosis in adult p107D/D;p130-/- mice. The absence of
DREAM increased MYB-MuvB recruitment to Apoa1 and Apoa4 promoters and is
correlated with reduced H2AZ levels and overexpression of Apoa1 and Apoa4 genes
(Figure 2.16A). These mice develop extensive amyloid deposition in the heart, kidney,
liver, and spleen but not in the brain or bone. Using mass spectrometry, we discovered
similar amyloidogenic and amyloid signature proteins in affected organs that implicated
apoA-IV as the most likely causative amyloidogenic protein in p107D/D;p130-/- mice
(Figure 2.16B). This condition lead to compromised renal function, and likely other organ
defects, and a shorter lifespan for p107D/D;p130-/- mice (Figure 2.16C). Overall, this mouse
model represents an important milestone in understanding idiopathic amyloidosis cases.
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Figure 2.16 Loss of DREAM assembly in p107D/D;p130-/- mice promotes MYB-MuvB assembly that drives systemic AApoAIV
amyloidosis due to constitutive overexpression of Apoa4
Figure 2.16. Loss of DREAM assembly in p107D/D;p130-/- mice promotes MYB-MuvB

assembly that drives systemic AApoAIV amyloidosis due to constitutive
overexpression of Apoa4. A schematic model illustrating the development of systemic
AApoAIV amyloidosis in p107D/D;p130-/- mice. At 3-months of age, ablation of p130 by
Cre activation combined with mutant p107D prevents DREAM assembly and promotes
MYB-MuvB activation of transcription. In the liver, MYB-MuvB occupies CHR and CDE
motifs at the transcriptional start sites of apolipoprotein genes, particularly Apoa4, leading
to reduced H2AZ occupancy within its gene body and constitutive overexpression (A). In
1-year old p107D/D;p130-/- mice, small amyloid deposits are evident in the heart, liver,
kidney, and spleen (B). By 2-years of age, apoA-IV deposition is more pronounced in the
heart, liver, and spleen. Deposition in the kidney of most p107D/D;p130-/- mice leads to
organ failure and reduced survival (C).
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The phenotype of p107D/D;p130-/- mice, characterized by AApoA-IV amyloidosis,
includes other provocative similarities with clinical reports of this condition. Amyloid
deposition in p107D/D;p130-/- mice was most apparent in kidneys and found throughout the
renal interstitium between the cortex and medulla. Similarly, the first reported case for
AApoAIV and subsequent analysis of additional AApoAIV patients revealed extensive
amyloid deposition in the interstitial space of the medulla16,58. LMD/MS analysis of these
patients identified apoA-IV as the major constituent of amyloid fibrils in the kidney along
with apoE, serum amyloid P-component, and serum albumin16,58, thus matching our
findings here. ApoA-I and immunoglobulin light chain peptides were also present in
AApoAIV, but at lower levels16,58. The involvement of apoE, serum amyloid P-component,
and serum albumin in forms of amyloidosis outside of the affected organs observed here
further suggests apoA-IV is most likely the causative component of the amyloid. Therefore,
our analysis of systemic amyloidosis in p107D/D;p130-/- adult mice is consistent with
clinically observed characteristics of AApoAIV. AApoAIV is a newly described form of
amyloidosis that has only begun to be appreciated when revealed by LMD/MS analysis.
The lack of an underlying mutation in the apoA-IV encoding gene in these patients has
created challenges in identifying the source of this disease and its classification. Our data
from p107D/D;p130-/- mice indicates that apolipoprotein misexpression and amyloid
deposition may result from a host of different sources that converge on H2AZ regulation
and underscores our discovery of this epigenetic source of amyloidosis.
Unlike hereditary amyloidosis caused by apoA-I or apoA-II whereby genetic
mutations in Apoa1 or Apoa2 lead to α-helix to β-sheet conformational changes in protein
structure that ultimately manifest as amyloid fibrils5, no such genetic variants have been
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implicated in AApoAIV15. Binding with HDL or protein-protein interactions are thought
to protect apoA-IV’s amyloidogenic hotspot regions within its core α-helices5. It can
therefore be surmised that overexpression of Apoa4 may create an imbalance in the
concentration of apoA-IV compared to its partner lipids or proteins, thereby increasing the
propensity to form amyloid fibrils. Herein, we showed loss of DREAM assembly in
p107D/D;p130-/- mice leads to consistent overexpression of Apoa4 at every age we
investigated whereas Apoa1 overexpression only occurred in 3-month old mice. We
observed a direct interaction of p107 and B-MYB with the Apoa1 and Apoa4 transcription
start sites which contain putative CHR and CDE sites20. It is known that loss of DREAM
causes a dynamic shift in which the transcriptional activator MYB-MuvB occupies the start
site and activates expression23,36. Our data demonstrates this switch occurs with a
concomitant reduction of the H2AZ repressive mark within Apoa1 and Apoa4 gene bodies.
This suggests that these are specific and important DREAM target genes and that a
combination of H2AZ reduction and MYB-MuvB activation increase their expression.
Prior work on worms and flies established DREAM as a regulator of gonadal and sex
specific gene expression in addition to cell cycle control59; our study indicates that
apolipoprotein gene expression is a critical category of DREAM target genes required in
mammalian physiology.
In this study we have shown that DREAM loss and gain of MYB-MuvB activates
expression of Apoa4 to drive AApoAIV-mediated amyloidosis. This suggests that
enhancement of DREAM or attenuation of B-MYB may offer therapeutic benefit in
treating AApoAIV. Additionally, understanding other epigenetic regulators that may help
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to control H2AZ deposition levels at these genes are also potential targets to ameliorate
expression of amyloidosis causing apolipoprotein genes in the future.

2.5 Materials and Methods
2.5.1

Mouse genetics
We utilized our mice that are homozygous for Rbl1tm1.1Fad (referred to as p107D/D

)36 and Rbl2tm2.1Tyj (referred to as p130f/f , stock# 008177 Jackson Labs)35, in which exon 2
of p130 is flanked by loxP sites. Experimental mice possessed the Ndor1Tg(UBC-cre/ERT2)1Ejb
transgene38 that was also obtained from Jackson Labs (stock# 007001), while control
animals were p107D/D;p130f/f. All mice received tamoxifen administration intraperitoneally
at 8 weeks of age (75 mg/kg body weight administered in corn oil every 24 hours for 3
consecutive days). This experimental design with a Cre deficient cohort allowed us to
control for potential tamoxifen induced liver injury in this study60,61.

2.5.2

Genotyping p130 exon 2 deletion in mice
DNA was isolated from the tail, muscle, liver, heart, brain, testis, and bone from

mice 1-week and approximately 2 years after tamoxifen administration. PCR was
performed to amplify the region surrounding exon 2 and the products were resolved on
agarose gels using standard protocols. Primer sequences are listed in Table 2.2.
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Table 2.2 Primers used for PCR experiments in Chapter 2
Primer
p130 (Rbl2) PCR forward
p130 (Rbl2) PCR reverse
Apoa1 qPCR forward
Apoa1 qPCR reverse
Apoa2 qPCR forward
Apoa2 qPCR reverse
Apoa4 qPCR forward
Apoa4 qPCR reverse
Alb qPCR forward
Alb qPCR reverse
Apcs qPCR forward
Apcs qPCR reverse
Apoe qPCR forward
Apoe qPCR reverse
Ighm qPCR forward
Ighm qPCR reverse
Gapdh qPCR forward
Gapdh qPCR reverse
Ccna2 probe forward
Ccna2 probe reverse (biotinylated)
Actb probe forward
Actb probe reverse (biotinylated)
Mybl2 -1kb body ChIP-qPCR
forward
Mybl2 -1kb body ChIP-qPCR
reverse
Mybl2 TSS ChIP-qPCR forward
Mybl2 TSS ChIP-qPCR reverse
Apoa1 -1kb ChIP-qPCR forward
Apoa1 -1kb ChIP-qPCR reverse
Apoa1 TSS ChIP-qPCR forward
Apoa1 TSS ChIP-qPCR reverse
Apoa1 gene body ChIP-qPCR
forward
Apoa1 gene body ChIP-qPCR
reverse
Apoa2 -1kb ChIP-qPCR forward
Apoa2 -1kb ChIP-qPCR reverse

Sequence
GTGTTGTAACATTCTCGTGGG
GTGTTGTAACATTCTCGTGGG
GTGGCTCTGGTCTTCCTGAC
ACGGTTGAACCCAGAGTGTC
GCCTGTTCACTCAGTACTTTCAG
CAGACTAGTTCCTGCTGACC
ATGCCAAGGAGGCTGTAGAA
CAGTTTCCTGGGCTAGATGC
CATGTTGCAAGGCTGCTGACAAG
AGTGACAAGGTTTGGACCCTCAG
TGGACCAAGCATGGACAAGCTAC
GGCTTCTGAAAGAAGGCTGGTG
GGACTTGTTTCGGAAGGAGCTGAC
TTGCCACTCGAGCTGATCTGTCAC
CACCCATCCACCTGGCTGCTCA
AATGGTGCTGGGCAGGAAGT
TGCACCACCAACTGCTTAG
GGATGCAGGGATGATGTTC
TGTCGCCTTGAATGACGTCA
ACCCACCCTCCTGCAGATAT
AGAGCTACGAGCTGCCTGAC
AGCACTGTGTTGGCGTACAG
GCCTGAGCCTAAAGGGCATT
TCTGATGGCAAGGGTTGTCTC
ACGCACTTGGCGGGAGATAG
CTCAGGCGTCAGCGTGTCT
CCAAGTGCAAAAACTGGCCA
GTCTTCCCAGAGTGGTGAGG
GGCCAGGCTGAGCTTATCAG
TCCGACAGTCTGGGTGTCCA
CAGAAGCTGCAGGAGCTGCAAG
CTAGCTGTGTGCGCAGAGAGTCTA
AGGAATTTCATTCATGAGACCTATCA
CACACACACACACACACACC
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Table 2.2 continued from previous page
Primer
Sequence
Apoa2 TSS ChIP-qPCR forward
GCCATTCTCCGTATCACCTGACGG
Apoa2 TSS ChIP-qPCR reverse
CTGCAGTCCTTCCCGTCTACTCT
Apoa2 gene body ChIP-qPCR
GAGCTTTGGTTAAGAGACAGGCAGAC
forward
Apoa2 gene body ChIP-qPCR
CAGAGACTTACTTGGCCTGGC
reverse
Apoa4 -1kb ChIP-qPCR forward
AGCAAATCAGACTGGGCACA
Apoa4 -1kb ChIP-qPCR reverse
GGGCATCCATCATACTGTCCC
Apoa4 TSS ChIP-qPCR forward
GCTGTCAGCTTCCACGTTGTCTTAG
Apoa4 TSS ChIP-qPCR reverse
TCCCCAGTGTGACTCCACGTTG
Apoa4 gene body ChIP-qPCR
CGACGCACTGTGGAGCCCATG
forward
Apoa4 gene body ChIP-qPCR
GCTCAAGTGGCTTTCCACCTCC
reverse
Alb -1kb ChIP-qPCR forward
TGAGGACACAAGATGAGGTCA
Alb -1kb ChIP-qPCR reverse
AGAGAGGAGGAGGAGGAAGAG
Alb TSS ChIP-qPCR forward
CTGAGCCAGACATTCCCCAA
Alb TSS ChIP-qPCR reverse
ATTCCAGCAGGTCACCATGG
Alb gene body ChIP-qPCR forward AGTGAGGTGGAGCATGACAC
Alb gene body ChIP-qPCR reverse AAGACATCCTTGGCCTCAGC
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2.5.3

Western blotting
Tissues were collected from mice and homogenized using an automatic

homogenizer in complete RIPA buffer with protease inhibitors (Sigma #S8820) and
incubated for 1 hour on ice. Samples were centrifuged at 12 000 g in a 4°C centrifuge. The
supernatant was collected, and protein concentration was determined by Bradford assay.
Lysates were mixed with 6x SDS loading dye buffer and resolved using standard SDSPAGE protocols in 8% acrylamide gels. Antibodies used for blotting were p107
(MyBioSource anti-p107 rabbit antibody #MBS440044), p130 (Santa Cruz anti-p130
rabbit antibody #SC-317), apoA-IV (Cell Signaling Technology anti-ApoA4 mouse
antibody #5700), tubulin (Cell Signaling Technology anti-Tubulin rabbit antibody #2125),
and vinculin (Cell Signaling Technology anti-Vinculin rabbit antibody #4650). Band
intensities were measured and analyzed in ImageJ version 1.53c.

2.5.4

Chromatin immunoprecipitation (ChIP)
ChIP assay was performed as described previously62,63. Livers were harvested from

3-month old p107D/D;p130f/f and p107D/D;p130-/- mice mid-morning. Livers were weighed
and cut into 60 mg pieces that were then homogenized in ice cold PBS using an automatic
homogenizer. Samples were incubated with 1% formaldehyde for 10 minutes on a rotator
at room temperature. Samples were then sonicated. 50 µL protein A/G Dynabeads
(Invitrogen) were premixed with ChIP antibodies (p107: 10 µg, MyBioSource anti-p107
rabbit antibody #MBS440044; B-MYB: 10 µg, Millipore Sigma anti-B-MYB mouse
antibody #MABE886; H2AZ: 5 µg, Abcam anti-Histone H2A.Z rabbit antibody #ab4174)
and then combined with lysed and sonicated samples and incubated overnight at 4°C with
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rotation. Dynabeads were then washed and chromatin was eluted using elution buffer (1%
SDS, 0.1 M NaHCO3) following de-crosslinking DNA was isolated. The resulting ChIP
DNA was analyzed by qPCR (as described above) with primers pairs designed to amplify
-1 kilobases (kb) upstream of the transcriptional start site (neutral location), primers to
amplify the proximal promoter regions, and primers to amplify within the gene bodies of
Apoa1, Apoa2, Apoa4, Alb, and Mybl2 (Table 2.2).

2.5.5

Ccna2 promoter pulldown
Primer pairs (Table 2.2) were used to amplify the promoter region of Ccna2

containing a cell cycle-dependent element (CDE) and a cell cycle genes homology region
(CHR) and Actb, such that only one primer was biotinylated resulting in the amplicon being
biotinylated at one end. These were purified using a PCR cleanup kit (Invitrogen).
Dynabeads were washed and prepared in 2x binding & washing buffer (10 mM Tris-HCl
pH 7.5, 1 mM EDTA, 2 M NaCl). An equal volume of purified PCR fragments in nuclease
free water were added and incubated for 15 minutes at room temperature on a rotator.
Dynabeads were then washed 3x with 1x binding and washing buffer and after the final
wash, all buffers were removed from the tube. Lysates obtained from livers of 3-month old
p107D/D;p130f/f and p107D/D;p130-/- mice as described above. one mg of protein in RIPA
lysis buffer was added to the Dynabeads as well as 0.1 µL of 10% NP-40 and mixed
overnight at 4°C. Dynabeads were then washed twice in lysis buffer and 50 µL release
buffer (10 mM EDTA pH 8.2 with 95% formamide) was added and incubated for 2 minutes
at 90°C. Supernatant containing bound proteins was collected, 5x SDS loading dye was
added, and proteins were resolved by SDS-PAGE and identified by western blotting.
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2.5.6

Tissue preparation and staining
Mice were either aged until their endpoints or sacrificed at an earlier time point.

The following organs were collected and fixed in formalin: brain, heart, lungs, liver,
kidney, spleen, ovaries, testes, and lymph nodes. Tissues were processed and sectioned in
the Molecular Pathology core facility at Robarts Research Institute (London, Canada).
Stained with H&E or Congo Red was carried out by the core facility using standard
methods.

2.5.7

Scoring amyloid damage to tissues
Tissues stained with H&E or Congo Red were scored for amyloid deposition,

cellular degeneration, and inflammation each on a scale of 0-3 as per the criteria shown in
Figure 2.8. Cumulative scores from all three categories were used to determine an
aggregated, semiquantitative pathology score for each tissue and timepoint.

2.5.8

Proteinuria assay
Urine from mice was collected and assayed for protein as previously described44.

Briefly, urine was directly collected into 1.5 mL tubes. 9-parts urine was mixed with 1-part
10x SDS loading dye buffer. 10 µL urine per mouse was resolved by SDS-PAGE gels and
proteins were stained with Coomassie Blue to visualize proteins.
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2.5.9

Creatinine assay
Whole blood was collected through cardiac puncture from approximately 2-year

old endpoint mice. Blood was allowed to clot undisturbed at room temperature for 15
minutes and the clot was removed by centrifugation at 2,000 g for 15 minutes to separate
serum. Serum was diluted 1:1000 and assayed in triplicates using Abcam Creatinine Assay
Kit (#ab65340). Samples were measured fluorometrically using a Wallac 1420 Victor2
microplate reader (Perkin Elmer Informatics, Waltham, MA) at Ex/Em 538/587 nm.

2.5.10

Protein identification

MALDI-MS was performed at the London Regional Proteomics Centre (London,
Canada). Briefly, Coomassie Blue stained bands were excised and in gel digested using a
MassPREP automated digester (PerkinElmer, Downers Grove, IL). Peptides were ionized
with an AB Sciex 5800 TOF/TOF using a TOF/TOF Series Explorer data acquisition
system. Protein identification was made using the Mascot search engine.

2.5.11

Transmission Electron Microscopy (TEM)

TEM was performed at the Biotron (London, Canada) on paraffin-embedded tissue
blocks. Fragments of paraffin embedded tissue were cut into 1 mm³ pieces using a biopsy
punch. Using the methods of Lighezan et al.64, tissues were deparaffinized in xylene three
times for 30 minutes at room temperature. Specimens were then rehydrated in a descending
series of ethanol solutions followed by rinsing in 0.1 M cacodylate buffer for 10 minutes.
Tissues were then post-fixed in a 3% glutaraldehyde in 0.1 M cacodylate buffer (pH 7.4)
overnight (~12 hours) at 4°C and then were rinsed in 0.1 M cacodylate buffer. Post-fixation
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was carried out for 1 hour with 1.0% osmium tetroxide in 0.1 M cacodylate buffer.
Specimens were dehydrated in an ascending series of ethanol solutions and embedded in
Spurr’s resin at 60°C for 2 days. Ultra-thin (70 nm) sections were cut using an
ultramicrotome (Ultramicrotome Reichert-Jung Ultracut E; Leica Microsystems, Wetzlar,
Denmark). Imaging was carried out using a Philips CM10 transmission electron
microscope (Philips Electron Optics, Eindhoven, The Netherlands) and amyloid fiber
diameters was measured using CM10 image analysis software.

2.5.12

Amyloid subtyping by laser microdissection mass
spectrometry (LMD/MS)

Sample preparation and proteomics analysis were performed at University Health
Network’s Laboratory Medicine Program (Toronto, Canada). A modified method
previously published by Dogan`s group65, was used for protein extraction from mouse
tissue. Briefly, a 10 μm thick section of formalin-fixed paraffin-embedded (FFPE) tissue
was mounted on a Director slide (NantOmics, Rockville, MD) and stained with Congo red.
Amyloid-positive regions were then extracted with the LMD7000 laser capture
microdissection (LMD) system (Leica Microsystems, Wetzler, Germany) and collected via
gravity in caps of 0.5 mL microtubes containing 35 μL of protein extraction buffer (mix
of 10 mM Tris, 1 mM EDTA, and 0.002% Zwittergent 3-16 (Calbiochem, San Diego,
CA)). After tissue collection, microtubes were centrifuged for 2 min at 9,295g (Eppendorf
microcentrifuge, 5417C). To extract proteins from FFPE matrix we heated the samples at
98 ˚C for 90 min with occasional vortexing. Samples were then sonicated in a water bath
for 1 h (VWR Scientific Aquasonic, P250D) and then digested with 0.5 μg of trypsin
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(Promega, Madison, WI) overnight at 37°C. Digested samples were reduced with 2 μL of
0.1 M dithiothreitol at 95°C for 5 min and diluted with 7 μL of 0.5% trifluoroacetic acid
and 0.15% formic acid solution made in LC-MS grade water. 18 μL of sample was
analyzed using nanoflow liquid chromatography-tandem mass spectrometry (nLCMS/MS).
All samples were analyzed using a hybrid Thermo LTQ Orbitrap XL mass
spectrometer coupled to a Thermo Easy nLC 1000 liquid chromatography system. Peptides
were applied to a trap C8 column (150 μm ID x 20 mm, New Objective, Woburn, MA; 5
μm Magic C8 packing, Michrom Bioresources, Auburn, CA) and separated on a reverse
phase C18 column (75 μm ID x 150 mm, New Objective, Woburn, MA; 3 μm Agilent
Pursuit C18 packing, Agilent Technologies, Santa Clara, CA) using a linear gradient from
1% to 65% acetonitrile containing 0.1% formic acid over 112 min at a flow rate of 300
nl/min. Eluting peptides were ionized using Nanospray Flex Ion source (Thermo Electron,
Bremen, Germany) and the corresponding spectra in the positive ion mode were obtained
under data-dependent acquisition mode. Full MS scans were collected in the orbitrap (400
– 1500 m/z range, 60,000 resolution) while the top 7 most intense precursor ions that
underwent collisionally induced dissociation at 35 V were detected by the linear ion trap.
The resulting raw data files were processed using the Proteome Discoverer 1.4
(Thermo Scientific) and the Sequest HT algorithm. The fragmentation spectra were
searched against the UniProt Mus musculus database (last modified January 15, 2020). The
search parameters were as follows: the precursor mass tolerance was 7 ppm and the
fragment mass tolerance was set to ±0.05 Da. The peptide false discovery rate (FDR) was
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less than 1%. Peptides associated with a high confidence level identification (probability
of identification >90%) were filtered and selected for protein identification.

2.5.13

RT-qPCR

Tissues were collected from mice at different time points (3 months, 1-year, and
endpoint mice) and processed using the Monarch Total RNA Miniprep Kit (NEB
#T2010S). RNA was reverse transcribed using iScript (Bio-Rad #1708891) and cDNA was
diluted 5x with nuclease-free water. Real-time qPCR was performed for Apoa1, Apoa2,
Apoa4, Alb, Apoe, Apcs, Ighm, using PowerUP SYBR (Applied Biosystems #A25742).
Gapdh was used as the internal control. Primer sequences are available in Table 2.2.

2.5.14

Statistics

Specific statistical tests used are indicated in the figure legends for each experiment.
Analysis was done using GraphPad Prism version 7. A P-value of less than 0.05 was
considered significant.

2.5.15

Study Approval

All animal experiments were approved by Western Universities animal use
committee in accordance with regulations from the Canadian Council on Animal Care.
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Chapter 3

3

BEAVR: A Browser-based tool for the Exploration and
Visualization of RNA-seq data

3.1 Abstract
Background: The use of RNA-sequencing (RNA-seq) in molecular biology research and
clinical settings has increased significantly over the past decade. Despite its widespread
adoption, there is a lack of simple and interactive tools to analyze and explore RNA-seq
data. Many established tools require programming or Unix/Bash knowledge to analyze and
visualize results. This requirement presents a significant barrier for many researchers to
efficiently analyze and present RNA-seq data.
Results: Here we present BEAVR, a Browser-based tool for the Exploration And
Visualization of RNA-seq data. BEAVR is an easy-to-use tool that facilitates interactive
analysis and exploration of RNA-seq data. BEAVR is developed in R and uses DESeq2
as its engine for differential gene expression (DGE) analysis, but assumes users have no
prior knowledge of R or DESeq2. BEAVR allows researchers to easily obtain a table of
differentially-expressed genes with statistical testing and then visualize the results in a
series of graphs, plots and heatmaps. Users are able to customize many parameters for
statistical testing, dealing with variance, clustering methods and pathway analysis to
generate high quality figures.
Conclusion: BEAVR simplifies analysis for novice users but also streamlines the RNA-seq
analysis process for experts by automating several steps. BEAVR and its documentation can
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be found on GitHub at https://github.com/developerpiru/BEAVR. BEAVR is available as a
Docker container at https://hub.docker.com/r/pirunthan/beavr.

3.2 Background
RNA-sequencing (RNA-seq) has revolutionized molecular biology research in the
last decade [1]. RNA-seq is a high-throughput sequencing method that allows for the
quantification of gene expression patterns between experimental groups using differential
gene expression (DGE) methods [2]. Analysis of DGE may guide the early phases of
studies by highlighting transcripts and/or pathways with altered expression in a given
experimental system or may be used to assess the downstream impacts of a treatment or
other experimental condition. RNA-seq experiments may follow almost any variation of in
vitro or in vivo study in which RNA is collected [3]. Most recently, RNA-seq has been
employed clinically, including in numerous cancer-related clinical trials [4-6].
Once the wet lab components of an RNA-seq experiment are completed, the data
must be analyzed computationally. To date, a multitude of tools are available to researchers
depending on the experimental question (e.g. the discovery of novel transcripts or
determining gene expression changes) [3, 7]. Regardless of the analysis tool selected, the
vast majority of currently available tools require knowledge of programming (C/C++, Perl,
Python, R) or shell scripting (Unix/Bash shell). DESeq2, one of the most popular
analytical software packages for DGE, is written in R and requires an understanding of this
language to manipulate data and visualize results [8]. The requirement for users to navigate
one or more computational languages in order to analyze RNA-seq data presents a
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substantial barrier for many researchers who are adept with respect to the wet lab
components of RNA-seq but unfamiliar with the computational aspects.
Here, we present BEAVR, a Browser-based tool for the Exploration And
Visualization of RNA-seq data. BEAVR is an operating system (OS)-independent software
package written in R that can run locally on a user’s computer or on a remote server.
BEAVR provides an easy-to-use graphical frontend to allow both novices and experts to
perform DGE analyses on RNA-seq datasets. Specifically, BEAVR simplifies the process
of visualization and exploration of results and allows users to generate visually-appealing
graphs, tables, plots, heatmaps and pathways maps. At its core, BEAVR uses the heavilycited DESeq2 as the engine for its analysis. While there is no single superior method for
RNA-seq analyses, DESeq2 is an ideal choice because it requires only raw, unnormalized
read counts and provides functions to perform DGE and statistical analyses. Our
implementation allows for the visualization of PCA plots, read count plots, volcano plots,
heatmaps and enriched pathways and facilitates the exploration of DGE results to aid
researchers in their study of known gene interactions as well as providing tools for the
discovery of novel gene interactions.

3.3 Implementation
3.3.1

Interface & typical workflow
BEAVR’s graphical user interface (GUI) is developed in R using the shiny

framework. The layout is divided into a main panel and a sidebar panel (Figure 3.1A). The
main panel presents the user with a tabbed environment that breaks the workflow of DGE
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Figure 3.1 Overview of BEAVR’s graphical user interface and typical workflow
Figure 3.1. Overview of BEAVR’s graphical user interface and typical workflow. (A)
BEAVR's easy-to-use graphical user interface (GUI) is divided into two areas; a main work
area and a sidebar. The main work area has a tabbed-interface to select data output and
figure displays. Depending on the tab selected in the main working area, the contextdependent sidebar will show appropriate options and parameters that allow the user to
customize analysis, data output and figures. (B) BEAVR breaks down the RNA-seq analysis
workflow into logical steps. Users begin by loading their data (raw read counts and sample
information) and select experimental settings for analysis and statistical tests. Then
differential gene expression (DGE) analysis is performed automatically using DESeq2,
lastly the data is displayed in interactive tables, graphs and plots that users can explore,
manipulate and customize.

151

analysis into easy-to-follow logical steps. Depending on which tab is open, the sidebar will
display context-dependent parameters that control the output and display of data in the
work area of the main panel. The user can manipulate these parameters at any time and the
results will be recalculated and updated in real-time, drastically reducing the amount of
time required compared to command-line based approaches.
A typical workflow for RNA-seq analysis using BEAVR is shown in Figure 3.1B.
Briefly, data is loaded into BEAVR, DGE analysis is performed using DESeq2 and the
results are visualized in interactive tables, in graphs and other displays. In the Load Data
tab, the user must provide a DESeq2 compatible read count table file containing
raw, unnormalized read counts (obtained using alignment tools such as STAR or HTSeq)
as well as a sample treatment matrix file (created in a text editor or spreadsheet
program). The read count table file (either TXT or CSV) should contain the read
quantities for all of the samples in the experiment (Figure 3.2A). The first column must
contain ENSEMBL identifiers for each gene. The heading for this column must be
gene_id. The next n columns must contain raw read counts for each of the n samples.
The headings for these n columns must be unique sample identifiers (e.g. wildtype-1,
wildtype-2,

wildtype-3,

sample treatment

mutant-1,

mutant-2,

mutant-3). The

matrix file (either TXT or CSV) informs BEAVR which

columns (samples) in the read count table file belong to which treatment groups
(Figure 3.2B). This allows multiple replicates to be grouped together across different
experimental conditions. The first column must list in each row the sample identifiers for
all n columns in the read count table file (e.g. wildtype-1, wildtype-2,
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Figure 3.2 BEAVR requires two inputs: a read count table file and a sample
treatment matrix file
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Figure 3.2. BEAVR requires two inputs: a read count table file and a sample
treatment matrix file. (A) BEAVR requires raw, unnormalized read counts as input.
This can be obtained using tools such as STAR or HTSeq. The first column of the read
count table file must have the heading gene_id and contain unique ENSEMBL IDs.
Every column after must contain read counts for one sample, each with a unique identifier
in the heading (e.g. Sample-1, Sample-2, …, Sample-n). The read count
table file must be either a TXT or CSV format. (B) BEAVR requires an additional file,
called a sample treatment matrix file, that contains important characteristics
about each sample, such as which treatment group the samples belong to. The first column
of this file must contain in each row all the samples found in the read count table
file (e.g. Sample-1, Sample-2, …, Sample-n) in the same order. The second column
must have the heading condition. The third column must have the heading
replicate. In the condition column, users must specify which experimental group
each sample belongs to (e.g. Wildtype, Mutant, or Drug-Treated). In the replicate
column, users can provide any other additional grouping information or replicate
information (e.g. Replicate-1, Replicate-2, …, Replicate-n). The sample
treatment matrix file must be either a TXT or CSV format.
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wildtype-3, mutant-1, mutant-2, mutant-3). The second column of the
sample treatment matrix file specifies which experimental condition each sample
belongs to (e.g. wildtype and mutant, or untreated and drug-treated). The
heading for this column must be condition. In the third column, the user may specify
any additional characteristics for each sample, such as replicate numbers/letters or
genotype groups (e.g. replicate-A,

replicate-B,

replicate-C). The

heading for this column must be replicate. Both the read count table file and
the sample

treatment

matrix file must contain at least two experimental

conditions with a minimum of 2 samples each. Treatment groups do not need to contain
the same number of samples in each group.
In the Settings tab, the user must select a control condition and a treatment
condition (condition choices are loaded from those available in the sample treatment
matrix file). For DGE analyses, DESeq2 is used to compare the selected treatment
condition against the selected control condition. The user may specify a minimum cutoff
for reads if desired (reads below this cutoff value are dropped before analysis), specify a
false discovery rate (FDR) to determine adjusted p values (padj) and also specify an effect
size shrinkage method using DESeq2 [8] or apeglm (approximate posterior estimation)
[9].

3.3.2

Representation of results & data exploration
Clicking on the Gene Table tab will initiate automated DGE analysis using the

parameters specified by the user. A progress bar will be shown in the bottom right of the
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main work area. Upon completion, an interactive table displays the results including gene
IDs as HUGO Gene Nomenclature Committee (HGNC) symbols, log2 fold changes (LFC),
p values and padj values for each gene. Controls in the sidebar may be used to filter the table
as desired and a copy may be saved using the Download Table button.
Visualization of all plots is implemented using ggplot2. The PCA tab will
generate a principal component analysis (PCA) plot and display all the samples found in
the read count table file. In the Sample Clustering tab, the user can select a
distance measurement method to use (Pearson correlation, Euclidean, Maximum,
Manhattan, Canberra, Binary, or Minkowski) which will compute a distance matrix using
the ComplexHeatmap and dist packages and display the sample variation as a
heatmap. The Read Count Plots tab will generate normalized read count plots, either
as boxplots or jitter plots, for desired genes. The user can enter gene names separated by a
comma and change the grid layout as desired (use a 1x1 grid for a single plot or increase
the grid size as necessary to fit multiple plots). The Heatmap tab will allow the user to
generate a heatmap with gene clustering for the top n significantly variable genes (where
n is a user-defined number), or for any list of genes entered by the user. Dependence of the
variance on the mean is removed using either variance stabilization (vst) or regularized
logarithm (rlog) transformations [8] as specified by the user. The user can also specify a
hierarchical clustering method (Ward.D/D2, Single, Complete, Average, McQuitty,
Median, or Centroid) to be used by the hclust package (for row and/or column
clustering) and a distance measurement method as described above. The Volcano Plot
tab will generate a volcano plot using the EnhancedVolcano package to illustrate
differentially-expressed genes that meet the user-defined LFC and padj cutoffs for the
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control and treatment conditions specified on the Settings tab. Pathway overrepresentation analysis and gene set enrichment analysis (GSEA) are performed using the
ReatomePA and enrichplot packages [10] and figures are shown in the Pathway
Enrichment Plot, Pathway Enrichment Map, GSEA Plot and GSEA Map
tabs with the tabular results being displayed in the Pathway Enrichment Table and
GSEA Table tabs. All customization options are presented in the sidebar and allow users
to control many parameters when plotting figures, including the ability to customize colors,
font sizes and legend positions and directions (horizontal or vertical) for all figures. The
size and aspect ratio of all figures can be adjusted by clicking and dragging the outside
edges of the plot area. The Save Plot button located above every plot allows figures to
be saved in multiple formats (JPEG, PDF, PNG, SVG, TIFF) while the Download
Table button in the sidebar allows data from any table to be saved (CSV).

3.3.3

Installation
Since BEAVR is developed in R (+3.5), it is OS-independent and runs on Linux,

Mac OS and Windows. We provide several methods to install and use BEAVR depending
on user preference: 1) the easiest method for those unfamiliar with R is to install Docker
(https://docker.com)

and

use

our

Docker

container

(https://hub.docker.com/r/pirunthan/beavr) which comes pre-installed with all of the
required components; or 2) users can use our OS-specific scripts to install and configure R
with all of the required packages for BEAVR; or 3) users who already have R installed can
download BEAVR from GitHub. Additionally, system administrators may install BEAVR
in a multi-user server environment which is useful for research groups that want to have a
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centralized

server

for

BEAVR.

This

is

implemented

using

ShinyProxy

(https://shinyproxy.io) and Docker which provide a secure, sandboxed environment for
every connected user. We provide automated install scripts on GitHub to easily accomplish
this and system administrators can customize the installation to their specific network
requirements. Each of these methods simplify and streamline setup for novice and expert
users alike and are well-documented on the GitHub page for BEAVR located at
https://github.com/developerpiru/BEAVR.

3.3.4

Run time consideration
Computation time is dependent on the user’s device specifications since all DGE

analyses, statistical tests and visualization steps are performed locally (or the server
specifications when running BEAVR on a shared server). For a typical mammalian RNAseq experiment containing two experimental groups with three replicates each using the
human genome as a reference (88 million reads total), automated calculations will take
approximately 1 minute with a dual-core Intel Core i5 CPU and 4 GB RAM or
approximately 30 seconds with a 6-core Core i7 and 16 GB RAM. Generation of each
figure, as well as subsequent modifications thereto, will take a few additional seconds.
These short processing times will allow users to repeatedly manipulate experimental
settings to recalculate DGE as desired with different parameters. Users may then explore
the results, generating figures and filtering and downloading the data for downstream
applications.
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3.4 Results & Discussion
3.4.1

A typical use case
To demonstrate a typical use case for BEAVR, we utilized a previously published

RNA-seq dataset by Sehrawat et al. [11]. In this study, LNCaP cell cultures were treated
with either DMSO or SP2509 (a small molecule lysine-specific demethylase 1 [LSD1]
inhibitor) for 24 hours [11]. RNA-seq was performed on RNA harvested from triplicate
cell cultures corresponding to each treatment condition. We downloaded raw,
unnormalized read counts from GEO (GSE59009) and merged the read counts from all
samples to make a single read count table file (TXT). We created a sample
treatment

matrix file (CSV) using Microsoft Excel to specify the treatment

condition group (either DMSO or SP2509) and replicate number for each sample. Once
these two files were prepared, they were loaded into BEAVR from the Load data tab. In
the Settings tab, we selected ‘DMSO’ as the control condition and ‘SP2509’ as the
treatment condition. The FDR was set to 10% and the minimum threshold to drop reads
was set to 10.
Figure 3.3A shows the DGE results from the Gene table tab, which has been
sorted by ascending padj values. This table can be saved as-is or it can be filtered. For
example, it is often desirable to have a list of only those genes that exceed a specific LFC
threshold (e.g. ±1.0) and fall below a padj threshold (e.g. < 0.05). These values can be set
using the sidebar (Figure 3.3B) and the results table will be updated automatically to
display genes meeting the selected criteria. These parameters also instruct the thresholds
used in generating the volcano plot and pathway analyses.
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Figure 3.3 DGE table output from a typical use case for BEAVR
Figure 3.3. DGE table output from a typical use case for BEAVR. (A) Once DGE
analysis completes in BEAVR, an interactive table is shown in the Gene Table tab. This
table provides users with log2 fold change (LFC) values for each gene as well as p values
and adjusted p values (padj). Users can search for a particular gene of interest by its gene
name or sort the table based on the contents of any column. A copy of the table can be
saved using the download button in the sidebar. The data shown here is the output of DGE
analysis performed on the Sehrawat et al. dataset. ‘DMSO’ was selected as the control
condition and ‘SP2509’ was selected as the treatment condition in the Settings tab. The
false discovery rate (FDR) was set to 10% and genes with less than 10 reads were dropped
from analysis. (B) The DGE results table in the Gene Table tab can be filtered by any
metric using the controls provided in the sidebar. The available filtering options are
min/max LFC, min/max p value, min/max padj, min/max baseMean (normalized mean),
min/max lfcSE (LFC standard error) and min/max stat (test statistic). The filtered table can
be downloaded using the download button in the sidebar. If filtering is enabled, the filtered
table will be used to generate the volcano plot in the Volcano Plot tab.
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PCA is an important consideration in RNA-seq analysis for small and large studies.
Depending on the experimental design, PCA plots can be used for quality control or as a
discovery tool [12]. In studies with only two control groups and just two or three biological
replicates, it can inform researchers of replicates that are not congruent and have high
variance which can skew results and reduce statistical power. In larger studies, it can
provide insight into the heterogeneity within experimental conditions. The PCA Plot tab
displays a PCA plot from our example dataset. The plot shows that there is a very small
amount of variance (1%) between replicates within each experimental group (DMSO- or
SP2509-treated), while there is very large variance, as expected, between the two
experimental groups (98%) (Figure 3.4A). Further quality control and insight into sample
and replicate variation can be interrogated through a distance matrix and subsequent
sample clustering. We defined the parameters in the Sample Clustering tab to
compute Pearson correlation distances and the result is shown in Figure 3.4B. Replicates
in the same experimental group cluster together and are very similar to each other,
indicating very low variance. Together, these two graphs provide researchers with useful
information about experimental groups and consistency of biological replicates.
Sehrawat et al. found inhibition of LSD1 in LNCaP cells caused downregulation of
previously characterized embryonic stem cell-like genes [11, 13]. Using the Read Count
Plots tab, we explored the normalized read counts of these genes and generated plots
that showed reduced normalized reads in the SP2509-treated cells compared to DMSOtreated cells (Figure 3.5A). In situations where genes or pathways of interest are already
known, read count plots can be used as a tool to investigate changes in gene expression
across samples. However, RNA-seq is also used in experimental systems to inform
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Figure 3.4 Illustrating variance across samples using principal component analysis (PCA) and sample clustering

Figure 3.4. Illustrating variance across samples using principal component analysis
(PCA) and sample clustering. (A) PCA is a useful tool to determine the variance within
and across different experimental groups and replicates. The PCA output from the PCA tab
is shown for the Sehrawat et al. dataset. High variance (98%), as expected, is observed
between the two experimental groups (DMSO- vs SP2509-treated) whereas low variance
(1%) is observed between replicates within each group. (B) Hierarchical sample clustering
is also a useful tool to determine variances. The output from the Sample Clustering
tab is shown for the Sehrawat et al. dataset. Pearson correlation was selected as the distance
measurement method in the sidebar. Similar to the PCA plot, the clustered heatmap shows
that replicates in each experimental group (DMSO- or SP2509-treated) cluster strongly
together, indicating low variance between biological replicates.
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Figure 3.5 Visualizing normalized read counts and differential gene expression
between experimental groups
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Figure 3.5. Visualizing normalized read counts and differential gene expression
between experimental groups. (A) Normalized read count plots are shown for ten
embryonic stem cell-like genes of interest from the Sehrawat et al. dataset to illustrate
changes between the DMSO- and SP2509-treated groups. BEAVR allows users to enter a
list of genes to illustrate expression behavior as jitter plots (shown) or boxplots (not
shown). A 5x2 (rows x columns) grid was selected to display these 10 genes. (B) The top
50 most differentially-expressed genes between DMSO- and SP2509-treated groups are
shown in the clustered heatmap for the Sehrawat et al. dataset. This heatmap was generated
in the Heatmap tab using the Ward.D hierarchical clustering method and Euclidean
distance measurements. Row (gene) clustering clustering was enabled. Clustered heatmaps
are useful for displaying expression changes across treatment groups. (C) A volcano plot
highlighting genes that meet both LFC and padj cutoffs are shown for the Sehrawat et al.
dataset. This volcano plot was generated in the Volcano Plot tab with the LFC cutoff
set to ±1 and the padj cutoff set to < 0.05. The volcano plot is another way to visualize the
data shown in the heatmap in (B), however the volcano plot also illustrates the statistical
significance of genes (the y-axis).
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researchers of genes and pathways that may be of interest. For such purposes, a heatmap
with gene clustering or a volcano plot are useful tools. The Heatmap tab generates
heatmaps for the top n genes (where n is a user-defined number) or for specific genes
entered by the user. Figure 3.5B shows the top 50 most differentially-expressed genes after
variance stabilization with hierarchical clustering performed across rows (Ward.D2
method). This provides information on the most strongly upregulated and downregulated
genes. Although the data for a heatmap is transformed and variance is stabilized, it does
not provide information on significance (p values or padj) [8]. The volcano plot from the
Volcano Plot tab illustrates genes that meet a specified LFC threshold as well as a padj
threshold (Figure 3.5C). We set the LFC threshold to ±1.0 and the padj cutoff to < 0.05.
Genes highlighted in red (meeting both the LFC and padj cutoffs) were also found in the
heatmap, demonstrating the usefulness of heatmaps and volcano plots and how the two can
be used together for discovery of novel gene expression patterns.
Following identification of upregulated and downregulated genes, it is useful to
perform pathway enrichment or gene set enrichment analysis (GSEA) [14, 15] to identify
important pathways of interest that will inform investigators of downstream experiments.
The Pathway Enrichment Plot tab performs over-representation analysis and
produces either a dot plot or bar graph of the top n pathways (where n is a user-defined
number) (Figure 3.6A). The Pathway Enrichment Map tab provides a broader look
at all enriched pathways using an interconnected network map (Figure 3.6B) that shows
the results of over-representation analysis, however users may also wish to perform GSEA
on the GSEA Map tab. The GSEA Plot tab displays a plot of the running enrichment
score for a specific enriched pathway as defined by the user (Figure 3.6C). The input data
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Figure 3.6 Identification of enriched pathways among differentially expressed genes
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Figure 3.6. Identification of enriched pathways among differentially expressed genes.
(A) Bar graph showing the results of over-representation analysis using the Pathway
Enrichment Plot tab. The maximum number of pathways/categories to show was set
to 10 and the enrichment p padj value cutoff was set to < 1 x 10-30. The gene count (x-axis)
indicates the number of genes enriched in each pathway and colors indicate level of
significant (padj). The pathways are plotted on the y-axis in order of increasing significance.
(B) While the Pathway Enrichment Plot tab shows a bar graph or dot plot for only
a subset of enriched pathways, the Pathway Enrichment Map tab shows all of the
enriched pathways in an interconnected network map. The size of each node indicates the
gene count (number of genes enriched in each category) and the color represents the padj
(the cutoff was set to < 1 x 10-30). (C) The GSEA Plot tab generates a plot of the running
enrichment score for a specified pathway/category. The plot for the category “cell cycle”
is illustrated here. Currently only Reactome pathways/categories are supported for each of
these figures. The input data for A-C is the filtered or unfiltered data from the Gene
Table tab (we set the LFC to < 0 and the padj cutoff to < 0.05).
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used to generate these figures is the filtered or unfiltered data from the Gene Table tab
(we filtered the data using LFC < 0 and padj < 0.05). The pathways identified in Figures
3.6A-C are consistent with the most downregulated genes shown in the heatmap (Figure
3.5B) and volcano plot (Figure 3.5C) (such as H2AX, CDC20, CCNB1, AURKA) and
indicate the most significantly enriched pathways among downregulated genes are related
to cell cycle and DNA replication processes. Together, the read count plots, heatmap,
volcano plot and pathway plots inform researchers of gene expression changes and provide
insight into which genes and pathways may play an important role in their experimental
system.

3.4.2

Future work
DGE analyses computes differences between two groups at a time, such as

Wildtype and Single-knockout, even though users can load data files containing
>2 groups (e.g. Wildtype, Single-knockout and Double-knockout).
Currently, users must perform one comparison first (e.g. Wildtype vs Singleknockout), download the results and then perform another comparison (e.g. Wildtype
vs Double-knockout) and download the new results. Users must then manually
perform comparisons outside of BEAVR to identify overlapping or non-overlapping genes.
Future updates to BEAVR will allow users to perform multiple DGE analyses and allow
them to interact with both results at once to perform direct comparisons within BEAVR.
Implementation of additional plotting tools, such as Euler or Venn diagrams, will allow for
the visualization of overlapping or non-overlapping dysregulated genes across different
comparisons such as Wildtype vs Single-knockout and Wildtype vs Double-
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knockout. These overlapping or non-overlapping datasets can then be used to perform
pathway analysis or GSEA within BEAVR.
Presently, BEAVR only supports Reactome categories for pathway analysis and
GSEA. Future updates will enable support for Gene Ontology (GO) [16], Disease Ontology
(DO) [17], KEGG [18], WikiPathways [19] and Molecular Signature Database (MSigDb)
[14, 20] to provide users with more options.

3.5 Conclusions
RNA-seq analyses has largely relied on command-line-driven tools, such as
DESeq2 [8], EdgeR [21] or ALDEx [22], thereby creating a barrier to entry for scientists
wishing to conduct RNA-seq analyses. Here we presented BEAVR, a graphically-driven
tool that greatly simplifies DGE analyses through a logical workflow that makes use of
DESeq2 as the core DGE engine. BEAVR is easy-to-use and allows researchers to not only
quickly and easily change experimental parameters in real-time to visualize results, but
also provides an intuitive interface for researchers to explore their results in-depth and
generate highly customizable figures. Various other tools have been developed to provide
users with graphical interfaces for RNA-seq analyses, most notably GENAVi [23], START
[24], iDEP [25], DEBrowser [26], DEIVA [27] and DEApp [28]. While these tools have
undoubtedly provided a significant evolution in RNA-seq analysis tools, we found that
BEAVR offers meaningful advantages in comparison. Specifically, the ease of installation
and usage, combined with more flexibility in data output features are important
advancements. None of these programs offers each of our key features in one complete
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package, such as filtering capabilities of gene lists, all of the different data displays that
BEAVR provides (heat-map, PCA plots, etc.), the ability to customize and export figures in
as many formats, or the ability to integrate pathway analysis. Based on these differences
we expect BEAVR will be widely utilized.
BEAVR was developed to be simple enough for novices, yet fast and powerful
enough for experts to streamline and automate DGE analyses. Even with modest computing
power by today’s standards, BEAVR is capable of completing analyses within minutes,
allowing researchers to quickly automate analyses of large datasets. With uses for RNAseq continuing to expand — both experimentally and clinically — BEAVR is wellpositioned to allow analysis of these datasets to be quick and efficient, while providing the
latitude for customization as per the user’s requirements.

3.6 Availability and Requirements
Project name: BEAVR
Project home page: https://github.com/developerpiru/BEAVR and
https://hub.docker.com/r/pirunthan/beavr
Project documentation:
https://github.com/developerpiru/BEAVR/blob/master/README.md
Operating system: Linux, Mac OS, Windows
Programming language: R
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Other requirements: R 3.5 or higher, web browser
License: GNU General Public License v3.0
Any restrictions to use by non-academics: None

3.7 Availability of data and materials
The dataset used in this article is available in the GEO repository (GSE59009).

3.8 Funding
PP was supported by CaRTT. FAD is the Wolfe Senior Fellow in Tumor
Suppressor Genes at Western University. This study was funded by the Canadian Institutes
of Health Research and funds provided by the London ‘Run for Ovarian Cancer’. No
funding sources participated in the design, data collection, analysis, interpretation of data,
or preparation of the manuscript.

3.9 Acknowledgements
We wish to thank Dr. John W. Barrett, Dr. Haider M. Hassan and Mike Roes
(London Regional Cancer Program, London Health Sciences Centre) for beta testing
BEAVR and providing key feedback.

171

3.10 References
1.

2.
3.

4.

5.

6.
7.
8.
9.

10.
11.

12.
13.

14.

15.

16.

Hrdlickova R, Toloue M, Tian B: RNA-Seq methods for transcriptome analysis.
Wiley Interdiscip Rev RNA 2017, 8(1).
Stark R, Grzelak M, Hadfield J: RNA sequencing: the teenage years. Nat Rev Genet
2019, 20(11):631-656.
Conesa A, Madrigal P, Tarazona S, Gomez-Cabrero D, Cervera A, McPherson A,
Szczesniak MW, Gaffney DJ, Elo LL, Zhang X et al: A survey of best practices for
RNA-seq data analysis. Genome Biol 2016, 17:13.
Kamps R, Brandao RD, Bosch BJ, Paulussen AD, Xanthoulea S, Blok MJ, Romano
A: Next-Generation Sequencing in Oncology: Genetic Diagnosis, Risk Prediction
and Cancer Classification. Int J Mol Sci 2017, 18(2).
Buzdin A, Sorokin M, Garazha A, Glusker A, Aleshin A, Poddubskaya E,
Sekacheva M, Kim E, Gaifullin N, Giese A et al: RNA sequencing for research and
diagnostics in clinical oncology. Semin Cancer Biol 2019, 60:311-323.
Marco-Puche G, Lois S, Benitez J, Trivino JC: RNA-Seq Perspectives to Improve
Clinical Diagnosis. Front Genet 2019, 10:1152.
Costa-Silva J, Domingues D, Lopes FM: RNA-Seq differential expression analysis:
An extended review and a software tool. PLoS One 2017, 12(12):e0190152.
Love MI, Huber W, Anders S: Moderated estimation of fold change and dispersion
for RNA-seq data with DESeq2. Genome Biol 2014, 15(12):550.
Zhu A, Ibrahim JG, Love MI: Heavy-tailed prior distributions for sequence count
data: removing the noise and preserving large differences. Bioinformatics 2019,
35(12):2084-2092.
Yu G, He Q-Y: ReactomePA: an R/Bioconductor package for reactome pathway
analysis and visualization. Molecular BioSystems 2016, 12(2):477-479.
Sehrawat A, Gao L, Wang Y, Bankhead A, 3rd, McWeeney SK, King CJ,
Schwartzman J, Urrutia J, Bisson WH, Coleman DJ et al: LSD1 activates a lethal
prostate cancer gene network independently of its demethylase function. Proc Natl
Acad Sci U S A 2018, 115(18):E4179-E4188.
Ma S, Dai Y: Principal component analysis based methods in bioinformatics
studies. Brief Bioinform 2011, 12(6):714-722.
Wong DJ, Liu H, Ridky TW, Cassarino D, Segal E, Chang HY: Module map of
stem cell genes guides creation of epithelial cancer stem cells. Cell Stem Cell 2008,
2(4):333-344.
Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA,
Paulovich A, Pomeroy SL, Golub TR, Lander ES et al: Gene set enrichment
analysis: A knowledge-based approach for interpreting genome-wide expression
profiles. Proceedings of the National Academy of Sciences 2005, 102(43):15545.
Mootha VK, Lindgren CM, Eriksson K-F, Subramanian A, Sihag S, Lehar J,
Puigserver P, Carlsson E, Ridderstråle M, Laurila E et al: PGC-1α-responsive genes
involved in oxidative phosphorylation are coordinately downregulated in human
diabetes. Nature Genetics 2003, 34(3):267-273.
The Gene Ontology Consortium: The Gene Ontology Resource: 20 years and still
GOing strong. Nucleic Acids Research 2018, 47(D1):D330-D338.

172

17.

18.

19.

20.

21.

22.

23.

24.

25.

26.

27.

28.

Schriml LM, Arze C, Nadendla S, Chang Y-WW, Mazaitis M, Felix V, Feng G,
Kibbe WA: Disease Ontology: a backbone for disease semantic integration. Nucleic
acids research 2012, 40(Database issue):D940-D946.
Kanehisa M, Sato Y, Furumichi M, Morishima K, Tanabe M: New approach for
understanding genome variations in KEGG. Nucleic acids research 2019,
47(D1):D590-D595.
Slenter DN, Kutmon M, Hanspers K, Riutta A, Windsor J, Nunes N, Mélius J,
Cirillo E, Coort SL, Digles D et al: WikiPathways: a multifaceted pathway database
bridging metabolomics to other omics research. Nucleic acids research 2018,
46(D1):D661-D667.
Liberzon A, Birger C, Thorvaldsdóttir H, Ghandi M, Mesirov JP, Tamayo P: The
Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst
2015, 1(6):417-425.
Robinson MD, McCarthy DJ, Smyth GK: edgeR: a Bioconductor package for
differential expression analysis of digital gene expression data. Bioinformatics
(Oxford, England) 2010, 26(1):139-140.
Fernandes AD, Macklaim JM, Linn TG, Reid G, Gloor GB: ANOVA-like
differential expression (ALDEx) analysis for mixed population RNA-Seq. PloS one
2013, 8(7):e67019-e67019.
Reyes ALP, Silva TC, Coetzee SG, Plummer JT, Davis BD, Chen S, Hazelett DJ,
Lawrenson K, Berman BP, Gayther SA et al: GENAVi: a shiny web application
for gene expression normalization, analysis and visualization. BMC Genomics
2019, 20(1):745.
Nelson JW, Sklenar J, Barnes AP, Minnier J: The START App: a web-based
RNAseq analysis and visualization resource. Bioinformatics (Oxford, England)
2017, 33(3):447-449.
Ge SX, Son EW, Yao R: iDEP: an integrated web application for differential
expression and pathway analysis of RNA-Seq data. BMC Bioinformatics 2018,
19(1):534.
Kucukural A, Yukselen O, Ozata DM, Moore MJ, Garber M: DEBrowser:
interactive differential expression analysis and visualization tool for count data.
BMC Genomics 2019, 20(1):6.
Harshbarger J, Kratz A, Carninci P: DEIVA: a web application for interactive
visual analysis of differential gene expression profiles. BMC Genomics 2017,
18(1):47.
Li Y, Andrade J: DEApp: an interactive web interface for differential expression
analysis of next generation sequence data. Source Code for Biology and Medicine
2017, 12(1):2.

173

Chapter 4

4

GO-CRISPR: a highly controlled workflow to improve
discovery of gene essentiality in loss-of-function
screens

4.1 Abstract
Genome-wide CRISPR screens are an effective discovery tool for genes that
underlie diverse cellular mechanisms that can be scored through cell fitness. Loss-offunction screens are particularly challenging compared to gain-of-function because of the
limited dynamic range of decreased sgRNA sequence detection. Here we describe GuideOnly control CRISPR (GO-CRISPR), an improved loss-of-function screening workflow,
and its companion software package, Toolset for the Ranked Analysis of GO-CRISPR
Screens (TRACS). We demonstrate a typical GO-CRISPR workflow in a non-proliferative
3D spheroid model of dormant high grade serous ovarian cancer and demonstrate superior
performance to standard screening methods. The unique integration of the pooled sgRNA
library quality and guide-only controls allows TRACS to identify novel molecular
pathways that were previously unidentified in tumor dormancy. Together, GO-CRISPR
and TRACS can robustly improve the discovery of essential genes in challenging
biological scenarios.

4.2 Introduction
Gene editing using CRISPR/Cas9 technology has seen widespread adoption across
most biomedical disciplines, including cancer research
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1,2

. In particular, the ability to

multiplex CRISPR gene knockouts on a genome-wide scale has stimulated systematic
interrogation of cell biology 3. Pooled single guide RNA (sgRNA) libraries are used to
create single-gene knockouts in individual cells and selective pressure is applied through
culture conditions or drug treatment. Genetic deficiencies that produce resistance or
susceptibility are quantitated using sgRNA coding sequences as barcodes to compare gene
knockout abundance between the start and end of the experiment 4. CRISPR screens can
therefore discover functional roles for genes and pathways not suggested by more
traditional hypothesis-driven research.
Gain-of-function genome-wide CRISPR screens can lead to several orders of
magnitude change in sgRNA sequence abundance because of resistant cell proliferation,
unequivocally identifying resistance genes

5-7

. Conversely, loss-of-function is more

challenging to quantitate because complete disappearance of sgRNA sequences for a gene
may represent technical failure of the screen design, or its execution 8. In addition,
knockout of an individual gene in the chosen culture condition may not cause lethality with
complete penetrance 9. Ultimately, identification of essential genes in loss-of-function
screens has relied on prolonged periods of cell proliferation to separate the abundance of
bystander sgRNA abundance from true deleterious changes 4. For this reason, CRISPR
screens have generally utilized rapidly proliferating 2D cell culture conditions. Scenarios
such as the tumor microenvironment, metastasis and tumor dormancy, are better assessed
in 3D culture models such as multicellular tumor spheroids or organoids

10-13

. However,

the inability of organoids to quantitatively regenerate from individual cells upon subculture
has prevented robust library representation 14, and in some cases this has been compensated
by screening more compact, partial genome libraries 15. Furthermore, most 3D spheroids
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exhibit slower growth kinetics due to hypoxia and necrosis which can further hamper
detection of gene loss events 16. All of these factors likely contribute to stochastic loss of
guides which can confound loss-of-function studies since current methods cannot
distinguish these Cas9-independent events from bona fide loss-of-function due to gene
editing. For these reasons, the classification of gene ‘essentiality’ is highly challenging in
3D culture conditions.
Therefore, there is a need for a screening method that can be adapted for a broad
range of complex culture conditions that include low proliferation rates to identify essential
genes. This motivated us to develop Guide-Only control CRISPR (GO-CRISPR). GOCRISPR is a scalable loss-of-function screening method that can be used to discover
essential genes in standard monolayer (2D) or complex 3D culture conditions such as
dormant tumor spheroids that exhibit arrested cell proliferation. To support broad usability,
we also developed TRACS (Toolset for the Ranked Analysis of GO-CRISPR Screens) to
automate the analysis of GO-CRISPR screens in an easy-to-use software package.
Together, GO-CRISPR and TRACS allowed us to discover novel survival pathways in
dormant ovarian cancer spheroids, whereas established CRISPR screening and analysis
approaches were unable to find essential genes. We expect that this approach can be
broadly applied to genome-wide loss-of-function CRISPR screens in low proliferation
biological contexts.
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4.3 Results
4.3.1

The GO-CRISPR Workflow
The challenges presented by genome wide CRISPR screening in growth arrested

populations of cells motivated us to develop a new workflow that could reveal critical
insights into mechanisms of survival in cancer cell dormancy. We developed GO-CRISPR
to overcome these challenges and its typical experimental workflow is illustrated in Figure
4.1A. CRISPR screens depend on high-level Cas9 expression to ensure maximum
efficiency of gene disruption in Cas9-positive cells transduced with a pooled sgRNA
library (L0) 4,17. GO-CRISPR uniquely incorporates sequencing data from a parallel screen
in which Cas9-negative cells are also transduced with the same pooled sgRNA library (L0).
Both the Cas9-positive and Cas9-negative cells are treated in an identical manner.
Following antibiotic selection for sgRNA transduction and expansion into triplicate
cultures, cells are harvested from the initial culture condition (T0). Next, both Cas9-positive
and Cas9-negative populations are exposed to the desired selective pressure or culture
conditions (Ps) and cells are harvested from the final culture condition (Tf). Nextgeneration sequencing (NGS) is then used to quantitate the abundance of PCR-amplified
sgRNA sequences from these 12 samples, as well the initial library preparation (L0).
To evaluate GO-CRISPR screens, we developed the TRACS algorithm that
integrates data from Cas9-positive and Cas9-negative populations to make gene
essentiality predictions (Figure 4.2). It is based on assigning genes enrichment scores
similar to the single gene score previously described by Wang et. al. 18. However, TRACS
differs by calculating three different enrichment scores for each gene (Figure 4.1A in red).
These include a Library Enrichment Score (Library ES) that compares sgRNA read counts
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Figure 4.1 Typical experimental workflow for GO-CRISPR screening and analysis
using TRACS
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Figure 4.1. Typical experimental workflow for GO-CRISPR screening and analysis
using TRACS. (A) iOvCa147 High-grade serous ovarian cancer (HGSOC) cells were
transduced with lentivirus expressing Cas9. High efficiency Cas9-positive cells (top row)
and Cas9-negative cells (bottom row) were transduced with the GeCKO v2 pooled sgRNA
library (L0). After antibiotic selection, both Cas9 positive and negative cells were split into
triplicates (x3) and maintained in initial culture conditions (T0) before being transferred to
suspension culture conditions in ULA plasticware (selective pressure, Ps) to induce
spheroid formation and select for cell survival. Viable spheroid cells were then transferred
to standard plasticware to facilitate reattachment in the final culture condition (Tf). The
initial pooled sgRNA library (L0) and Cas9-positive and Cas9-negative cells were collected
at T0 and Tf for sgRNA quantitation by NGS. TRACS was used to calculate Library, Initial
and Final Enrichment Scores (ES) using read quantities from L0 and Cas9-positive and
Cas9-negative samples. (B) 3D plot output from TRACS illustrating the Library ES, Initial
ES and Final ES for each gene. Genes highlighted in dark blue have low Library ES
(determined by calculating the first quartile value across all Library ES; < 985 in this
experiment). (C) Euler diagram showing the distribution of retained (in red) and discarded
genes based on the Library ES (16,284 genes had Library ES > 985). (D) 2D scatter plot
output from TRACS showing the distribution of Initial ES and Final ES for all genes.
Genes highlighted in light blue (6,717 genes) met the low Library ES cutoff and had a
negative Enrichment Ratio (ER) and padj < 0.05, indicating their sgRNA abundance
decreases in Tf compared to T0.
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Figure 4.2 Typical analysis workflow using TRACS to identify essential genes
Figure 4.2. Typical analysis workflow using TRACS to identify essential genes. (A)
The TRACS workflow is separated into five steps. Step 1: Experiment parameters are
entered in the graphical user interface (GUI). Step 2: Library reference file (.csv format)
and raw read files (.fastq format) for all Cas9-positive replicates are selected in the GUI.
Step 3: Raw read files (.fastq format) for all Cas9-negative replicates are selected in the
GUI. Step 4: Raw reads are trimmed and aligned to generate read counts, then the TRACS
algorithm runs to calculate Library ES, Initial ES, Final ES and the ER for each gene. Step
5: TRACS saves the results with all scores in an output file which can then be explored
using the accompanying VisualizeTRACS data explorer. (B) Screenshot of the easy-to-use
TRACS GUI asking user to enter experimental parameters (Step 1). Subsequent displays
provide a similar interface for selecting input data files for Steps 2-4. (C-D) Screenshot of
the accompanying VisualizeTRACS data explorer that researchers can use to visualize and
inspect their TRACS output files and generate publication-ready figures. Researchers can
control all aspects of filtering and data manipulation (Library ES, Initial ES, Final ES, ER,
padj) to fine-tune selection of genes.
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for each gene between Cas9-negative cells and the library (L0) to determine Cas9independent non-gene-editing-related changes in abundance. This is an important
consideration since pooled sgRNA library preparations do not uniformly represent all
genes
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. An Initial Enrichment Score (Initial ES) is calculated by comparing sgRNA

abundances for each gene in Cas9-positive cells relative to their abundances in Cas9negative cells where they cannot direct gene editing. Lastly, a Final Enrichment Score
(Final ES) determines sgRNA abundance between Cas9-positive and Cas9-negative cells
following the exposure of both populations to the desired selective pressure or culture
conditions (Ps). For each gene, the Library ES, Initial ES and Final ES are weighted
according to the number of sgRNAs that are detected for that gene. Thus, a relatively low
Initial ES or Final ES indicate reduced sgRNA abundance in the Cas9-positive population
and these scores incorporate a penalty for undetected sgRNAs to emphasize the most
reliable sgRNA measurements. Finally, TRACS calculates an Enrichment Ratio (ER) that
is the log2-fold-change (LFC) value between the Final ES and Initial ES to reveal changes
in relative abundance between T0 and Tf culture conditions to detect sgRNAs that depleted
under the selective pressure (Ps), thereby identifying gene essentiality. The ER informs
researchers if a gene shows essentiality for fitness (negative ER) or is non-essential
(positive ER) in the experimental conditions.

4.3.2

Discovering Ovarian Cancer Spheroid Vulnerabilities
To demonstrate the value of the GO-CRISPR and TRACS workflow, we performed

a genome-wide screen in iOvCa147 high-grade serous ovarian cancer (HGSOC) cells.
HGSOC is a highly metastatic disease in which cells detach from primary tumors and
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aggregate to form 3D spheroids in the abdomen 20. These spheroid cells are growth arrested
and highly resistant to chemotherapy, emphasizing the need to discover their vulnerabilities
to improve treatment 21. We designed a GO-CRISPR screen experiment (Figure 4.1A) to
elucidate the genes and pathways that are critical to spheroid cell survival using ultra-low
attachment (ULA) plasticware to induce spheroid formation in vitro
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. Ovarian cancer

cells undergo significant cell death in suspension culture while spheroids form, therefore
after 48-hours we transferred cells back to standard plasticware to allow reattachment and
purification of viable cells.
Following analysis with TRACS, we sought to discover genes that were most
selectively required for survival in suspension conditions; these represent potential
therapeutic targets for dormant ovarian cancer cell spheroids. Figure 4.1B displays each
ES in a 3D plot that reveals the distribution of scores in each dimension and highlights
genes with low Library ES in dark blue. A low Library ES means that a gene’s sgRNA
sequences were poorly represented at T0 due to non-gene-editing events that occurred
between viral transduction of the pooled sgRNA library and antibiotic selection. This is an
important consideration because when a gene’s Library ES is low, its initial sgRNA
abundance is also low, and relatively small changes in sgRNA abundance can lead to
extreme enrichment scores at T0 (Initial ES) or Tf (Final ES) (Figure 4.3A). To avoid these
false positives, we excluded the first quartile of Library ES from further analysis (Library
ES < 985 in this experiment) (Figure 4.1C and Figure 4.3B). To discover genes essential
for spheroid cell survival, we focused our attention on those that had a negative ER. In
Figure 4.1D, genes highlighted in light blue met the Library ES cutoff (> 985) and had ER
< 0 and padj < 0.05 at a false discovery rate (FDR) of 10%. We found 6,717 genes that met
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Figure 4.3 Genes with low Library ES tend to have extreme Initial ES and/or Final
ES
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Figure 4.3. Genes with low Library ES tend to have extreme Initial ES and/or Final
ES. (A) TRACS 3D plot illustrating the distribution of Library ES, Initial ES, Final ES in
an extreme case example screen that had very poor representation of sgRNAs at T0 in Cas9negative cells. Genes that have low Library ES (genes that fall into the first quartile of all
Library ES across all genes) are shown in dark blue. These genes also tend to have extreme
values for Initial ES and/or Final ES which can lead to potential false positives. This
extreme example demonstrates how initial sgRNA abundances can be low due to non-geneediting events and skew gene scores at T0 (Initial ES) and Tf (Final ES). (B) Histogram
illustrating the distribution of Library ES across all genes in our GO-CRISPR experiment.
To diminish the effects of poorly represented sgRNAs, TRACS determines the distribution
of the Library ES across all genes and computes the cutoff value for the first quartile (the
bottom 25% of all Library ES; highlighted in dark blue). TRACS then discards genes that
have Library ES below this threshold (< 985 for our iOvCa147 screen), however
researchers can increase or decrease the threshold within the TRACS software suite for
further fine-tuning.
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these criteria and the top 10 genes with the most negative ER are shown in Table 4.1. This
data suggests these are the ten most essential genes required for spheroid cell viability in
iOvCa147 cells.

4.3.3

Validation of TRACS Gene Essentiality Predictions
To determine the validity of gene essentiality predictions made by TRACS, we

measured its ability to categorize the 1,000 non-targeting control (NTC) sgRNAs from the
GeCKO v2 pooled library. These NTC sgRNAs target non-coding intergenic sequences
and should rank as non-essential 19. We computed a receiver operating characteristic curve
(ROC) and determined the area under the curve (AUC) was 98.5%, demonstrating that
TRACS correctly identified NTC sgRNAs as non-essential (Figure 4.4A). This is a critical
control because amplified genome regions produce false essential calls among non-coding
controls 23,24. HGSOC is characterized by extensive amplifications and deletions 25 and this
data demonstrates TRACS eliminates this potentially confounding interpretation. For
added validation, we used CRISPR/Cas9 to disrupt the top five genes with the most
negative ER (Table 4.1) in iOvCa147 cells. Independent knockout of each gene showed
significant loss of viability under suspension culture conditions (Figure 4.4B). Conversely,
knockout of the top five genes with the most positive ER did not compromise viability,
suggesting our GO-CRISPR screen approach reliably discovers loss-of-function events
(Figure 4.4C).
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Table 4.1 Top 10 genes with the most negative Enrichment Ratio (ER) in TRACS

Gene

Library ES Initial ES Final ES ER

padj

AGPS

2648.39

1384.00

16.61

-6.38

1.01 x 10-2

SLC2A11

2421.17

2216.28

37.33

-5.89

1.06 x 10-2

ZC3H7A

2397.67

2592.22

62.67

-5.37

5.19 x 10-3

PDCD2L

1449.39

3018.56

82.67

-5.19

1.86 x 10-3

NPM1

2966.72

2070.89

68.06

-4.93

9.78 x 10-3

KIAA1731 3063.72

2050.61

83.78

-4.61

4.92 x 10-3

MAP3K6

1741.61

2206.22

93.39

-4.56

2.76 x 10-4

SSH1

1281.61

1347.67

57.50

-4.55

1.64 x 10-2

MFN2

2779.67

2080.00

89.83

-4.53

1.16 x 10-2

CREBL2

1449.78

2211.22

96.67

-4.52

6.69 x 10-3
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Figure 4.4 Validation of TRACS gene essentiality predictions
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Figure 4.4. Validation of TRACS gene essentiality predictions. (A) The GeCKO v2
pooled library contains 1,000 non-targeting control (NTC) sgRNAs that should not elicit a
change in cell fitness. We evaluated the ability of TRACS to classify these sgRNAs by
computing a receiver operating characteristic curve (ROC). The area under the curve
(AUC) was determined to be 98.5%, indicating TRACS accurately classifies these NTC
sgRNAs as non-essential. (B) We evaluated the essentiality of the top five genes with the
most negative ER: AGPS, SLC2A11, ZC3H7A, PDCD2L, NPM1 (see Table 4.1).
CRISPR/Cas9 was used to disrupt each gene in iOvCa147 cells and pure single-gene
knockout populations were assayed for spheroid cell viability in suspension culture
conditions. Disruption of these genes resulted in significantly reduced cell viability. Genes
in bar graph are arranged from most negative ER to least negative ER. (C) We similarly
knocked out the top five genes with the most positive ER (EPS15, hsa-mir-761, RPAP1,
SYAP1, TRAF3IP1) and assayed for viability in suspension culture conditions. Disruption
of these genes did not adversely affect viability. Genes in bar graph are arranged from
smallest to largest ER. (D) We performed gene ontology and pathway enrichment analysis
with the 6,717 genes identified by TRACS to have negative ER and plotted the results. The
minimum genes required for enrichment per category was set to 45 to ensure stringent
selection of pathways. The dashed vertical line represents a padj value of 5 x 10-9. Pathways
to the right of this line have padj < 5 x 10-9 after controlling for FDR at 10%. Pathways
labelled in blue are previously undescribed in HGSOC. For (B) and (C), each point
represents a biological replicate (n = 6). Bars represent means and error bars represent
standard deviation. Statistics was performed using one-way ANOVA; ** denotes p < 0.01;
*** denotes p < 0.001; **** denotes p < 0.0001; ns denotes not significant (p > 0.05).
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4.3.4

GO-CRISPR and TRACS Identify Novel Pathways in
HGSOC
To further explore the genes identified, we performed gene ontology and pathway

enrichment analysis with genes that had a negative ER and padj < 0.05 and found 109
significantly enriched pathways (Figure 4.4D). Among these are cell cycle regulation 22,
MAPK signaling
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and TP53 signaling

25

which are known to be involved in HGSOC

progression and metastasis. Remarkably, our analysis also found novel pathways that have
not yet been implicated in HGSOC including Rho GTPase signaling and interleukin
signaling. Together, these data demonstrate that GO-CRISPR and TRACS can robustly
identify functionally connected genes to enable novel pathway discoveries.

4.3.5

Comparison of GO-CRISPR with conventional CRISPR
screen workflows
Formation of growth arrested HGSOC spheroids in suspension culture is a stressful

process in which many cells die without being incorporated into a spheroid. Moreover, the
communal nature of spheroids further suggests that individual gene loss events in single
cells may be masked in loss-of-function CRISPR screens through non-cell autonomous
mechanisms. Thus GO-CRISPR and TRACS were born out of the desire to screen a
significantly challenging biological scenario. To fully illustrate the advantages of GOCRISPR and TRACS, we have analyzed the triplicate replicates of T0 and Tf solely in Cas9expressing cells using MAGeCK-RRA, MAGeCK-MLE
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and BAGEL
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as this

represents a commonly used CRISPR screen workflow that lacks guide only controls
(Figure 4.5). A basic premise for genome-wide CRISPR screens using only Cas9expressing cells is that poorly represented sgRNAs, or stochastic changes unrelated to the
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experiment in question, will be removed through statistical cutoffs. Analysis of this data
using MAGeCK-RRA/MLE did not detect any essential genes using standard statistical
cutoffs (Figure 4.5A-D), including the genes with the most negative ER that were found
to be essential by TRACS (Figure 4.5I). BAGEL did not discover essential genes either
(Figure 4.5G-H). We then removed statistical cutoffs in MAGeCK-RRA/MLE and found
approximately 30% of top-ranked genes had low Library ES according to TRACS,
reinforcing the previously described phenomenon of identifying false positives due to low
initial sgRNA abundances (Figure 4.5E-F and Figure 4.6). Additionally, our computed
ER discriminates essentiality of NTCs effectively (Figure 4.4A), whereas MAGeCK
(without statistical cutoffs) frequently misclassifies NTCs as essential (Figure 4.7A).
TRACS was also noticeably more reliable at identifying universally essential and nonessential gene sets
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(Figure 4.7B-C). TRACS penalizes genes that have low sgRNA

numbers and favors those with higher sgRNA values to further mitigate the effects of
stochastic sgRNA loss and ensure that gene essentiality predictions are made using the
largest possible sample size (Figure 4.8A). Without statistical cutoffs, many MAGeCKMLE top-ranked gene decisions are based on single gRNAs (Figure 4.8B). Overall,
integrating data from the pooled sgRNA library and Cas9-negative populations allows
TRACS to outperform other methods to accurately predict gene essentiality in a
challenging low proliferation, suspension culture scenario.
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Figure 4.5 MAGeCK and BAGEL are unable to identify essential genes in our
screen using Cas9 positive read data
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Figure 4.5. MAGeCK and BAGEL are unable to identify essential genes in our screen
using Cas9 positive read data. (A) We analyzed our screen data using Cas9-positive
replicates from T0 and Tf using the MAGeCK-RRA (robust rank aggregation) method with
a controlled FDR of 10%. The dashed horizontal line represents p < 0.05; any genes above
this line are significant. Genes to left of the dashed vertical line have log2-fold-change
(LFC) < 0 indicating their sgRNA abundances decrease from T0 to Tf. We did not find any
genes to be significant using these typical parameters for MAGeCK-RRA. (B) Removal of
FDR control with MAGeCK-RRA revealed 932 genes (highlighted in purple) that had LFC
< 0 and unadjusted p value < 0.05. Genes shown in grey did not meet these criteria. (C)
We analyzed our screen data using Cas9-positive replicates from T0 and Tf using the
MAGeCK-MLE (maximum likelihood estimation) method with a controlled FDR of 10%.
Genes above the dashed horizontal line have p < 0.05 and are significant. Genes to the left
of the dashed vertical line have LFC < -1, the typically used cutoff for gene essentiality
using this method. We did not find any genes that met both of these criteria. (D) Removal
of FDR control with MAGeCK-MLE and increasing the LFC cutoff to < 0 revealed 1,918
genes (highlighted in green) that had LFC < 0 and p value < 0.05. Genes shown in grey did
not meet these criteria. (E) Venn diagram showing overlap of the 932 genes (in purple)
identified by MAGeCK-RRA with the genes identified by TRACS as having low Library
ES (5,424 genes total). 259 genes overlap between the two sets (27.8%). (F) Venn diagram
showing overlap of the 1,918 genes (in green) identified by MAGeCK-MLE with the genes
identified by TRACS as having low Library ES. 499 genes overlap between the two sets
(26%). (G) We analyzed our screen data using Cas9-positive replicates from T0 and Tf
using BAGEL and plotted the Bayes factor output for each gene in relation to the gene
ranking. The Bayes factors for all genes were negative, indicating BAGEL did not discover
any perturbations in sgRNA abundances between T0 and Tf. (H) A graphical representation
of Bayes factors calculated by BAGEL for the top 15 genes with the highest integer value
Bayes factors. All Bayes factors are < 0 indicating gene essentiality was not detected. Error
bars show standard deviation for each gene as calculated by BAGEL. (I) We explored the
output from MAGeCK-RRA and MAGeCK-MLE to determine how each method ranked
the top five most essential genes we identified using TRACS. TRACS found these genes
to have an ER of at least -4.93 (see Table 4.1). MAGeCK-RRA and MAGeCK-MLE found
these genes to have LFC near 0 and were not significant. The dashed vertical line represents
a typical LFC or ER cutoff of -1 and the dashed horizontal line represents a p value of 0.05.
Genes above and to the left of these lines are significant.
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Figure 4.6 Top-ranked genes by MAGeCK have low representation in the T0 pool of cells

Figure 4.6. Top-ranked genes by MAGeCK have low representation in the T0 pool of
cells. The 3D plot highlights in dark blue the genes that TRACS determined to have low
Library ES. The vertical axis represents Library ES. The volcano plots illustrate genes that
were found to be essential by MAGeCK-RRA or MAGeCK-MLE (LFC < 0 and unadjusted
p value < 0.05; no FDR cutoffs). Dark blue data points in volcano plots indicate genes that
TRACS found to have low Library ES, demonstrating that removing the FDR cutoff selects
for genes with poor sgRNA representation. In all three plots, genes in red have Library ES
> 985 and genes in dark blue have Library ES < 985.
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Figure 4.7 TRACS accurately classifies non-targeting controls and robustly classifies known essential and non-essential gene sets

Figure 4.7. TRACS accurately classifies non-targeting controls and robustly classifies
known essential and non-essential gene sets. (A) We evaluated the ability of MAGeCK
to classify the 1,000 NTC sgRNAs in the GeCKO v2 pooled library as non-essential and
compared it to TRACS as shown in Figure 4.4A. The AUC for MAGeCK-RRA (51.3%)
and MAGeCK-MLE (56.3%) were considerably lower than TRACS (98.5%). (B) We
evaluated the ability of TRACS and MAGeCK to classify the previously described Hart et
al. gene set of universally non-essential genes. TRACS (AUC: 93.5%) outperformed
MAGeCK-RRA (AUC: 86.9%) and MAGeCK-MLE (AUC: 85.8%) suggesting it can
reliably identify these non-essential genes. (C) We also evaluated the ability of TRACS
and MAGeCK to classify a known set of universally essential genes. TRACS (AUC:
92.6%) consistently outperformed MAGeCK-RRA (AUC:78.1%) and MAGeCK-MLE
(AUC: 85.9%) indicating it can robustly identify essential genes.
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Figure 4.8 TRACS selects for essential genes based on the most sgRNAs
Figure 4.8. TRACS selects for essential genes based on the most sgRNAs. (A) Bar plot
showing the distribution of the number of sgRNAs per gene for the 6,717 genes that had
ER < 0 and padj < 0.05 in TRACS. Light blue color corresponds to light blue data points
shown in Figure 4.1D. (B) Bar plots showing the distribution of sgRNAs per gene
discovered by MAGeCK-RRA and MAGeCK-MLE with LFC < 0 and unadjusted p value
< 0.05. Purple and green colors correspond to the colored data points in the volcano plots
in Figure 4.5. Most top-ranked genes identified by MAGeCK-RRA had 6 sgRNAs per
gene although at reduced frequency which is attributed to fewer genes discovered by
MAGeCK. MAGeCK-MLE had wider disparity across genes as it made essentiality calls
using as low as 1 sgRNA per gene. The peaks at 4 sgRNAs per gene in each of the three
histograms represent miRNAs which have a maximum of 4 sgRNAs instead of 6.
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4.4 Discussion
The GO-CRISPR and TRACS workflow offers an important alternative to
conventional genome-wide loss-of-function CRISPR screens. It rigorously identifies genes
that contribute to survival and facilitates novel mechanistic discoveries in low proliferation
culture conditions by controlling for the stochastic effects of Cas9-independent sgRNA
loss. Most notably, we demonstrated the use of this screening workflow in a 3D ovarian
cancer spheroid model to identify novel pathways that have not yet been described in
HGSOC. This would not have been possible using conventional screening methods that
lack guide-only controls.
To accommodate guide-only controls, we needed a new analysis pipeline. CRISPR
screen analysis pipelines generally require an understanding of programming or advanced
Unix/Linux knowledge to setup and manipulate raw NGS read files. In contrast, the
TRACS software suite (https://github.com/developerpiru/TRACS) presents researchers
with an easy-to-use graphical environment for analysis and data exploration. TRACS fully
automates the analysis process – from raw NGS files to output – which will significantly
reduce the barrier for many researchers to use GO-CRISPR. Furthermore, TRACS is fully
scalable and can be deployed on a local workstation or a multi-CPU platform such as
Amazon Web Services, Google Cloud Platform, or Microsoft Azure. We also provide
example workflows and documentation to use TRACS on these platforms, including
Docker containers for Linux, Mac OS and Windows that will automate setup.
We used the GeCKO v2 pooled sgRNA library
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in our screen. However, the

modularity of GO-CRISPR and TRACS will allow for the use of any pooled sgRNA library
as long as Cas9 expression is separate from sgRNA viral delivery. In addition, the
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flexibility of TRACS in terms of unrestricted replicates and sgRNA library size will
support the use of validated libraries, such as GeCKO v2, or custom libraries to answer
novel questions across biological systems of interest. Taken together, we anticipate GOCRISPR and TRACS will open new opportunities for loss-of-function screens across
diverse model systems and biological questions.

4.5 Materials and methods
4.5.1

Generation of Cas9-positive cells
High-grade serous ovarian cancer (HGSOC) iOvCa147 cells have previously been

reported 22. They were transduced with viral particles encoding a Cas9 expression cassette
(lentiCas9-Blast, Addgene #52962) to generate cells constitutively expressing Cas9 (Cas9positive cells). Cells were selected with blasticidin (20 µg/mL). Single-cell clones were
isolated by limiting dilution. Lysates were collected from clones and western blots were
performed to determine Cas9 expression (Cell Signaling #14697). Cas9 editing efficiency
was determined by viability studies using sgRNAs targeting selected fitness genes
(PSMD1, PSMD2, EIF3D) and a non-targeting control (LacZ) as previously reported 28. A
single clone showing the most effective Cas9 activity was selected for all further studies.

4.5.2

GeCKO v2 library preparation
HEK293T cells were transfected with the combined A and B components of the

GeCKO v2 (Addgene #1000000048, #1000000049) whole genome library (123,411
sgRNAs in total) along with plasmids encoding lentiviral packaging proteins. Media was
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collected 2-3 days later and any cells or debris were pelleted by centrifugation at 500 x g.
Supernatant containing viral particles was filtered through a 0.45 µM filter and stored at 80°C with 1.1 g/100 mL BSA.

4.5.3

GO-CRISPR screen in iOvCa147 cells
iOvCa147 Cas9-positive or Cas9-negative cells were transduced with virus

collected as described above at a multiplicity of infection of 0.3 and with a predicted library
coverage of >1000-fold. Cells were grown in media containing 2 µg/mL puromycin (Sigma
#P8833) to eliminate non-transduced cells. Cells were maintained in complete media
containing puromycin in all following steps. A total of 1.1 x 109 cells were collected and
split into three groups consisting of approximately 3.0 x 108 cells each and were cultured
for an additional 2-3 days in complete media, then collected and counted. Triplicate
samples of 6.2 x 107 cells were saved for sgRNA sequence quantitation at T0. The
remaining cells (approximately 1.4 x 109/set) were plated at a density of 2.0 x 106 cells/mL
in each of twenty 10 cm ULA plates (total of 60 ULA plates). Following 2 days of culture,
media containing spheroids was transferred to ten, 15 cm adherent tissue culture plates
(total of 30 plates). The next day unattached spheroid cells were collected and re-plated
onto additional 15 cm plates. This process was repeated for a total of 5 days at which point
very few spheroids remained unattached. The attached cells were collected for DNA
extraction and this population represents Tf. Complete media refers to DMEM/F12 media
(Gibco #11320033) supplemented with 10% FBS (Wisent FBS Performance lot #185705),
1% penicillin-streptomycin glutamine (Wisent #450-202-EL) and 2 µg/mL puromycin
(Sigma #P8833).
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4.5.4

High-throughput next generation sequencing (NGS)
Cells were harvested and DNA was extracted using QIAmp Blood Maxi Kits

(QIAGEN #51194). Genomic encoded sgRNA sequences were PCR amplified as
previously described 29. Two rounds of PCR were performed. The initial round serves to
increase the abundance of the initial sgRNA population, while the second round inserts
barcodes necessary for identification of group and replicate number (sample barcode). PCR
products were gel purified, quantitated by Qubit (Invitrogen), pooled and sequenced using
an Illumina NextSeq 550 75-cycle high output kit (#20024906). FASTQ files were
obtained containing raw reads and were demultiplexed to obtain individual FASTQ files
for each sample. FASTQ files were processed accordingly for downstream analysis with
TRACS, MAGeCK, or BAGEL.

4.5.5

Analysis with MAGeCK
FASTQ files were trimmed with Cutadapt (1.15) to remove adapter sequences and

sample barcode identifiers. The library reference file (CSV) for the GeCKOv2 library was
used in Bowtie2 (2.3.4.1) to align the initial library read FASTQ file and generate a BAM
file (Samtools 1.7) in order to increase the read depth of the initial library. This library
BAM file and trimmed FASTQ files for all samples were then inputted into the MAGeCK
(0.5.6) count function to generate read counts. Differences in sgRNA abundance were
computed using the MAGeCK-RRA (robust ranking aggregation) or MAGeCK-MLE
(maximum likelihood estimation) methods. All plots and comparisons to TRACS were
performed in R (3.6.2).
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4.5.6

Analysis with BAGEL
BAGEL (0.91) was run using read counts generated by the MAGeCK (0.5.6) count

function as described above. Standard non-essential and essential training gene sets were
used as previously described 28. Bayes factors (BFs) obtained by BAGEL were plotted in
R (3.6.2).

4.5.7

Analysis with TRACS
The library reference file containing a list of all sgRNAs and their sequences (CSV

file), raw reads for the pooled sgRNA library (FASTQ files (L0) and raw reads (FASTQ
files) for all Initial (T0) and Final (Tf) replicates for Cas9-positive and Cas9-negative cells
(12 replicates) were loaded into TRACS (https://github.com/developerpiru/TRACS).
TRACS then automatically trimmed the reads using Cutadapt (1.15). TRACS builds a
Bowtie2 (2.3.4.1) index and aligns the trimmed initial sgRNA library read file to generate
a BAM file using Samtools 1.7. MAGeCK (0.5.6) is then used to generate read counts from
this library BAM file and all the trimmed sample FASTQ files. Instead of dropping all
reads below a certain threshold (e.g. <30 counts), all reads were incremented by 1 to
prevent zero counts and division by zero errors. The TRACS algorithm was then run using
this read count file to determine the Library Enrichment Score (ES), Initial ES, Final ES
and the Enrichment Ratio (ER) for each gene (see The TRACS algorithm section).

4.5.8

Data exploration using VisualizeTRACS
The VisualizeTRACS feature, part of the TRACS software suite, was then used to

visualize and explore the data output from TRACS. Gene filtering (Library ES > 985, ER
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< 0, padj < 0.05 for our example ovarian cancer workflow) was performed, figures were
generated and the final table of essential genes that met these criteria were downloaded for
further analysis.

4.5.9

The TRACS algorithm
After read count preprocessing, TRACS first determines a Gene Score, 𝐺𝑆, for

every gene in the supplied library reference file by calculating the log2-fold-change (LFC)
from all sgRNAs for that gene for 𝑛 replicates (minimum of 2 replicates required) of Cas9positive and Cas9-negative samples:
[𝑛𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑 𝑠𝑔𝑅𝑁𝐴 𝑎𝑏𝑢𝑛𝑑𝑎𝑛𝑐𝑒]

𝐶𝑎𝑠9+
𝐺𝑆𝑗 = ∑𝑠𝑖=1 (log 2 [𝑎𝑣𝑔 𝑛𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑 𝑠𝑔𝑅𝑁𝐴 𝑎𝑏𝑢𝑛𝑑𝑎𝑛𝑐𝑒]
)
𝐶𝑎𝑠9−

Where 𝑠 is the number of unique sgRNAs for a gene 𝑗. This is done for each replicate such
that for 𝑛 replicates, there are 𝑛 gene scores, 𝐺𝑆, for a gene 𝑗. For each 𝑛 replicates, the 𝐺𝑆
for all genes are then ranked in ascending order from 1 to 𝑥, where 𝑥 is the rank of the gene
with the highest 𝐺𝑆 in each respective replicate. TRACS then determines the Enrichment
Score, 𝐸𝑆𝑗 , which is the average rank across all 𝑛 replicates of a gene 𝑗, divided by the total
number of sgRNAs, 𝑠, identified for that gene.
1 𝑛
∑𝑖=1 𝐺𝑆 𝑟𝑎𝑛𝑘
𝐸𝑆𝑗 = 𝑛
𝑠
TRACS then determines the Enrichment Ratio, 𝐸𝑅, for gene 𝑗 by determining the LFC of
the 𝐸𝑆𝑗𝑇𝑓 compared to 𝐸𝑆𝑗𝑇0 .
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𝐸𝑅𝑗 = log 2

𝐸𝑆𝑗𝑇𝑓
𝐸𝑆𝑗𝑇0

TRACS calculates the p value for each gene using a paired t-test by pairing each of
the 𝑛 replicates together per gene per the initial (T0) condition and final (Tf) condition. The
Benjamini–Hochberg procedure is used to control the false discovery rate (FDR) at the
user-defined level (10% in our example workflow).
After the ER is calculated, TRACS determines the distribution of Library ES values
across all genes. The cutoff value for the Library ES was set to the first quartile for our
example screen.

4.5.10

Pathway analysis

Using the final list of essential genes from TRACS, we performed gene ontology
and pathway enrichment analysis using the ConsensusPathDB enrichment analysis test
(Release 34 (15.01.2019)) for top-ranked genes of interest. padj values and ER values for
each gene were used as inputs. The minimum required genes for enrichment was set to 45
and the FDR-corrected padj value cutoff was set to < 0.01. The Reactome pathway dataset
was used as the reference. For each identified pathway, ConsensusPathDB provides the
number of enriched genes and a q value (padj) for the enrichment. Scatter plots were
generated in R (3.6.2) using these values to depict the significant pathways identified.
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4.5.11

Generation of single-gene knockouts

Gibson Assembly (NEB #E2611) was used to clone a pool of four sgRNAs per
gene (AGPS, SLC2A11, ZC3H7A, PDCD2L, NPM1, EPS15, hsa-mir-761, RPAP1, SYAP1,
TRAF3IP1, and EGFP) into lentiCRISPR v2 (Addgene #52961). iOvCa147 cells were
transduced with viral particles encoding a Cas9 and sgRNA expression cassettes. Cells
were selected for 2-3 days in media containing 2 µg/mL puromycin. Knockout cells were
cultured for 72 hours in suspension conditions using ULA plasticware (2 x 106 cells per
well) to induce spheroid formation. Spheroid cells were then collected and transferred to
standard plasticware to facilitate reattachment for 24 hours. Reattached cells were fixed
with fixing solution (25% methanol in 1x PBS) for 3 minutes. Fixed cells were incubated
for 30 minutes with shaking in crystal violet staining solution (0.5% crystal violet, 25%
methanol in 1x PBS). Plates were carefully immersed in ddH2O to remove residual crystal
violet. Plates were incubated with detaining solution (10% acetic acid in 1x PBS) for 1
hour with shaking to extract crystal violet from cells. Absorbance of crystal violet at 590
nm was measured using a microplate reader (Perkin Elmer Wallac 1420) for each knockout
and normalized to the EGFP control. Percent survival is inferred from relative absorbance.

4.5.12

Statistics

All error bars in the bar graphs represent standard deviation. Statistical
significances were determined using two-way ANOVA. * denotes P < 0.05, *** denotes P
< 0.001, **** denotes P < 0.0001 and ns denotes not significant (P > 0.05).
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4.6 Data and Code Availability
High throughput sequencing data from the GO-CRISPR screen is available from
the GEO repository (accession number GSE150246). TRACS is available for download
from the GitHub repository at https://github.com/developerpiru/TRACS or on Docker Hub
at https://hub.docker.com/r/pirunthan/tracs. Complete documentation, reference sgRNA
library file and TRACS output files are also available on the GitHub repository.
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Chapter 5

5

Netrin and its dependence receptors are mediators of
high-grade serous ovarian cancer cell survival

5.1 Abstract
We previously showed that DYRK1A is essential for ovarian cancer spheroid cell
survival. DYRK1A regulates transcription by assembling the DREAM repressor complex
and also regulates RNA polymerase II. However, the present understanding of how
DYRK1A regulates transcription in high-grade serous ovarian cancer (HGSOC) spheroid
cells to promote quiescence and survival is lacking. Here we performed GO-CRISPR
screens in a panel of HGSOC spheroid cells in combination with transcriptional analyses
of DYRK1A deficient spheroid cells. We identified netrin signaling components as
essential factors of HGSOC spheroid cell survival. Netrin is well-characterized in axon
development but has recently been implicated in other cancer types. We found that
knockout of netrin ligands or receptors affects viability of spheroid cells. Netrin ligands
and receptors are upregulated in HGSOC cells in suspension conditions. Together, this
work suggests that the netrin signaling pathway may be a potential therapeutic target to
specifically eliminate spheroid cells in HGSOC and highlights it as an important area
requiring further investigation in the context of ovarian cancer.

5.2 Introduction
Ovarian cancer is the leading cause of death among gynecologic malignancies.
Although awareness of ovarian cancer has increased over the last decade, patient survival
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trends have failed to increase significantly1,2. Poor prognosis of ovarian cancer patients is
attributed to late diagnosis; over 70% of women are not diagnosed until the disease has
progressed to stage III or IV primarily due to non-specific symptoms which are common
to non-malignant diseases2-4. By late-stage disease, tumours spread beyond the site of
origin and form numerous distant metastatic nodules that are difficult to remove by surgical
debulking5. This metastatic spread is facilitated by multicellular spheroids that are clusters
of tumour cells that shed from primary tumours and disseminate into the peritoneal cavity
through malignant ascites to colonize new sites5. The non-proliferative state of spheroid
cells renders them chemoresistant and contributes to recurrence6-8; more than 80% of
patients with late-stage disease will experience recurrence9, further complicating treatment
and resulting in poor survival5. A comparison of the five-year survival rate of women with
stage I disease (90%) to those with late-stage metastatic disease (< 25%) reveals a critical
need to improve diagnostics and therapeutics for advanced stage ovarian cancer2,3,10.
Malignant ascites and spheroids are observed in almost all patients with late-stage
high-grade serous ovarian cancer (HGSOC), the most common form of ovarian cancer1,11,
yet the processes controlling ovarian cancer spheroid formation and survival are not well
understood. Unlike other cancers which metastasize hematogenously or lymphatically,
ovarian cancer cells shed directly from primary tumours to the peritoneal cavity that
immediately requires adaptability to non-adherent or suspension conditions12,13. It has been
suggested that shedding ovarian tumour cells undergo epithelial-to-mesenchymal transition
(EMT), but spheroid cells within ascites maintain epithelial features and cell-cell
interactions with neighboring spheroid cells14 which affords them the ability to escape
anoikis and decreases responsiveness to chemotherapy15-17. It can therefore be surmised
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that spheroid cells are influenced by pro-survival signals which allow entry into quiescence
while retaining epithelial features, and withdrawal of these factors would reduce
chemoresistance and survival. Recent studies have revealed that HGSOC spheroid cells
require AMPK-LKB1 signaling18,19 and STAT3-DKK signaling20 for survival and
chemoresistance. We have also previously shown that HGSOC spheroids are dependent on
dual-specificity tyrosine phosphorylation regulated kinase 1A (DYRK1A) and DREAM6.
Loss of DYRK1A or DREAM components inhibited entry into dormancy and reduced
spheroid cell viability6. These studies have demonstrated that HGSOC spheroids harbor
vulnerabilities which can be exploited to increase drug sensitivity, however, as in the case
of DYRK1A/DREAM, such vulnerabilities may only be present during non-adherent
conditions to offer spheroid cells protection in suspension6. In the present study, we
performed a genome-wide CRISPR screen in parallel with transcriptomic analyses to
identify a novel role for netrin signaling in HGSOC spheroid survival.
The netrin family is a highly conserved family of proteins that participate in
neuronal guidance cues. Netrins, together with their receptors, have been implicated in
cancer progression and metastases. Netrin-1, netrin-3, netrin-4, and netrin-5 are secreted
netrin ligands whereas netrin-G1 and netrin G2 are membrane bound21. Netrin-1 (NTN1)
is the most studied due to its importance in nervous system development. It has been
characterized as an oncogene in several cancers22-26 and has been used as a reliable
diagnostic biomarker in breast cancer, colorectal cancer, and gastric cancer27-30. NTN1 over
expression in both cancer cell lines and animal models lead to pro-survival signals21,23-25,3134

. In glioblastoma, melanoma, and pancreatic cancer, NTN1 stimulates metastases25,26.

The functions of other netrin family members in cancer are not yet fully understood. Netrin-
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4 (NTN4) has been shown to have either a positive or negative effect on tumour survival
depending on the cancer type21. NTN4 over expression in breast cancer has been correlated
with improved patient outcomes35-37, but its expression in gastric cancer, neuroblastoma,
and melanoma are associated with more aggressive disease38-41. Both netrin-3 (NTN3) and
netrin-5 (NTN5) – the most recently discovered netrins – have not been characterized
outside of the nervous system21.
A growing number of studies are focusing on netrins in cancer. They present an
attractive therapeutic target not only because they act on accessible extracellular receptors,
but also because netrin receptors belong to a family of receptors called dependence
receptors (DRs)42-44. DRs are grouped not for their similar homology – of which they have
none – but for their dual function21,42. DRs offer cells a protective function by propagating
anti-apoptotic signals only in the presence of a ligand. In the absence of a ligand, DRs
induce programmed cell death42. DCC, the prototypical netrin DR, and the UNC5
homology (UNC5H) DRs have been found to be mutated in various cancers45,46. Here we
show that netrins and its family of receptors act as DRs in HGSOC spheroid cells. Our
novel genome-wide GO-CRISPR screen identified netrin signaling components, including
NTN1 and UNC5H (UNC5 homology) DRs as vulnerabilities for HGSOC spheroid cell
survival. Parallel transcriptomic analyses of HGSOC spheroids revealed netrin signaling
components were enriched in HGSOC spheroids compared to adherent cells. We show that
individual knockdown of netrin signaling components decreases viability of spheroid cells
in suspension and that different patient-derived HGSOC cell lines have differing
sensitivities towards specific receptors. Our study highlights netrin signaling as a
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requirement for HGSOC spheroid survival and suggests it may be a potential therapeutic
target for HGSOC therapies.

5.3 Results
5.3.1

Components of netrin signaling are essential factors for
HGSOC spheroid cell survival
We performed a genome-wide CRISPR screen on three HGSOC cell lines

(iOvCa147, OVCAR8 and TOV1946) to identify genes and pathways that are important
for spheroid cell survival. We utilized the GO-CRISPR (Guide Only CRISPR) workflow
in our three-dimensional spheroid cell culture model to recapitulate metastatic
dissemination of spheroids in vitro (Figure 5.1A). GO-CRISPR uniquely incorporates
sgRNA abundances from non-Cas9-expressing cells to control for stochastic death in
challenging three-dimensional culture conditions and the data was analyzed using the
accompanying software, TRACS (Toolset for the Ranked Analysis of GO-CRISPR
Screens)47. To identify genes that contributed to spheroid cell survival and reattachment
after 48 hours in suspension, we filtered the results for genes that had an Enrichment Ratio
(ER) less than 0 which is indicative of sgRNAs that were relatively depleted in suspension
conditions. We found 6,717 genes with an ER < 1.0 and padj < 0.05 in iOvCa147 cells;
7,637 genes in TOV1946 cells; and 7,640 genes in OVCAR8 cells (Figure 5.1B). Among
these genes, 1,382 were commonly depleted in all three cell lines and had an ER below 1.0
and padj < 0.05 (Figure 5.1C). To discover common molecular pathways that may be
broadly important for HGSOC spheroid survival and metastasis, we performed gene
ontology and pathway enrichment analysis on the 1,382 genes that were common across
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Figure 5.1 Components of netrin signaling are essential factors for HGSOC
spheroid viability
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Figure 5.1. Components of netrin signaling are essential factors for HGSOC spheroid
viability. (A) iOvCa147, TOV1946, or OVCAR8 HGSOC cells were transduced with
lentivirus expressing Cas9. High efficiency Cas9-positive cells (top row) and Cas9negative cells (bottom row) were transduced with the GeCKO v2 pooled sgRNA library
(L0). After antibiotic selection, both Cas9 positive and negative cells were split into
triplicates (x3) and maintained in initial culture conditions (T0) before being transferred to
suspension culture conditions in ULA plasticware (selective pressure, Ps) to induce
spheroid formation and select for cell survival. Viable spheroid cells were then transferred
to standard plasticware to facilitate reattachment in the final culture condition (Tf). The
initial pooled sgRNA library (L0) and Cas9-positive and Cas9-negative cells were collected
at T0 and Tf for sgRNA quantitation by NGS. TRACS was used to calculate Library, Initial
and Final Enrichment Scores (ES) using read quantities from L0 and Cas9-positive and
Cas9-negative samples. (B) Scatter plots representing spheroid score (Tf) on y-axis and
adherent (T0) score on x-axis calculated in TRACS for each gene in each cell line
(iOvCa147, TOV1946, OVCAR8). Diagonal black line represents y = x; genes on this line
did not have altered sgRNA levels in spheroid conditions (Tf) compared to adherent
conditions (T0); genes below this line had reduced sgRNA levels in spheroid conditions
(Tf), indicating loss of that gene decreased survival in spheroid conditions, suggesting the
gene was essential; genes above this line had increased sgRNA levels in spheroid
conditions (Tf), indicating loss of that gene increased survival in spheroid conditions.
Colored data points represent genes with ER < 0 and padj < 0.05 (5% FDR). 6,717 essential
genes were identified in iOvCa147 spheroid cells (highlighted in light green); 7,637
essential genes were identified in TOV1946 spheroid cells (highlighted in purple); 7,640
essential genes were identified in OVCAR8 spheroid cells (highlighted in warm pink). (C)
Venn diagram illustrating overlap of genes with ER < 0, padj < 0.05 in iOvCa147,
TOV1946, and OVCAR8 spheroid cells. 1,382 genes (shown in bright green) were found
to be commonly essential across all three cell lines. Colors are coordinated with those in
(B). (D) Venn diagram depicting overlapping enriched pathways identified in GO-CRISPR
screen from the commonly essential genes found in all three cell lines (iOvCa147,
TOV1946, OVCAR8) shown in bright green in (C). Genes with ER < 0 and padj < 0.05
were evaluated for enriched pathways. 433 pathways were found to be both significantly
enriched (padj < 0.05) and common between all three cell lines (shown in bright green).
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all three cell lines. We identified several significantly enriched pathways including those
related to metabolism, GPCR signaling, receptor tyrosine kinase signaling, WNT signaling,
MAPK signaling, and axon guidance, which includes components of the netrin signaling
pathway (Figure 5.1D).

5.3.2

Netrin signaling components are enriched in HGSOC
spheroid cells
We previously discovered DYRK1A as supporting survival of ovarian cancer

cells6. Since DYRK1A is a direct regulator of RNA polymerase II transcriptional
initiation48,49, we sought to determine if it facilitates spheroid cell dormancy and survival
in suspension conditions through the regulation of gene expression. To this end, we used
CRISPR/Cas9 to delete DYRK1A in iOvCa147 cells (DYRK1A-/-). We excised exon 2
(Figure 5.2A-C) to disrupt DYRK1A protein expression (Figure 5.2D) and inhibit its
kinase activity (Figure 5.2E). As expected, DYRK1A-/- spheroid cells failed to repress
known target genes, MYBL2 and CDK1 (Figure 5.2F-G), and had reduced viability
(Figure 5.3A) and increased sensitivity to carboplatin (Figure 5.3B). We next sought to
identify transcriptional programming changes that occur in HGSOC spheroid cells during
the transition from adherent to suspension conditions. Using the parental iOvCa147 cells
and DYRK1A-/- cell lines, we performed RNA-seq in adherent and spheroid cells (Figure
5.4A). We collected spheroids following a 6-hour incubation period in suspension
conditions since over expression of known DREAM targets due to DYRK1A loss were
first evident at this time point (Figure 5.2F-G).
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Figure 5.2 Generation of DYRK1A-/- iOvCa147 cells and validation of abrogated
DYRK1A activity
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Figure 5.2. Generation of DYRK1A-/- iOvCa147 cells and validation of abrogated
DYRK1A activity. (A) Strategy to knockout DYRK1A in iOvCa147 cells to generate
DYRK1A-/- cells. A pair of sgRNAs (sgRNA A and sgRNA B) that flank exon 2 of DYRK1A
were designed for use with wild type Cas9 to completely excise a 322 bp region containing
exon 2. Dotted red lines show where cuts were made relative to exon 2. After nonhomologous end joining (NHEJ), the cut DNA is repaired without the excised fragment
containing exon 2. PCR “For” and PCR “Rev” primers flank exon 2 as indicated and were
used to detect deletion events. (B) Agarose gel showing PCR products for parental
iOvCa147 cells and DYRK1A-/- cells. DNA was extracted from parental iOvCa147 cells or
iOvCa147 cells treated with sgRNAs and Cas9 to delete exon 2 of DYRK1A (indicated as
DYRK1A-/-). Full length amplicon containing exon 2 was detected in parental iOvCa147
cells (1,348 bp). A smaller amplicon (1,026 bp) was detected in DYRK1A-/- cells, indicting
successful excision of the 322 bp region encompassing exon 2. (C) Sequence alignments
of PCR fragments identified from parental iOvCa147 cells and DYRK1A-/- cells. The
dashed lines in DYRK1A-/- indicate where the deletion occurred leading to mismatch with
exon 2 of DYRK1A in parental iOvCa147 cells. (D) Western blot depicting DYRK1A
protein expression in parental iOvCa147 cells and DYRK1A-/- cells. DYRK1A is present in
parental iOvCa147 cells but not in DYRK1A-/- cells. (E) Immunoprecipitation (IP) kinase
assay to evaluate kinase activity in DYRK1A-/- cells. DYRK1A or IgG was
immunoprecipitated from either iOvCa147 or DYRK1A-/- cells and incubated with ATP and
Tau protein (a DYRK1A substrate). Samples were resolved by SDS-PAGE and probed
with phosphospecific Tau antibody. DYRK1A that was immunoprecipitated from
DYRK1A-/- cells was not able to phosphorylate Tau. (F)-(G) Gene expression of known
DREAM targets (MYBL2 (F) and CDK1 (G)) in parental iOvCa147 cells and DYRK1A-/cells. Cells were incubated in adherent conditions for 24 hours, or in suspension conditions
for 6 hours, 12 hours, or 24 hours to induce spheroid formation prior to RNA extraction.
Transcript levels of MYBL2 and CDK1 were increased in DYRK1A-/- cells indicating a
failure to repress genes by DREAM as a result of DYRK1A deficiency. Bar graphs show
mean expression values and error bars represent one standard deviation. Values are
normalized to parental iOvCa147 cells for each gene. Two-way ANOVA was performed
for each gene and significance levels are indicated (* denotes P < 0.05; and ns denotes not
significant, P > 0.05).
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Figure 5.3 DYRK1A-/- spheroid cells have reduced viability and increased
chemosensitivity.
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Figure 5.3. DYRK1A-/- spheroid cells have impaired reattachment ability and
increased chemosensitivity. (A) Parental iOvCa147 or DYRK1A-/- cells were incubated in
suspension conditions for 24 hours, 72 hours, or 4 days to induce spheroid formation, and
then re-plated in adherent conditions for 24 hours to allow reattachment. Reattached
spheroid cells were stained with crystal violet and absorbance was quantified. DYRK1A-/spheroid cells had impaired reattachment compared to parental iOvCa147 spheroid cells at
each time point. Bar graphs indicate mean relative absorbance (n=6). Two-way ANOVA
was performed and significance levels are indicated (**** denotes P < 0.0001). (B)
Parental iOvCa147 or DYRK1A-/- cells were incubated in suspension conditions for 24
hours to induce spheroid formation with or without carboplatin (0 um or 100 um), and then
re-plated in adherent conditions for 24 hours to allow reattachment. Reattached spheroid
cells were stained with crystal violet and absorbance was quantified. DYRK1A-/- spheroid
cells had increased sensitivity to carboplatin compared to parental iOvCa147 spheroid
cells. Bar graphs indicate mean relative absorbance (n=6). Two-way ANOVA was
performed and significance levels are indicated (**** denotes P < 0.0001).
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We first compared parental iOvCa147 adherent cells to 6-hour parental iOvCa147
spheroid cells to identify transcriptional changes that occur as these cells transitioned from
adherent conditions to suspension conditions (Figure 5.4B). We identified 1,937 genes that
were downregulated and 1,834 genes that were upregulated. We then compared parental
spheroid cells to DYRK1A-/- spheroid cells to identify transcriptional changes caused by
DYRK1A deficiency during the transition to spheroids (Figure 5.4C). We identified 744
genes that were downregulated and 96 genes that were upregulated in spheroid cells in the
absence of DYRK1A.
We used the 1,834 upregulated genes identified in parental iOvCa147 spheroid cells
(Figure 5.4B) to perform pathway enrichment analysis to elucidate signaling processes
that may be important for the normal transition from adherent to suspension conditions
(Figure 5.4D). Many of these pathways – including metabolism, GPCR signaling, and
axon guidance – resembled the pathways that were enriched among the 1,382 genes we
found to be commonly essential across iOvCa147, TOV1946, and OVCAR8 spheroid cells
in our GO-CRISPR screen (Figure 5.1D). Pathway enrichment analysis using the 744
downregulated genes identified in DYRK1A-/- spheroid cells (Figure 5.4C) also revealed
pathways similar to those found in the GO-CRISPR screen (Figure 5.4E). 78 pathways
were commonly enriched across the GO-CRISPR screen and transcriptomic analyses,
including 78 of the 83 pathways identified in DYRK1A-/- spheroid cells (Figure 5.4F). The
axon guidance pathway was consistently and significantly one of the most enriched among
these common pathways (Figure 5.4G). These data show our GO-CRISPR screen and
transcriptomic analyses converge on this axon guidance category, which includes netrin
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Figure 5.4 Netrin signaling pathway components are upregulated in iOvCa147
spheroid cells but downregulated in DYRK1A-/- spheroid cells.

220

Figure 5.4. Netrin signaling pathway components are upregulated in iOvCa147
spheroid cells but downregulated in DYRK1A-/- spheroid cells. (A) Experimental design
for RNA-seq in parental iOvCa147 or DYRK1A-/- cells. Cells were incubated in either
adherent conditions for 24 hours or suspension conditions to induce spheroid formation for
6 hours. Cells were collected in triplicates and then processed for bulk RNA-seq. (B)
Volcano plot showing differentially expressed genes in parental iOvCa147 spheroid cells
compared to parental iOvCa147 adherent cells. 1,937 genes were found to be
downregulated in iOvCa147 spheroid cells (log2 fold change < 1, padj < 0.05, FDR 10%,
highlighted in grey) and 1,834 genes were upregulated (log2 fold change > 1, padj < 0.05,
FDR 10%, highlighted in blue). Genes highlighted in black did not meet log2 fold change
cutoff or padj cutoffs. (C) Volcano plot showing differentially expressed genes in DYRK1A/spheroid cells compared to iOvCa147 spheroid cells. 744 genes were found to be
downregulated in DYRK1A-/- spheroid cells (log2 fold change < 1, padj < 0.05, FDR 10%,
highlighted in red) and 96 genes were upregulated (log2 fold change > 1, padj < 0.05, FDR
10%, highlighted in grey). Genes highlighted in black did not meet log2 fold change cutoff
or padj cutoffs. (D) Top 15 most significantly enriched pathways (padj < 0.05) that were
represented by the significant upregulated genes highlighted in blue in (B). The axon
guidance pathway, containing netrin signaling components, was 9th overall. (E) Top 15
most significantly enriched pathways (padj < 0.05) that were represented by the significant
downregulated genes highlighted in red in (C). The axon guidance pathway, containing
netrin signaling components, was 15th overall. (F) Venn diagram depicting overlapping
enriched pathways identified in GO-CRISPR screen in three cell lines (iOvCa147,
TOV1946, OVCAR8) in green; enriched pathways identified in upregulated genes in
parental iOvCa147 spheroid cells in blue; and enriched pathways identified in
downregulated genes in DYRK1A-/- spheroid cells in red. 78 pathways were commonly
enriched in all three datasets (shown in yellow). (G) Top 10 most significant pathways (padj
< 0.05) commonly enriched pathways from all three datasets identified in and highlighted
in yellow in (F). The axon guidance pathway, which was 8th overall, was enriched with
netrin signaling components.
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signaling components, suggesting it may play an important role in HGSOC spheroid
formation and viability.

5.3.3

Netrin signaling components are commonly essential in
HGSOC spheroid cells
The axon guidance gene ontology category encompasses a network of ligands and

receptors that make up the axon pathfinding processes50. Key among these processes are
guidance cues regulated by the netrin family of ligands and their receptors which have been
shown to provide pro-survival cues in various other cancer types50. To better understand
the role of netrin signaling in HGSOC and how it contributes to spheroid cell survival, we
compiled the results from our GO-CRISPR screen in a pathway map using colors to
indicate how often a particular component was identified across the three cell lines (Figure
5.5). This pathway map illustrates that extracellular components, such as the NTN1 ligand
and receptors (UNC5 homologs and DCC), as well as intracellular components such as
such as FAK, Fyn, Cdc42, DIP13α, MAPK, AKT, and NFκB were identified by the GOCRISPR screen across the three cell lines. This data suggests that netrin signaling is a
potential mediator of HGSOC spheroid cell viability.
Netrin’s role in other cancers have positioned the UNC5H and DCC receptors as
DRs that regulate apoptosis and provide tumour cells with pro-survival signals42,45,51.
Additionally, the extracellular nature of netrin ligands and their DRs present an opportunity
to use therapeutic modalities that disable their interactions. Netrin signaling is therefore a
compelling target for cancer therapy. To confirm its requirement in HGSOC spheroid cell
survival, we independently knocked out NTN1, DCC, DSCAM, the UNC5 receptor
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Figure 5.5. Netrin signaling components are commonly essential in HGSOC spheroid cells

Figure 5.5. Netrin signaling components are commonly essential in HGSOC spheroid
cells. Pathway map highlighting essential factors of netrin signaling in HGSOC cell
survival. Netrin signaling components are highlighted in either green, blue, or red to
indicate the frequency of observations across the three cell lines (iOvCa147, TOV1946,
OVCAR8) investigated in the GO-CRISPR screen. Green indicates the encoding gene was
found to be essential in only one cell line; blue indicates it was found to be essential in two
cell lines; red indicates it was found to be essential across all three cell lines.
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homologs (UNC5A, UNC5B, UNC5C, and UNC5D), and FAK in a panel of HGSOC cell
lines (iOvCa147, TOV1946, OVCAR3, OVCAR4, OVCAR8, and COV318). We induced
spheroid formation for 5 days in suspension conditions and then quantified their ability to
reattach after reintroduction to adherent conditions as a proxy for spheroid viability as
previously described6 (Figure 5.6A). Loss of netrin signaling components resulted in
reduced spheroid cell survival across all cell lines however it varied depending on which
component of netrin signaling was knocked out. Loss of the ligand NTN1 reduced spheroid
survival by approximately 23-48% in iOvCa147, OVCAR3, OVCAR4, and COV318
spheroid cells. Loss of the DCC DR reduced survival by approximately 62% in OVCAR3
and OVCAR4 spheroid cells while only a 9-20% reduction was observed in iOvCa147 and
TOV1946 spheroid cells, respectively. Variable sensitivity to loss of UNC5 homologs
(UNC5A, UNC5B, UNC5C, UNC5D) was observed in iOvCa147, TOV1946, OVCAR3,
OVCAR4, and COV318 spheroid cells. Independent loss of these DRs reduced survival by
approximately 13-71% in these cells (Figure 5.6A). As the hierarchical clustering
indicates, iOvCa147, OVCAR3, and OVCAR4 spheroid cells were more sensitive to loss
of these netrin components than TOV1946, OVCAR8, or COV318 spheroid cells (Figure
5.6A). Knockout of UNC5A reduced the viability of TOV1946 spheroid cells by
approximately 54% whereas knockout of DCC reduced viability by approximately 20%.
Only loss of NTN1, UNC5C, or FAK reduced survival of COV318 spheroid cells. The
viability of OVCAR8 spheroid cells was only reduced upon loss of FAK. (Figure 5.6A).
This data shows that these HGSOC spheroid cells are differentially affected by loss of
netrin signaling components.
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Figure 5.6. Netrin signaling components are upregulated in HGSOC spheroid cells
and mediate viability.
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Figure 5.6. Netrin signaling components are upregulated in HGSOC spheroid cells
and mediate viability. (A) We deleted genes encoding netrin signaling components
(NTN1, DCC, DSCAM, UNC5A, UNC5B, UNC5C, UNC5D, FAK, or EGFP) in a panel of
HGSOC cell lines (iOvCa147, TOV1946, OVCAR3, OVCAR4, OVCAR8, or COV318).
A pooled Lentiviral CRISPR/Cas9 strategy (4 sgRNAs per gene) was used to disrupt each
gene to generate pure single-gene knockout populations. Spheroid formation was induced
for 5 days in suspension conditions and then spheroids were transferred to adherent
conditions for 24 hours to facilitate reattachment. Cells were stained with crystal violet and
absorbance was measured as a proxy for spheroid viability. Heatmap shows spheroid cell
viability relative to control spheroid cells (EGFP). Disruption of these genes involved in
netrin signaling reduced viability of spheroid cells. (B) Expression of genes encoding netrin
ligands (NTN1, NTN3, NTN4, NTN5, NTNG1, and NTNG2) and receptors (UNC5A,
UNC5B, DSCAM, and NEO1) was detected by RT-qPCR in a panel of HGSOC cell lines
(iOvCa147, TOV1946, OVCAR4, or OVCAR8). Heatmap represents gene expression in
24 hour spheroid cells relative to 24 hour adherent cells. HGSOC cells variably over
express netrin signaling components in suspension conditions.
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We next hypothesized that some cell lines may upregulate different ligands or
receptors that may compensate for loss of individual components. To investigate this, we
interrogated the expression of a panel of genes that encoded netrin ligands (NTN1, NTN3,
NTN4, NTN5, NTNG1, and NTNG2) and receptors (UNC5A, UNC5B, DSCAM, and NEO1)
in iOvCa147, TOV1946, OVCAR4, and OVCAR8 cells (Figure 5.6B). We found that
OVCAR8 spheroid cells had increased expression of each of these genes compared to
adherent cells. Compared to adherent cells, both iOvCa147 and TOV1946 spheroid cells
had increased expression of NTN1, NTN5, NTNG2, UNC5B, and NEO1. OVCAR4
spheroid cells had increased expression of NTN3, NTN5, NTNG2, and UNC5A relative to
adherent cells (Figure 5.6B). This data shows that these HGSOC cell lines increase
expression of various netrin ligands and receptors upon spheroid formation in suspension
conditions.

5.4 Discussion
HGSOC spheroid cell biology has presented a unique challenge to cancer
chemotherapies. Spheroids present in patients with late-stage disease – which constitute
the vast majority of ovarian cancer patients – and their dormancy and metastatic potential
complicate chemotherapies or surgical debulking that may otherwise be effective in earlystage patients5,10,17. Hence there is a strong need to understand HGSOC spheroid cell
biology in order to develop effective therapies. In this study, we highlighted an important
role for netrin signaling in ovarian cancer spheroid cell survival. Our novel GO-CRISPR
screen paired with our transcriptomic analyses identified netrin signaling components as
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essential mediators of HGSOC spheroid cell viability and potentially as a regulator of
metastases and disease progression.
While netrin’s functions outside of the central nervous system are not well
understood, several studies have highlighted its contributions to cancer progression and
metastases in breast cancer, colorectal cancer, glioblastoma, melanoma, neuroblastoma,
non-small cell lung cancer, and pancreatic cancer21. Comparatively, very few studies have
focused on netrin in ovarian cancer52-54. A 2011 study showed NTN1 was over expressed
in malignant but not benign ovarian cancer tumours and suggested it may have value as a
biomarker for ovarian cancer53. More recently, NTN1 was shown to counteract the tumour
suppressor function of SOX6 in an ovarian teratocarcinoma cell line and a grade III ovarian
adenocarcinoma cell line52.
We found that individual knockout of netrin components across a panel of HGSOC
cell lines adversely affected spheroid cell viability (Figure 5.6A). Quantification of
spheroid cell viability showed that it was reduced at varying amounts across all cell lines.
However, we only observed a reduction in viability in OVCAR8 spheroids upon loss of
FAK but not any of the other components. This is in contrast to the results from our GOCRISPR screen which found netrin signaling components were essential across all three
cell lines (iOvCa147, TOV1946, and OVCAR8). Interrogation of gene expression showed
that OVCAR8 spheroid cells upregulate every netrin ligand and receptor we investigated
(Figure 5.6B). Over expression of these various ligands and receptors in the spheroid state
may explain our inability to detect loss of viability in OVCAR8 spheroids. The divergent
homology of netrin ligands may allow binding to different receptors to elicit
complementary or compensatory effects within cells21,55. This suggests the need to
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simultaneously disrupt multiple components of netrin signaling to study the effects within
spheroid cells. For example, our pooled lentiviral CRISPR/Cas9 approach to disrupt each
component individually could easily be adapted to knockout combinations of secreted
netrins or UNC5 DR homologs in the same cell. This also beseeches the need to perform a
broader investigation of gene expression in ascites-derived HGSOC cell lines to determine
the expression patterns of netrin signaling components. A broader panel of cells could
inform reliance on different netrin family members or different DRs. Moreover, we only
deleted NTN1, DCC, DSCAM and the UNC5H DRs; we did not target other netrin ligands
(NTN3, NTN4, NTN5, NTNG1, or NTNG2) or the neogenin (NEO1) receptor (Figure
5.6A). Indeed, our data shows that iOvCa147, TOV1946, OVCAR4, and OVCAR8
spheroid cells increase expression of these components in suspension conditions (Figure
5.6B). Different ligand-DR combinations may provide survival advantages to HGSOC
spheroid cells. For example, netrin ligands may bind to neogenin to stimulate HGSOC
spheroid cells with survival signals even in the absence of NTN1, DCC, or UNC5H. Both
NTN1 and NTN4 are known to bind to the NEO1 receptor to promote survival and
metastases in neuroblastoma39.
The multitude of ligands and receptors that comprise the netrin signaling network
may present difficulty in developing a universal drug candidate that can block netrins
ligands from binding to DRs. This is especially true if multiple ligand-DR signals converge
on the same downstream effectors due to complementary or compensatory effects. Our
GO-CRISPR screen implicated all three HGSOC cell lines (iOvCa147, TOV1946,
OVCAR8) with dependence on FAK (Figure 5.5). Further work is required to characterize
the mechanisms by which netrin regulates survival in HGSOC spheroid cells. Netrin has
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also been shown to stimulate angiogenesis and invasiveness in xenograft tumour models
and may act as factors for spheroid cell survival44,56-59. Future xenograft models will
demonstrate if loss of netrin components in spheroid cells confers reduced spheroid
viability or metastases in vivo. Additionally, several downstream mediators of netrin
signaling converge on actin polymerization and cytoskeletal restructuring60,61, which may
play an important role during HGSOC spheroid formation. Our GO-CRISPR screen also
identified FAK as an essential component for spheroid cell survival in all three HGSOC
cell lines (iOvCa147, TOV1946, OVCAR8) (Figure 5.5). Consistent with our findings,
FAK have been shown to promote chemoresistance in HGSOC patients62,63. FAK
inhibition may therefore present another opportunity to inhibit netrin signaling downstream
of DRs to block pro-survival cues. Further studies are required to elucidate the mechanism
of action for netrin in HGSOC which may be a combination of these possibilities. The
netrin signaling pathway provides an attractive therapeutic target since its ligands or
receptors are extracellularly accessible and could potentially be inhibited. A clinical trial
(NCT02977195) is already underway for a humanized monoclonal netrin-1 antibody
(NP137) that prevents binding of NTN1 to its DRs in patients with advanced solid tumours.
This trial marks the first time a drug candidate targeting DRs is evaluated in humans and
presents a promising new therapeutic opportunity for several cancers.
This study revealed multiple signaling pathways that are differentially expressed in
spheroid cells including those that are disrupted upon loss of DYRK1A. Specifically, our
study highlighted netrin signaling components as appealing factors that mediate spheroid
cell viability. Further work is required to fully elucidate how netrins and their receptors
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cooperate to provide spheroid cells with pro-survival cues and these findings may
potentially inform new therapeutic strategies to treat dormant ovarian cancer.

5.5 Materials and methods
5.5.1

Engineering Cas9+ cells
High-grade serous ovarian cancer (HGSOC) iOvCa147 cells have previously been

reported (MacDonald et al., 2017). Cas9-positive and Cas9-negative TOV1946 cells were
provided by Rob Rottapel. iOvCa147 and OVCAR8 cells were engineered to express Cas9
as follows: cells were transduced with viral particles encoding a Cas9 expression cassette
(lentiCas9-Blast, Addgene #52962) to generate cells constitutively expressing Cas9 (Cas9positive cells). Cells were selected with Blasticidin (20 µg/mL) and single-cell clones were
isolated by limiting dilution. Lysates were collected from clones and western blots were
performed to determine Cas9 expression (Cell Signaling #14697). Cas9 editing efficiency
was determined by viability studies using sgRNAs targeting selected fitness genes
(PSMD1, PSMD2, EIF3D) and a non-targeting control (LacZ) as previously reported (Hart
et al., 2015). A single clone showing the most effective Cas9 activity was selected for all
further studies.

5.5.2

GeCKO v2 library preparation
HEK293T cells were transfected with the combined A and B components of the

GeCKO v2 (Addgene #1000000048, #1000000049) pooled whole-genome library
(123,411 sgRNAs in total) along with plasmids encoding lentiviral packaging proteins.
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Media was collected 2-3 days later and any cells or debris were pelleted by centrifugation
at 500 x g. Supernatant containing viral particles was filtered through a 0.45 µM filter and
stored at −80°C with 1.1 g/100 mL BSA.

5.5.3

GO-CRISPR screen in iOvCa147, OVCAR8, and TOV1946
cells
GO-CRISPR screening was carried out separately in each of iOvCA147, OVCAR8,

and TOV1946 as follows: Cas9-positive or Cas9-negative cells were transduced with virus
collected as described above at a multiplicity of infection of 0.3 and with a predicted library
coverage of >1000-fold. Cells were grown in media containing 2 µg/mL puromycin (Sigma
#P8833) to eliminate non-transduced cells. Cells were maintained in complete media
containing puromycin in all following steps. A total of 1.1 × 109 cells were collected and
split into three groups consisting of approximately 3.0 × 108 cells each and were cultured
for an additional 2-3 days in complete media, then collected and counted. Triplicate
samples of 6.2 × 107 cells were saved for sgRNA sequence quantitation at T0. The
remaining cells (approximately 1.4 × 109/set) were plated at a density of 2.0 × 106 cells/mL
in each of twenty 10 cm ULA plates (total of 60 ULA plates). Following 2 days of culture,
media containing spheroids was transferred to ten, 15 cm adherent tissue culture plates
(total of 30 plates). The next day unattached spheroid cells were collected and re-plated
onto additional 15 cm plates. This process was repeated for a total of 5 days at which point
very few spheroids remained unattached. The attached cells were collected for DNA
extraction and this population represents Tf. Complete media refers to DMEM/F12 media
(Gibco #11320033) supplemented with 10% FBS (Wisent FBS Performance lot #185705),

232

1% penicillin-streptomycin glutamine (Wisent #450-202-EL) and 2 µg/mL puromycin
(Sigma #P8833).

5.5.4

GO-CRISPR screen analysis with TRACS
GO-CRISPR screening from each of the three cell lines (iOvCa147, OVCAR8,

TOV1946) was analyzed as follows: The library reference file containing a list of all
sgRNAs and their sequences (CSV file), raw reads for the pooled sgRNA library (FASTQ
files (L0) and raw reads (FASTQ files) for all Initial (T0) and Final (Tf) replicates for Cas9positive and Cas9-negative cells (12 replicates) were loaded into TRACS47
(https://github.com/developerpiru/TRACS). TRACS then automatically trimmed the reads
using Cutadapt (1.15). TRACS automatically built a Bowtie2 (2.3.4.1) index and aligned
the trimmed initial sgRNA library read file to generate a BAM file using Samtools 1.7.
TRACS then invoked the MAGeCK read count function (0.5.6) to generate read counts
from this library BAM file and all the trimmed sample FASTQ files. TRACS incremented
all reads by 1 to prevent zero counts and division-by-zero errors. The TRACS algorithm
(as previously described47) was then run using this read count file to determine the Library
Enrichment Score (ES), Initial ES, Final ES and the Enrichment Ratio (ER) for each gene
(see The TRACS algorithm section). The VisualizeTRACS feature was then used to
visualize the results and generate figures.

5.5.5

Generating DYRK1A knockout cells
A double cutting CRISPR/Cas9 approach with a pair of sgRNAs (sgRNA A and B)

was used to completely excise exon 2 (322 bp region) of DYRK1A using a px458 vector
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(Addgene #48138) that was modified to express the full CMV promoter. PCR primers that
flank the targeted region of DYRK1A were used to verify deletion. Single-cell clones were
generated by liming dilutions and evaluated for DYRK1A status by PCR, western blot, and
sequencing. See Table 5.1 for sgRNA and primer sequences.

5.5.6

DYRK1A immunoprecipitation kinase assay
Whole-cell lysates from adherent parental iOvCa147 cells and DYRK1A-/- cells

were extracted using complete RIPA buffer and incubated overnight with DYRK1A
antibody (Cell Signaling Technology anti-DYRK1A rabbit antibody #8765). Samples were
then washed with buffer and Dynabeads (Thermo Fisher Scientific Dynabeads Protein G
#10003D) were added for 2 hours. Samples were then washed with buffer and recombinant
Tau protein (Sigma recombinant Tau protein #T0576) and ATP (Sigma #A1852) were
added and samples were incubated for 30 minutes at 37°C. 5x SDS was then added and
samples were resolved SDS-PAGE. Antibodies used for western blotting were
phosphospecific Tau antibody (Cell Signaling Technology phospho-Tau Ser-404 rabbit
antibody #20194) and Tau protein (Cell Signaling Technology anti-Tau rabbit antibody
#46687)

5.5.7

Real-time qPCR (RT-qPCR)
Parental iOvCa147 cells and DYRK1A-/- cells were cultured in regular 6-well

plasticware for adherent conditions or in 6-well ultra-low attachment (ULA) plates to
induce spheroid formation in suspension conditions for 6, 12, or 24 hours. Spheroids were
then collected from wells (2 x 105 cells per well; 3 wells pooled together per replicate in
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Table 5.1 Primers used for experiments in Chapter 5
sgRNAs for DYRK1A deletion
sgRNA A Top
sgRNA A Bottom
sgRNA B Top
sgRNA B Bottom
PCR primers
DYRK1A Exon2 Forward
DYRK1A Exon2 Reverse
RT-qPCR primers
β-Actin Forward
β-Actin Reverse
CDK1 Forward
CDK1 Reverse
DCC Forward
DCC Reverse
DSCAM Forward
DSCAM Reverse
GAPDH Forward
GAPDH Reverse
MYBL2 Forward
MYBL2 Reverse
NEO1 Forward
NEO1 Reverse
NTN1 Forward
NTN1 Reverse
NTN3 Forward
NTN3 Reverse
NTN4 Forward
NTN4 Reverse
NTN5 Forward
NTN5 Reverse
NTNG1 Forward
NTNG1 Reverse
NTNG2 Forward
NTNG2 Reverse
UNC5A Forward
UNC5B Reverse
UNC5C Forward
UNC5C Reverse

Sequence
CACCGCTCACTTATCTTCTTGTAGG
AAACCCTACAAGAAGATAAGTGAGC
CACCGCAACGTGGGATTATGGATT
AAACAATCCATAATCCCACGTTGC
Sequence
GGTTTCACCTGGTTTGGGGA
TCCGTGGGGCAAGAAACTTT
Sequence
AGAGCTACGAGCTGCCTGAC
AGCACTGTGTTGGCGTACAG
TAAGCCGGGATCTACCATACCC
TCATGGCTACCACTTGACCTGTAG
AGCCAATGGGAAAATTACTGCTTAC
AGGTTGAGATCCATGATTTGATGAG
GATGGTCCACCTCAGGAAGTTC
CCAGTGCTGTACTCTCGGTAAC
CGGAGTCAACGGATTTGGTCGTAT
AGCCTTCTCCATGGTGGTGAAGAC
TGCCCAAGTCTCTATCCTTGCC
CCTGGTTGAGCAAGCTGTTGTC
GTCACTGAGACCTTGGTAAGCG
TCAGCAGACAGCCAGTCAGTTG
TGCAAGAAGGACTATGCCGTC
GCTCGTGCCCTGCTTATACAC
TGCAAGCCCTTCTACTGCGACA
CAGTCGGTACAGCTCCATGTTG
CAGAAGGACAGTATTGCCAGAGG
GCAGAAGGTCACTGAGTTGGCA
CTTGCCACTACTCCTGGTGCTT
AGTACCTCCGAAGGCTCATGTG
GCACGCTACTTTTACGCGATCTC
CTGGACCTGTAGTGTTGTGCTC
ATGCGCCTGAAGGACTACGTCA
TTGGAGGCGTCACACTCGTTGC
ATCACCAAGGACACAAGGTTTGC
GGCTGGAAATTATCTTCTGCCGAA
GCAAATTGCTGGCTAAATATCAGGAA
GCTCCACTGTGTTCAGGCTAAATCTT
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triplicates), pelleted, and washed twice with 1x PBS. For adherent cells grown in 6-well
plates (1 x 105 cells per well; 3 wells pooled together per replicate in triplicates), media
was aspirated, wells were washed twice in 1x PBS, then cells were scraped off in 1x PBS.
All cell pellets were then processed for total RNA extraction using the Monarch Total RNA
Miniprep Kit (NEB #T2010S). RNA was reverse transcribed using iScript (Bio-Rad
#1708891). cDNA was diluted 5x with nuclease-free water. Real-time qPCR was
performed for MYBL2 and CDK1 using PowerUP SYBR (Applied Biosystems #A25742).
Human β-actin or GAPDH was used as the internal control. See Table 5.1 for primer
sequences.

5.5.8

RNA preparation and RNA-sequencing
Total RNA was collected from parental iOvCa147 cells and DYRK1A-/- cells from

24-hour adherent or 6-hour spheroid conditions using the Monarch Total RNA Miniprep
Kit (NEB #T2010S) as described above. RNA was collected in three replicates for each
condition (adherent and spheroids). Samples were submitted to the London Regional
Genomics Centre (Robarts Research Institute, London, Ontario, Canada) for quantification
using Qubit 2.0 Fluorometer (Thermo Fisher Scientific) and quality control analysis using
Agilent 2100 Bioanalyzer (Agilent Technologies #G2939BA) and RNA 6000 Nano Kit
(Agilent Technologies #5067-1511). Ribosomal RNA removal and library preparation was
performed using ScriptSeq Complete Gold Kit (Illumina #BEP1206). High-throughput
sequencing was performed on an Illumina NextSeq 500 platform (mid-output, 150cyclekit).
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5.5.9

RNA-sequencing analyses
Raw FASTQ data was downloaded from Illumina BaseSpace. Reads were aligned

using

2.6.1a64

STAR

to

the

human

genome

(Homo_sapiens.GRCh38.dna.primary_assembly.fa;

sjdbGTFfile:

Homo_sapiens.GRCh38.92.gtf) to generate read counts. BEAVR65 was then used to
analyze read counts (settings: False discovery rate (FDR): 10%; drop genes with less than
1 reads) to identify differentially expressed genes (log2 fold change > 1 for upregulated
genes; or log2 fold change < -1 for downregulated genes; padj < 0.05) for the following
comparisons: parental iOvCa147 adherent cells vs. parental iOvCa147 spheroid cells; or
parental iOvCa147 spheroid cells vs. DYRK1A-/- spheroid cells.

5.5.10

Pathway enrichment analyses

For GO-CRISPR screen, we used the filtered list of genes obtained using TRACS47
and performed gene
ConsensusPathDB

ontology and pathway enrichment analysis

enrichment

analysis

test

(Release

34

using

the

(15.01.2019),

http://cpdb.molgen.mpg.de/) for top-ranked genes of interest. padj values and ER values for
each gene were used as inputs. The minimum required genes for enrichment was set to 45
and the FDR-corrected padj value cutoff was set to < 0.01. The Reactome pathway dataset
was used as the reference. For each identified pathway, ConsensusPathDB provides the
number of enriched genes and a q value (padj) for the enrichment. Bar plots were generated
in R 3.6.2 using these values to depict the significant pathways identified. For RNA-seq
pathway analyses, we formed pathway analyses in BEAVR65 and downloaded the pathway
enrichment table to construct bar plots and determine overlapping pathways using R 3.6.2.
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5.5.11

Western blots

Cells were washed in 1x PBS and lysed in complete RIPA buffer with protease
inhibitors (Sigma #S8820) and incubated for 1 hour on ice. Samples were then centrifuged
at 14,000 RPM at 4°C for 10 minutes. The supernatant was collected and protein
concentration was determined by Bradford assay. Lysates were mixed with 6x SDS loading
dye buffer and resolved using standard SDS-PAGE protocols. Antibodies used for blotting
were DYRK1A (Cell Signaling Technology anti-DYRK1A rabbit antibody #8765), p130
(Santa Cruz anti-p130 rabbit antibody #SC-317), and tubulin (Cell Signaling Technology
anti-Tubulin rabbit antibody #2125).

5.5.12

Generation of single-gene knockouts

Gibson Assembly (NEB #E2611) was used to clone a pool of four sgRNAs per
gene (NTN1, DCC, DSCAM, UNC5A, UNC5B, UNC5C, UNC5D, FAK, and EGFP control)
into lentiCRISPR v2 (Addgene #52961). Sequences for sgRNAs were obtained from the
GeCKO v2 library. For each gene, HEK293T cells were transfected with the assembled
plasmid along with plasmids encoding lentiviral packaging proteins. Media was collected
2-3 days later and any cells or debris were pelleted by centrifugation at 500 x g. Supernatant
containing viral particles was filtered through a 0.45 µM filter. For each targeted gene,
iOvCa147, OVCAR3, OVCAR4, OVCAR8, COV318, or TOV1946 cells were transduced
with viral particles encoding Cas9 and sgRNA expression cassettes. Cells were selected
for 2-3 days in media containing 2 µg/mL puromycin.
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5.5.13

Spheroid viability assays

For each targeted gene in iOvCa147, TOV1946, OVCAR3, OVCAR4, OVCAR8,
or COV318 cells, spheroid viability was assayed as follows: Knockout cells were cultured
for 5 days in suspension conditions using ULA plasticware (2 × 106 cells per well) to allow
spheroid formation. Spheroid cells were then collected and transferred to standard
plasticware to facilitate reattachment for 24 hours. Reattached cells were fixed with fixing
solution (25% methanol in 1x PBS) for 3 minutes. Fixed cells were incubated for 30
minutes with shaking in crystal violet staining solution (0.5% crystal violet, 25% methanol
in 1x PBS). Plates were carefully immersed in ddH2O to remove residual crystal violet.
Plates were incubated with destaining solution (10% acetic acid in 1x PBS) for 1 hour with
shaking to extract crystal violet from cells. Absorbance of crystal violet was measured at
590 nm using a microplate reader (Perkin Elmer Wallac 1420). Each knockout and
normalized to the EGFP control. Percent of spheroid cells surviving suspension and
reattachment is inferred from relative absorbance.

5.5.14

Statistical analyses

Statistical tests for GO-CRISPR screens were performed in TRACS47. Statistical
tests for RNA-seq were performed in BEAVR65. Specific statistical tests used for RT-qPCR
and spheroid viability assays are indicated in the figure legends for each experiment. These
were performed in GraphPad Prism 6.
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Chapter 6

6

Discussion

6.1 Summary of findings
Chemoresistance and dormancy are a major challenge in the treatment of HGSOC
leading to treatment failure and disease recurrence in up to 90% of patients1,2. This is
facilitated by spheroids, which are multicellular aggregates of tumour cells that have
exfoliated from primary tumours and are carried throughout the peritoneal cavity by ascites
fluid to invade distant tissues3,4. Spheroid cells reversibly exit the cell cycle to become
quiescent, allowing them to evade chemotherapy5-10. This process is mediated by the
DREAM complex and its initiating kinase, DYRK1A5,11-13. Depletion of DYRK1A
significantly reduces spheroid cell survival while also increasing sensitivity to
chemotherapy5. Additionally, pharmacologic inhibition of DYRK1A is sufficient to
enhance sensitivity to chemotherapy in ovarian cancer as well as other dormant cancers in
vitro5,14-17. Thus, DREAM and DYRK1A are attractive targets to specifically inhibit
dormancy in disseminated spheroid cells. However, pharmacological DYRK1A inhibitors
used in in vitro studies have not been approved for clinical use18,19. Additionally, while in
vivo studies have indicated a requirement for DREAM in normal growth arrest during early
development, a role for DREAM in adults has not been identified. Furthermore, while we
have previously shown that DYRK1A is required for HGSOC spheroid cell survival, the
mechanisms of how it affects survival in terms of the genes and pathways it regulates is
still not understood5.
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6.2 Prolonged loss of DREAM causes systemic amyloidosis
in mice
To characterize the role of DREAM in adults, we developed a conditional mouse
model to disrupt DREAM assembly. We did not observe any defects in proliferation or the
development of neoplasms in DREAM deficient mice. Our previous mouse model that
constitutively disrupted DREAM assembly had endochondral bone defects due to loss of
growth arrest in chondrocytes20. This was not observed in the conditional knockout model
presented in Chapter 2 and this was consistent with our expectations. Endochondral
ossification is finished by adulthood and growth plates of bones are closed21. The absence
of these early developmental defects allowed us to characterize the role of long-term
DREAM loss in adult mice.
We identified a significant difference in survival of DREAM deficient mice relative
to wild type mice. The cause of this early mortality was due to amyloidosis. Specifically,
loss of DREAM assembly led to an overexpression of Apoa1 and Apoa4 in liver tissue.
These genes specifically encode for the apolipoproteins apoA-I and apoA-IV,
respectively22. Our work showed that these genes have putative CDE/CHR motifs in their
promoters that can bind DREAM leading to transcriptional repression which is mediated
by H2AZ deposition within their gene bodies. Upon loss of DREAM, MMB is found at the
Apoa1 and Apoa4 promoters and this is concomitant with decreased H2AZ in their gene
bodies. Transcriptional activation of these promoters led to increased apolipoprotein levels
which circulated to other tissues, including kidney, spleen, and heart and deposited as
amyloid fibrils. Kidneys in DREAM-deficient mice were most affected as they had
widespread amyloid deposition in the cortex and medulla likely leading to kidney
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disfunction which was detected by albuminuria and increased serum creatinine. Together,
this model uncovered a previously unknown role for DREAM and MMB in adults and
showed an important connection between transcriptional de-repression and amyloidosis.
Our conditional mouse model demonstrated that the consequence of DREAM
deficiency in adults is systemic amyloidosis (Chapter 2). This is an important finding in
the context of cancer. Several in vitro studies in cancer cell lines, including those in
quiescent colon, pancreatic, and ovarian cancer cells, have shown that DYRK1A/B
inhibition enhances sensitivity to chemotherapy and reduces viability of cancer cells5,14-17.
DYRK1A/B is therefore an appealing target for treating dormant cancer in patients. The
three clinical trials (NCT03904862, NCT03897036, and NCT01199718) presently
underway for the DYRK1A inhibitor, CX-4945, have not reported any results to date hence
no conclusions can be made about its toxicity18,23. However, our study suggests that
constitutive, long-term disruption of DREAM could result in systemic amyloidosis in
patients. The extent of potential amyloid development may depend on the dose of CX4945. As our data shows, Apoa1 and Apoa4 gene expression are dynamically controlled by
DREAM and MMB. Upon complete ablation of DREAM, the balance is shifted towards
the MMB complex which abundantly occupies its target promoters24-26. This suggests that
side effects of DREAM loss due to DYRK1A inhibition may be potentiated by the dose of
the inhibitor. Furthermore, while DREAM deficient mice were short-lived compared to
their wild type counterparts, the amyloid deposition observed in these mice was chronic
and occurred between 8 weeks of age (the age of tamoxifen administration) to 1 year
(earliest

amyloid detected) and beyond. Therefore, appropriately coordinated

pharmacological inhibition of DYRK1A that is administrated with adjuvant or neoadjuvant
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therapy may mitigate development of amyloidosis in patients. Further preclinical studies
will be required to explore these challenges. The completion of the aforementioned clinical
trials will also inform safe dosage for CX-4945 administration.

6.3 Components of netrin signaling are essential factors for
spheroid cell viability
The role of DREAM in cancer has become increasingly apparent over the last
decade. Several studies – including our own in ovarian cancer – have identified a role for
DREAM in quiescence and dormant cancer5,16,27-29. DREAM and DYRK1A cooperate to
facilitate cell cycle exit and re-entry in HGSOC spheroid cells5. However, the
transcriptional programming and cellular pathways under the control of DREAM and
DYRK1A in the context of ovarian cancer is not known. Elucidating these processes will
improve our understanding of HGSOC spheroid cell biology and highlight the selective
advantages that spheroid cells acquire to remain viable in suspension conditions. To this
end, we devised an integrated strategy that consisted of transcriptional analyses of spheroid
cells and a loss-of-function genome-wide CRISPR screen. This required the development
of new tools: BEAVR, a bioinformatics tool to allow rapid analysis of RNAseq data
(Chapter 3); and GO-CRISPR and TRACS (Chapter 4), a new method and software that
reduces confounding biases caused by non-gene editing events in CRISPR screens. We
later used these tools in Chapter 5 to identify the netrin signaling pathway as a critical
mediator of HGSOC spheroid cell viability. Transcriptional analysis of parental iOvCa147
and DYRK1A-/- spheroid cells with BEAVR uncovered differential gene expression
patterns. Components of netrin signaling were found to be upregulated in iOvCa147 cells
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upon spheroid formation. In contrast, netrin signaling components were downregulated in
DYRK1A-/- spheroid cells compared to parental spheroid cells. Additionally, we used
TRACS to analyze GO-CRISPR screen data from three cell lines and found that netrin
signaling sgRNAs were depleted in the loss-of-function screens. Together, this data
indicated that netrin signaling was required for spheroid cell survival.
The significance of the data presented in Chapter 5 is twofold. First, validation
experiments in which knockout of netrin components led to loss of cell viability in ovarian
cancer spheroids demonstrates that GO-CRISPR and TRACS can robustly identify
essential genes in loss-of-function screens. This is of particular importance to CRISPR
screen studies involving three-dimensional in vitro models, such as spheroids or organoids.
Such models more accurately represent the tumour microenvironment (TME) compared to
two-dimensional monolayer cell culture systems30-33. However, the challenges imposed by
these models, such as dormancy, slow cycling, or hypoxia, can contribute to poor
representation of sgRNA libraries and may also lead to stochastic loss of sgRNAs34,35. For
example, as described in Chapter 4, established CRISPR screening methods and tools were
unable to find essential genes in our experimental system. In comparison, GO-CRISPR and
TRACS not only correctly identified genes that are universally known to be essential across
all cell lines, including AGPS, SLC2A11, ZC3H7A, PDCD2L, and NPM1 (Chapter 4), it
also identified several pathways that are known to promote survival of quiescent cancer
cells such as p38 MAPK and cell cycle genes (Chapter 4)36-42. Furthermore, the
identification of netrin signaling as a critical mediator of survival in the GO-CRISPR
screens was consistent with upregulation of these components in unperturbed iOvCa147
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spheroid cells. Therefore, we have validated the usefulness and reliability of GO-CRISPR
and TRACS in a three-dimensional cell culture system using independent assays.
Secondly, the identification of netrin signaling as a mediator of HGSOC spheroid
cell survival advances our understanding of spheroid cell biology. Our study indicates
netrin signaling is downstream of DYRK1A and DREAM. Netrin was originally
discovered for its role in axon guidance and it is well-characterized in this process43.
Recently it has been implicated in cancer and has been characterized as an oncogene, but
its role in cancer is still poorly understood44,45. Netrin ligand binding to receptor homo- or
heterodimers appear to protect cells from apoptosis46,47. The DCC and UNC5H receptors
are therefore known as dependence receptors (DRs)48,49. However, there are several
receptor and ligand homologs that may impart a positive or negative growth signal on
tumour cells as evidenced by the overexpression of the NTN4 ligand in other cancer
types44,50-53. Additionally, multiple ligands and receptors may play complementary or
divergent roles in ovarian cancer44. Therefore, while the netrin signaling data presented
herein is encouraging as a therapeutic target for HGSOC, it requires further investigation.
Specifically, downstream effectors must be identified to better understand how netrin
signaling affects viability. Knowledge from axon guidance pathways indicate netrin is
positioned upstream of PI3K/AKT/mTOR, p38 MAPK, and NFκB signaling pathways5457

. Activation or de-activation of these effectors can be detected upon depletion or

overexpression of netrin ligands or receptors in HGSOC spheroid cells. The in vitro data
presented in Chapter 5 must also be followed by in vivo xenograft studies. Specifically,
HGSOC spheroid cells with netrin receptor knockouts (either individually or in
combination) need to be transplanted into mice intraperitoneally to characterize
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tumorigenesis, metastases, and ascites development relative to unperturbed HGSOC
spheroid cells. Knockout of receptors instead of ligands in spheroid cells is important since
murine netrin ligands secreted into the peritoneum may activate receptors on transplanted
cells58. Finally, netrin ligands are secreted into the ECM and netrin receptors are
extracellular43. This presents opportunities to antagonize the pathway using targeted
antibodies. Indeed, a monoclonal antibody targeting the NTN1 ligand has been developed
and is currently undergoing clinical trials (NCT02977195). It will be interesting to
determine if this antibody is sufficient to inhibit spheroid viability and potentially suppress
metastases in vivo in xenograft models. These investigations are currently underway.

6.4 Transcriptional control by DREAM and DYRK1A
In chapter 2 we identified Apoa1 and Apoa4 gene expression are regulated by
DREAM and MMB. These genes were not described in the 2007 study which established
DREAM as a regulator of several hundred cell cycle genes11. The authors of that study
employed a liquid chromatography-based approach to identify promoters which bound
DREAM subunits11,59. Our findings illustrate that this list is not exhaustive. More advanced
technologies such as ChIP-seq can be used in subsequent studies to identify novel DREAM
targets. Additionally, in Chapter 5 we found that genes involved in netrin signaling were
differentially expressed in DYRK1A-/- spheroid cells compared to parental iOvCa147
spheroid cells. We have also performed transcriptional analysis of p130-/- spheroid cells
and did not find extensive overlap of differentially expressed genes. This suggests that
DYRK1A can regulate transcription independently of DREAM in spheroid cells. Indeed,

250

DYRK1A has been shown to be a transcriptional regulator that phosphorylates the Cterminal domain of RNA polymerase II to promote transcription60,61.
In chapter 2 we also demonstrated that loss of DREAM leads to a decrease in H2AZ
deposition within gene bodies of target genes (Apoa1, Apoa4, and Mybl2). This provides a
mechanistic link to studies performed in C. elegans and Drosophila which have shown that
DREAM repression is marked by gene body deposition of H2AZ13,62. A recent study in
MEFs suggests the SIN3B/HDAC complex is among the chromatin remodeling factors
recruited by DREAM63. The epigenetic mechanisms behind DREAM mediated repression
of target genes is an evolving story and there are important differences between mammals
and lower organisms13. Our DREAM deficient mouse model is an important advancement
because it will allow for these mechanisms to be investigated in a mammalian system.

6.5 Significance of bioinformatic tools
A focus of this thesis has been on the development and importance of bioinformatic
tools. Studies have demonstrated the use of novel computational methods to aid in highthroughput genomic and transcriptional studies, particularly in ovarian cancer. For
example, in the 2011 study that characterized the genomic landscape of HGSOC, only
about 6-8% of cases were found with PTEN alterations64. However, it was later suggested
that the stromal signature of tumours can confound analysis and a new computational
approach that corrected for stromal signatures identified PTEN alterations in 50-70% of
cases65. Similarly, there have been studies which have identified transcriptomic signatures
across ovarian cancer that allows patient samples to be stratified into subtypes 66,67.
Subsequent studies have built on these findings, and as computational approaches improve,
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researchers have found that subtypes can be further divided into more distinct clusters66,68.
This shows how our current understanding of ovarian cancer is continuously evolving, in
part due to the advancement of bioinformatic tools and computational methods.
Likewise, the tools presented here have allowed for the identification of new genes
and pathways that are important for HGSOC spheroid cell survival. We have developed
these tools to have broad usability. Both BEAVR and TRACS have a graphical user
interface that is more user-friendly compared to typical command-line driven tools. This
reduces a substantial barrier to entry that many researchers face during computation
analysis. Both tools support collaboration and allow data to be analyzed and visualized by
multiple users. Additionally, both tools can be scaled on high-compute clusters which are
becoming more common in research settings69-71. We anticipate BEAVR and TRACS will
provide researchers the ability to efficiently analyze transcriptional studies and GOCRISPR screens in-house.

6.6 Conclusion
The data presented in this thesis highlight the role of the mammalian DREAM
complex and DYRK1A in ovarian cancer spheroid cell survival. The data presented in
chapter 2 characterized the effects of long-term DREAM loss in adult mice and uncovered
a link between DREAM and amyloidosis. Chapters 3 and 4 described novel tools to rapidly
analyze transcriptional studies and perform loss-of-function CRISPR screening,
respectively. Chapter 5 utilized these tools to identify a role for netrin signaling in HGSOC
spheroid cell survival. The work presented herein advances our knowledge of ovarian
cancer and presents DREAM, DYRK1A, and the netrin signaling pathway as critical
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mediators of spheroid cell survival. Advancing our understanding of the molecular
mechanisms orchestrating dormancy, chemoresistance, and survival in spheroid cells may
allow us to exploit these vulnerabilities with novel therapies that can effectively eliminate
them in patients.
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